Document:

<PAGE>

                                                                    Exhibit 10.2

                              SUBLICENSE AGREEMENT

                                     between

                               Novartis Pharma AG

                                       and

                           Vanda Pharmaceuticals, Inc.

----------
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

<PAGE>

SUBLICENSE AGREEMENT

THIS SUBLICENSE AGREEMENT effective as of the 4th day of June, 2004, ("Effective
Date") between Vanda Pharmaceuticals, Inc., a corporation organized and existing
under the laws of the State of Delaware and having its principal office at 47
Hulfish Street, Suite 310, Princeton, NJ 08542, The United States ("Vanda") and
Novartis Pharma AG, a corporation organized under the laws of Switzerland and
having its principal office at Lichtstrasse 35, CH-4056 Basel, Switzerland
("Novartis")

WITNESSETH THAT:

WHEREAS Novartis is the exclusive worldwide licensee of Titan Pharmaceuticals,
Inc. ("Titan") under a sublicense agreement between Novartis and Titan having an
Effective Date of 20th November, 1997 and as amended by two Amendments between
the parties dated 30th November 1998 and 10th April, 2001 (the "Titan
Agreement"); and

WHEREAS Titan is the exclusive worldwide licensee of Hoechst Marion Roussel Inc.
("HMRI") under a license agreement between Titan and HMRI having an Effective
Date of 31st December, 1996 (the "HMRI Agreement"); and

WHEREAS as a result of corporate restructuring, Aventis Pharmaceuticals Inc., a
corporation organized under the laws of the State of Delaware and with offices
at 200 Crossing Boulevard, Bridgewater, NJ 08807-0890 ("Aventis") acquired
substantially all of the tangible operating assets of HMRI and, as a result, the
HMRI Agreement has been assigned to Aventis; and

WHEREAS under such Titan Agreement and the Novartis Patents, Novartis has rights
with respect to certain patents and patent applications, identified in APPENDIX
A hereto, and know-how relating to a compound known as Iloperidone; and

WHEREAS Vanda desires to obtain certain exclusive licenses from Novartis under
the Titan Agreement and the Novartis Patents, and Novartis is willing to grant
to Vanda such licenses;

NOW, THEREFORE, in consideration of the covenants and obligations expressed
herein, and intending to be legally bound, the parties agree as follows:

                                  Page 2 of 56

<PAGE>

1. DEFINITIONS

1.1 "Affiliate" shall mean any corporation, firm, partnership or other entity,
whether de jure or de facto, which directly or indirectly owns, is owned by or
is under common ownership with a party to this Sublicense Agreement, to the
extent of more than fifty percent (50%) of the equity (or such lesser percentage
which is the maximum allowed to be owned by a foreign corporation in a
particular jurisdiction) having the power to direct the affairs of the entity
and any person, firm, partnership, corporation or other entity actually
controlled by, controlling or under common control with a party to this
Sublicense Agreement.

1.2 "Commercially Reasonable Efforts" shall mean efforts and resources
customarily used in the pharmaceutical business for a product of a market
potential similar to the market potential of Product under evaluation, at a
similar stage of its product life, taking into account the establishment of the
product in the marketplace, the competitiveness of the marketplace, the
proprietary position of the product, regulatory status involved, and the
profitability of the product.

1.3 "Competitive Industry Standard Level" shall mean the level to which the
Product shall be marketed by or on behalf of Vanda, its Affiliates or
Sublicensees in the countries of the Territory where Patents are issued and
enforced with at least the same diligence that Vanda would use in marketing its
own products in such countries, in a manner consistent with the effort devoted
by the pharmaceutical industry to products having the same or similar potential
value of the Product in those countries when the Product is launched.

1.4 "Compound" shall mean the chemical compound known as Iloperidone, whose
specific chemical name is [*], including any salts, hydrates, solvates, and/or
stereoisomers thereof, and only the metabolites listed in APPENDIX B hereto,
including any salts, hydrates, solvates and/or stereoisomers of such
metabolites.

1.5 "EEA" shall mean the European Economic Area, which consists of the European
Union and Iceland, Liechtenstein and Norway.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 3 of 56

<PAGE>

1.6 "European Union" shall mean the member states of the European Union, as may
exist from time to time, which as of the date hereof include Austria, Belgium,
Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the
Netherlands, Portugal, Spain, Sweden and the United Kingdom and all other
countries which accede to the European Union during the term of this Sublicense
Agreement.

1.7 "Exclusive" shall have the meaning specified in Section 2.1 hereof.

1.8 "FDA" shall mean the United States Food and Drug Administration.

1.9 "FD&C Act" shall mean the Federal Food, Drug and Cosmetic Act (21 U.S.C.
301ff), as amended from time to time.

1.10 "Field" shall mean application to all conditions, disorders and diseases in
humans.

1.11 "IND" shall mean an Investigational New Drug Application.

1.12 "Know-How" shall mean all technical information and know-how: (a) presently
developed and owned or controlled by HMRI or Titan and their Affiliates and made
available to Novartis, (b) developed and owned or controlled by Novartis and its
Affiliates after the date of the Titan Agreement, and (c) developed and owned or
controlled by HMRI, Titan or Novartis and their respective Affiliates, after the
date hereof and included within this definition of "Know-How" by operation of
Section 2.3 hereof, which relates to the Compound or Product in the Field and
which constitutes a proprietary "trade secret" or other valid intellectual
property right under U.S. or other applicable law which is substantial, secret
and identifiable, including, without limitation, all biological, chemical,
pharmacological, toxicological, clinical, regulatory, analytical, quality
control and manufacturing data and any other information (whether technical or
commercial) relating to the Compound or Product that may be useful for the
development, regulatory approval, manufacture and commercialization of the
Compound or Product.

1.13 "Major Market Country" shall mean each of France, Germany, Italy, Spain and
the United Kingdom.

                                  Page 4 of 56

<PAGE>

1.14 "NDA" shall mean any and all applications (new drug applications) submitted
to the FDA under Sections 505, 507 or 512 of the FD&C Act and applicable
regulations related to the Product, including without limitation, full NDAs,
"paper" NDAs and abbreviated NDAs (ANDAs) and all amendments and supplements
thereto or equivalent applications in the European Union.

1.15 "Net Sales" shall be calculated as follows: From the gross invoice price of
the Product sold by Vanda or its Affiliates or Sub-licensees to independent
third parties in bona fide, arms-length transactions there shall be subtracted,
if not previously deducted in the amount invoiced or received, (i) quantity and
cash discounts actually allowed or taken, (ii) freight, postage and shipping
insurance allocated in accordance with Vanda's standard allocation procedure,
(iii) customs duties and taxes, if any, directly related to the sale, (iv)
amounts repaid or credited by reason of rejections, return of goods and
retroactive price reductions mandated by or granted in response to state,
provincial or federal law or regulation and specifically identifiable as
relating to the Product, (v) amounts incurred as a result of governmental (or
governmental agency) mandated rebate programmes, (vi) third party rebates and
wholesale chargebacks related to the sale of the Product to the extent actually
allowed and (vii) as agreed by the parties in writing, any other specifically
identifiable amounts included in the Product's gross sales that were or
ultimately will be credited and that are substantially similar to those listed
above. The computation of Net Sales shall not include sales between or among a
party and its Affiliates or Sub-licensees, except where such Affiliates or
Sub-licensees are end users. For the purposes of this Sublicense Agreement,
sales of the Product to independent distributors, wholesalers or other parties
who purchase and take title to the Product are considered to be sales to third
parties. If the Product is sold through intermediaries such as agents or
co-promoters who do not purchase and take title to the Product, royalties shall
be due on Net Sales to third parties who purchase the Product through such
intermediaries. It is agreed that there shall be no sales of the Compound to
Third Parties by or on behalf of Vanda, its Affiliates or Sub-licensees. In the
event there are sales of Compound to Third Parties by or on behalf of Vanda, its
Affiliates or Sub-licensees, such sales shall be subject to the payment of
royalties by Vanda to Novartis (as the case may be) to the same extent as
payments of royalties are due on sales of the Product pursuant to this
Sublicense Agreement.

In the event that the Product is sold as part of a combination product, the Net
Sales of the Product, for the purposes of determining royalty payments, shall be
determined by

                                  Page 5 of 56

<PAGE>

multiplying the Net Sales (as defined above in this Section) of the combination
product by the fraction A/(A+B), where A is the weighted (by sales volume)
average sale price of Product when sold separately in finished form and B is the
weighted average sale price of the other product(s) sold separately in finished
form. In the event that such average sale price cannot be determined for both
Product and the other product(s) in combination, Net Sales for purposes of
determining royalty payments shall be mutually agreed by the parties within a
reasonable period of time prior to the first commercial sale of such combination
product based on all relevant factors including relative cost and the relative
value contributed by each component, and such agreement shall not be
unreasonably withheld.

1.16 "Patents" shall mean all patents and patent applications set forth in
APPENDIX A, including continuations, continuations-in-part, divisions, patents
of addition, reissues, re-examinations, renewals or extensions thereof, along
with supplementary protection certificates and other administrative protection
of any kind in the Territory owned by or licensed to Novartis or its Affiliates
to the extent that such patents claim the Compound or Product, or use,
formulations or manufacture thereof, for use in the Field, but not any other
compound or use outside of the Field disclosed or claimed in those patents or
patent applications. Any Patent having claims covering the Compound or Product
or its use formulation and manufacture thereof for use in the Field which is
issued during the term of this Sublicense Agreement in any Country of the
Territory shall automatically be deemed as of the date of such issuance to be
included in the Patent, as defined hereunder.

1.17 "Product" shall mean any bulk or finished pharmaceutical composition
containing the Compound as a pharmaceutically active ingredient for use in the
Field, whether as a sole active ingredient or in combination with another active
ingredient.

1.18 "SEC" shall mean the United States Securities and Exchange Commission.

1.19 "Sub-licensee" shall mean a Third Party (as defined below) to whom a party
sublicenses rights to manufacture and sell (or have manufactured and sold) the
Compound under Patents, but shall not include any Third Parties to whom rights
to manufacture the Compound have not been granted. Unless such party grants to
such Third Party the right to manufacture Compound, the following Third Parties
shall not be considered Sublicensees under this Sublicense Agreement: agents,
distributors, wholesalers, subcontractors, co-marketers,

                                  Page 6 of 56

<PAGE>

co-promoters, partners or joint venturers. Sub-licensees shall not include
compulsory licensees as described in Section 4.1(a).

1.20 "Territory" shall mean all countries and territories of the world provided
that any country(ies) in which this Sublicense Agreement is terminated shall be
removed from the scope of this definition.

1.21 "Third Party" shall mean any party other than a party to this Sublicense
Agreement, HMRI, Titan or an Affiliate of any of these.

2. GRANT

2.1 Novartis hereby grants to Vanda an Exclusive sublicense in the Field under
the Patents (to the extent, but only to the extent, that such patents or patent
applications claim the Compound or Product or the manufacture, formulation, or
use thereof) and Know-How to develop, have developed, make, have made, use,
import, sell, offer for sale and have sold the Compound and Product in the
Territory, subject to the terms and conditions of this Sublicense Agreement. All
rights granted by Novartis to Vanda in this Sublicense Agreement shall remain
subject to the rights and obligations of HMRI and Titan within the HMRI
Agreement. The sublicense granted to Vanda by Novartis shall include the right
of Vanda to sublicense its rights under this Sublicense Agreement, but only upon
Novartis', HMRI's and Titan's prior written consent, which consent shall not be
unreasonably withheld. Any such sublicensee(s) shall impose upon a
Sublicencee(s) of Vanda substantially the same terms and conditions as Vanda
assumes in this Sublicense Agreement. As used in this Sublicense Agreement, the
term "Exclusive" shall mean that neither Novartis, nor its Affiliates shall
grant any other license to, nor themselves exploit, the Patents and Know-How
with respect to the Compound and Product in the Field (unless otherwise
specified herein) and be limited as follows:

(a) With respect to all geographic areas outside of the EEA, such sublicense
shall be exclusive for the duration and validity of the intellectual property
rights constituting the Patents and/or Know-How.

(b) With respect to all geographic areas within the EEA, such sublicense shall
be exclusive for the following time periods:

                                  Page 7 of 56

<PAGE>

     (i) For each of the countries within the EEA where only Patents (and not
     Know-How) exist and are sublicensed to Vanda hereunder, the period of
     exclusivity for each such country shall be limited to the duration of the
     relevant Patents in such country, provided that "Patents" for the purposes
     of the interpretation of this paragraph shall be limited to patents
     existing, and patents issuing from patent applications existing, and
     patents issuing from patent applications covering inventions existing as of
     the date of the Titan Agreement;

     (ii) For each of the countries within the EEA where Patents and Know-How
     exist and are sublicensed to Vanda hereunder, the period of exclusivity for
     each such country shall be limited to the duration of the relevant Patents
     in such Country, provided that "Patents" for purposes of the interpretation
     of this paragraph shall be limited to patents existing, and patents issuing
     from patent applications existing, as of the date of the Titan Agreement
     and, provided, further, that if the duration of such Patents is less than
     ten (10) years from the date of first marketing of the Product in the EEA
     but the Know-How continues to be sublicensed hereunder, the duration of
     exclusivity shall be for ten (10) years from the date of first marketing of
     the Product in the EEA; and

     (iii) For each of the countries within the EEA where Know-How (and not
     Patents) exists and is sublicensed to Vanda hereunder, the period of
     exclusivity for each such country shall be limited to ten (10) years from
     the date of first marketing of the Product in the EEA. Thereafter, such
     sublicense within the EEA shall be on a non-exclusive basis.

(c) deleted

(d) Novartis and its Affiliates and licensed Third Parties and Sub-licensees
shall also be entitled to utilise the Patents and Know-How in the Field within
the Territory for the development and manufacture of the Compound and Product
for marketing, distribution and sale where Vanda's rights under this
Sublicense Agreement have been terminated. The duration of the sublicense
granted by this Section 2.1 shall be limited to the duration, on a
country-by-country basis, of the intellectual property rights which comprise the
Patents and Know-How with respect to a relevant country, provided that the
termination of any portion of any sublicense shall be without prejudice to the
requirement of Vanda to pay royalties pursuant to the terms of this Sublicense
Agreement. Notwithstanding the foregoing but subject to Sections 3.4 and 3.5
hereof, Novartis acknowledges and agrees that Vanda shall have the right to
continue to use on a royalty-free, non-exclusive basis the information which

                                  Page 8 of 56

<PAGE>

constitutes the Patents and Know-How on a country-by-country basis in the
Territory for the Field after the Patents expire or cease to be valid or
enforceable and/or Know-How has entered into the public domain.

2.2 deleted

2.3 deleted.

2.4 Novartis grants to Vanda a non-exclusive, worldwide sublicense to make or
use any analytical reference standards, intermediate or metabolite of the
Compound or Product not listed in Appendix B hereto which may be claimed in
Patents limited solely to making or using the Compound or Product. The foregoing
sublicense shall include the right to sublicense, but only upon the prior
written consent of each of HMRI, Titan and Novartis which consent shall not be
unreasonably withheld. Any such sublicense shall impose upon the Sublicensee(s)
substantially the same terms and conditions as Vanda assumes in this Sublicense
Agreement.

2.5 Vanda shall promote, market and sell the Product under a registered
trademark(s) approved by HMRI, Titan and Novartis. Vanda will promptly inform
HMRI, Titan and Novartis of the selected trademark(s) and each of the three
parties will have twenty (20) business days in which to either approve or reject
the selection(s). Vanda shall be responsible for the selection and registration
of such trademark(s) in all countries of the Territory at its own cost. In the
event the sublicense granted hereunder is terminated in a particular country,
other than pursuant to Section 10.3 or as a result of Vanda's termination of
this Sublicense Agreement for breach pursuant to Section 10.5, and Novatis
exercises the right to promote, market or sell the Product in such country then
upon Novartis' request (a) Vanda shall grant to Novartis or its designee(s) a
trademark license at a royalty to be negotiated in good faith (which royalty
shall not be less than [*] percent ([*]%) and no more than [*] percent ([*]%) on
Net Sales of the Product by Novartis and/or its designees) at such time to use
such trademark in connection with marketing the Product in such country, subject
to reasonable quality control by Vanda with respect to the Product sold under
this Section 2.5(a), or (b) Novartis or its designee(s) shall select and
register at Novartis' cost a trademark of its own in connection with the
marketing of the Product in such country, provided such Novartis trademark is
not in any way confusingly similar to the Vanda trademark. Novartis shall use
the trademark that

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 9 of 56

<PAGE>

that party acting alone has chosen as a trademark (rather than a Vanda
trademark) in promoting, marketing or selling the Product in any country that is
a member of a free trade union or other economic grouping (e.g., the European
Union, EEA, NAFTA, ASEAN and ANDEAN Pact countries) where Vanda is promoting,
marketing or selling the Product under a Vanda trademark.

2.6 If Vanda notifies Novartis in writing that Vanda (and/or its Affiliate(s))
is not willing or does not have the capability itself or cannot enter into a
Sublicense or other agreement (providing the necessary expertise and resources)
in country(ies) outside those covered by NAFTA and the European Union to:(a)
develop the Compound or Product (as the case may warrant), and (b) manufacture
the Compound and/or market the Product (as the case may warrant) at a
Competitive Industry Standard Level at the date of Product approval in such
country(ies), then Novartis shall have the right to terminate the sublicense
granted by this Sublicense Agreement but only with respect to such country(ies),
unless the parties agree in writing to extend such time frame.

2.7 If the Product is not launched in the United States or a Major Market
Country at a Competitive Industry Standard Level by Vanda, its Affiliate and/or
Sublicensee within [*] after the date of receiving the approvals necessary to
commercialise the Product in the United States or a Major Market Country Vanda
and Novartis shall review the progress of launch efforts, it being understood
that the parties, at the request of a party, may review the progress of launch
efforts prior to the end of such [*] period, and Vanda shall keep Novartis and
HMRI informed on a regular basis of the status of its launch efforts after
receiving the approvals necessary to commercialize the Product in the United
States or a Major Market Country until such time that launch is achieved in the
United States or a Major Market Country. If launch in the United States or a
Major Market Country is not achieved within one (1) year after the date of
receiving the approvals necessary to commercialize the Product in such
country(ies) (circumstances shall not include events of force majeure as defined
in Section 13), or in any event within two (2) years after Product approval then
the sublicense granted by this Sublicense Agreement shall terminate, but only
with respect to the particular country where launch was not achieved within such
one (1) year or two (2) year time frame, as the case may be, unless the parties
agree in writing to extend such time frame (the parties shall discuss in such
event, factors including but not limited to the necessity to obtain approval of
Product for its target indication(s)).

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 10 of 56

<PAGE>

2.8 If an NDA or equivalent ex-U.S. regulatory approval in the European Union
(Marketing Authorization Application via the Centralized Procedure or marketing
approvals for the member countries of the European Union via the mutual
recognition procedure) for the Product not obtained within three (3) years of
Vanda's or its Affiliate's or Sub-licensee's filing of an NDA or such other
equivalent ex-U.S. filing, and such failure is solely due to circumstances
within Vanda's reasonable control, then the parties shall discuss the reasons
and proposed remedies (or such failure in good faith; provided, however, that if
the parties are unable to agree on any such remedies, Novartis shall have the
right to terminate the sublicense granted by this Sublicense Agreement, but only
with respect to the United States or the European Union where such approval was
not obtained, unless the parties agree in writing to extend such time frame. If,
however, Novartis determines that such failure is due to circumstances beyond
the reasonable control of Vanda (including without limitation delays on the part
of the regulatory agencies), the three (3) year period shall be extended to take
into account such circumstances, the duration of any such extension to be
mutually agreed.

2.9 Subject to the provisions of Section 2.9(d), Novartis shall not be obligated
to refund any up front license fees and milestone payments paid by Vanda with
respect to any country(ies) which cease to be included within the Territory, and
in the event that (i) Novartis or its Affiliate(s) or Sub-licensee(s) elects to
commercialise the Product or Compound in such country(ies) and (ii) Vanda, its
Affiliate(s) or Sublicensee(s) has an NDA filing in the United States or an
equivalent filing in the European Union, then in consideration for the use of
any IND, NDA or other governmental approval or associated developmental work
held or owned by Vanda related to the Compound or Product:

(a) At Novartis' request, and subject to Sections 6.3 and 11.5 hereof, Vanda
shall license or otherwise make available under applicable law the benefit of
such approvals or work to Novartis or an Affiliate or Third Party designated by
Novartis (which third party could be HMRI or Titan), who shall thereafter have
the rights to develop, register, manufacture, market and sell the Compound and
Product in such country(ies) utilizing such approvals or work, and Novartis (or
such Affiliate or Third Party) shall pay to Vanda a royalty to be negotiated in
good faith at the time that Novartis exercises such option, on Net Sales of the
Product by Novartis or its designees in such country to equitably recognize the
value added by Vanda to the Compound and/or Product through its development
efforts. Such royalty shall not be greater than [*] percent ([*]%) on net sales
of Product by Novartis or its

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 11 of 56

<PAGE>

designees. Upon expiration of the Patent in such country, only the royalty paid
to Vanda for the use of the Vanda trademark under Section 2.5 shall be paid to
Vanda for so long as such trademark is utilized. If a trademark license has not
been granted to HMRI, Titan or Novartis in such country, no royalty shall be
paid to Vanda upon the expiration of the Patent.

(b) Novartis shall share [*] with Vanda any up front license fees, milestone
payments or other payments such as prepaid royalties received from a Third Party
in connection with the exercise of such option only. If Vanda has not paid to
Novartis the up front license fee and all of the milestone payments provided for
in Sections 3.1(a) through (c), then Vanda's share of the amount shall be
multiplied by a fraction, the numerator of which is equal to the total of the
payments that have been made by Vanda to Novartis under Sections 3.1(a) through
(c), and the denominator of which is equal to the total of the payments that
Vanda otherwise would have been required to pay to Novartis under Sections
3.1(a) through (c) had the sublicense not been terminated.

(c) Notwithstanding anything contained herein to the contrary, Novartis shall
not be required to pay to Vanda a royalty on sales of the Product that, when
added to the royalty payments for a license under the Vanda trademark payable
under Section 2.5, exceeds in the aggregate [*] percent ([*]%).

(d) If the circumstances leading up to the termination of the Sublicense
Agreement pursuant to Section 2.8 are due to any misrepresentations, omissions
(of information owned or controlled by Novartis or its Affiliates; as of the
date hereof) or falsifications with respect to such Know-How, information or
data or fraud by Novartis or its Affiliates, then subject to the following
sentence, Novartis shall repay to Vanda, within ninety-five (95) days of such
termination, that portion of the up front license fee and milestone payments
Novartis had received from Vanda up to the date of such termination. In the
case of misrepresentations, omissions (of information owned or controlled by
HMRI, Titan or their Affiliates as of the date hereof) or falsifications with
respect to such Know-How, information or data or fraud only by HMRI, Titan or
their Affiliates, and a termination of the HMRI Agreement pursuant to Section
2.5 of the HMRI Agreement, Novartis shall be obligated to make the foregoing
repayments to Vanda if, and only if, Titan has repaid the up front license fee
and milestone payments to Novartis under Section 2.9(d) of the Titan Agreement.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 12 of 56

<PAGE>

2.10 In the event that Vanda or a Sublicensee intends to seek a co-promotion or
co-marketing partner for the Product in the United States, Vanda shall notify
Novartis thereof in writing. Novartis shall then notify Titan thereof, and HMRI
shall have a right of first negotiation with Vanda or the Sublicensee on such a
collaboration. If HMRI exercises its right of first negotiation, then HMRI and
Vanda or the Sublicensee shall negotiate in good faith for a period of ninety
(90) days from the date of notification by Novartis to HMRI. If the negotiating
parties are unable to enter into a separate definitive written agreement
regarding such collaboration by the end of such ninety (90) day period, first
Novartis and then Titan will have the right to negotiate with Vanda in good
faith for a single period of ninety (90) days. In the event that Vanda or its
Sublicensee is unable to enter into a separate definitive written agreement
regarding such collaboration by the end of such ninety (90) day period with
Novartis or Titan, Vanda or the Sublicensee shall be free to enter into a
collaboration with any Third Party subject to all other terms of this Sublicense
Agreement and shall have no further obligation to negotiate with HMRI. For the
purposes of this Section 2.10, the term "co-promotion or co-marketing
partner" will not include an independent contract field sales force that may be
engaged by Vanda or a Sublicensee.

3. PAYMENTS AND ROYALTIES.

3.1 As consideration for the sublicenses granted to Vanda by Novartis under this
Sublicense Agreement, Vanda shall make the following payments to Novartis:

(a) An up front license fee of Five Hundred Thousand United States Dollars
(U.S.$500,000) shall be paid by Vanda to Novartis in cash within ten (10)
business days of both parties' execution of this Sublicense Agreement.

(b) A first development milestone payment of [*] be payable by Vanda to Novartis
one time only upon [*] for the Product in the Field [*]. As used in this
Section, [*].

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 13 of 56

<PAGE>

Such milestone payment shall be paid in cash by Vanda directly to Novartis
within seven (7) business days of the date of [*]. The [*] payment provided for
herein shall, unless otherwise expressly provided for herein, be non-refundable.

(c) A second development milestone payment of [*] which shall be payable one
time only by Vanda to Novartis on [*].

(d) Vanda shall notify Novartis in writing thirty (30) business days prior to
Vanda's estimated achievement of each milestone event described in Sections
3.1(b) and 3.1(c)(i) above and Vanda shall make each such payment within seven
(7) business days of the achievement of the milestone event for which such
payment is due.

3.2 (a) Unless Novartis instructs Vanda in writing otherwise, all cash payments
by Vanda to Novartis (including, without limitation, up front payments,
milestone payments, and royalties) shall be made by bank wire transfer as
follows:

Bank: [*]

Swift: [*]

Correspondent Bank for USD: [*]

USD Account Novartis AG, Basel / Switzerland: [*]

USD Account Novartis Pharma AG, Basel / Switzerland: [*]

(b) At least two (2) business days prior to the planned wire transfer to either
of the above accounts, Vanda shall notify Novartis of the amount and date the
cash shall be transferred.

(c) In the event of a late payment hereunder by Vanda to Novartis, Vanda shall
pay to Novartis interest [*] ([*]%) on the outstanding balance until such
balance, including interest, is paid in full to Novartis. The acceptance of such
late

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 14 of 56

<PAGE>

payment shall act as a waiver of any rights Novartis may have hereunder due to a
breach by Vanda relating solely to such payment being made late.

3.3 As consideration for the sublicense granted to Vanda in this Sublicense
Agreement, Vanda shall pay to Novartis, in those countries where, and for the
period, Patents claiming a priority date of May 19, 1989 and December 29, 1989
or Patents owned by Novartis AG in a particular country in the Territory for
which a patent had been granted validly claiming Iloperidone or the manufacture,
formulation or the use thereof for use in the Field:

(a) [*] per cent ([*]%) royalty on annual Net Sales of the Product of Vanda, its
Affiliates' and Sublicensees' annual Net Sales of the Product in the Territory.

(b) Vanda shall also pay to Novartis the following milestone payments:

<TABLE>
<CAPTION>
Net Sales Milestone      Milestone payment from Vanda to Novartis
-------------------      ----------------------------------------
<S>                      <C>
(A) Achievement of [*]                      [*]

(B) [*]                                     [*]

(C) [*]                                     [*]
</TABLE>

No [*] shall be payable by Vanda within one calendar year. In the event that a
[*] becomes due and payable [*]. Milestone (C) shall be payable at the earliest
on [*].

3.4 (a) In order to spread royalty payments hereunder over a sufficient period
of time, in each of those countries in the Territory where the Patents claiming
a priority date of May 19, 1989 and December 29, 1989 or Patents owned by
Novartis AG in a particular country for which a patent had been granted validly
claiming Iloperidone or the manufacture, formulation or use hereof for use in
the Field have expired, Vanda's obligations to pay royalties for use of Patents
in such country shall cease, and Vanda and/or any of its Sublicensees shall pay

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 15 of 56

<PAGE>

directly to HMRI a royalty for Know-How not relating to manufacturing (whether
or not such Know-How continues as a valid intellectual property right or is in
the public domain) of [*] percent ([*]%) on Vanda's, its Affiliates' and any
Sublicensees' annual Net Sales of the Product in each such country for a period
of ten (10) years after the expiration of the final remaining Patent claiming a
priority date of May 19, 1989 and December 29, 1989 or Patents owned by Novartis
AG in each such country. After the end of such ten (10) year period, no further
royalties arising from sales of the Product in such country shall be due to HMRI
and Vanda shall be entitled to continue to use the Know-How on a fully-paid,
irrevocable basis in accordance with Section 10.3.

(b) In the event that a Third Party's generic version of Iloperidone is actively
marketed in a process patent country (that is, any country in which the only
protection in relation to processes for the manufacture of Iloperidone has been
obtained and not protection for Iloperidone as a new chemical entity per se) in
the Territory where a Patent(s) has been granted validly claiming Iloperidone or
the manufacture, formulation or use thereof for use in the Field exists, then
subject to Sections 3.4(c) and (d) below, the royalty rate that Vanda shall pay
to Novartis on Vanda's or its Affiliate's or Sublicensees annual Net Sales of
the Product in that process patent country shall be [*] percent ([*]%) until
such Patent(s) expires, provided; (i) Vanda has obtained, or has made every
effort to obtain, the maximum allowable period of exclusivity to which it is
entitled based on the Product's registration data in that process patent country
to the extent such exclusivity in available; and (ii) The parties in accordance
with Article 8 of this Sublicense Agreement, will implement an appropriate
strategy for addressing the commercialization of Iloperidone by said Third
Party. Unless otherwise agreed to by the parties, Vanda shall at its sole cost
be obligated to diligently enforce the Patent(s) until there is a binding,
unappealable judicial determination as to whether the manufacture, formulation
or use of such generic version of Iloperidone infringes Patent(s) or until it is
demonstrated to the satisfaction of both Parties that such Patent(s) are not
being infringed in such country.

(c) If it is demonstrated to the satisfaction of both Parties or the binding
unappealable judicial determination under Section 3.4(b)(ii) holds that
Patent(s) are not being infringed in such process patent country, the royalty
rate that Vanda shall pay to Novartis on Vanda's or its Affiliate's or
Sublicensee's annual Net Sales of Product in that process patent country shall
continue to be [*] percent ([*]%) until such Patent(s) expires.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 16 of 56

<PAGE>

(d) If the binding, unappealable judicial determination under Section
3.4(b)(ii) holds that Patent(s) are being infringed in such process patent
country, Vanda shall take reasonable steps to have enforced such determination.
If as a result, the commercialization of Iloperidone by the Third Party in that
country is discontinued:

     (i) the royalty rate(s) that Vanda shall pay to Novartis on Vanda's or its
     Affiliate's or Sublicensee's annual Net Sales of the Product in that
     process patent country shall be, commencing on the later of: (A) the date
     such binding, unappealable judicial determination is rendered, and (B) the
     date (if any) specified in such determination that commercialization of
     such Third Party generic version of the Product is to be discontinued,
     those royalty rates provided for in Section 3.3 until such Patent(s)
     expires; and

     (ii) Vanda shall repay to Novartis, within thirty (30) days after the later
     of: (A) the date such binding, unappealable judicial determination was
     rendered, and (B) the date (if any) specified in such determination that
     commercialization of such Third Party generic version of the Product is to
     be discontinued, an amount equal to the difference between the royalties
     that Vanda would have paid to Novartis under Section 3.3, and the amount of
     royalties that Vanda actually paid to Novartis at the [*] percent ([*]%)
     rate, for the period commencing on the date the royalty rate for that
     process patent country was reduced to [*] percent ([*]%) pursuant to
     Section 3.4(b), and ending on the later of: (A) the date such binding,
     unappealable judicial determination was rendered, and (B) the date (if any)
     specified in such determination that commercialization of such Third Party
     generic version of the Product is to be discontinued.

(e) After a Patent(s) in any process patent country expires, Vanda and/or its
Sublicensee shall pay directly to Novartis royalties as provided for in Section
3.4(a).

3.5 As consideration for the sublicense granted to Vanda under this Sublicense
Agreement in those countries in the Territory for which (a) a Patent application
for the Compound or Product is pending or (b) no Patent application has been
filed or (c) Patents have been abandoned or been held invalid or unenforceable
by a decision of a court or tribunal of competent jurisdiction from which no
appeal is or can be taken (collectively, "Non-Patent Countries"), Vanda shall
pay to Novartis, on a country-by-country basis, a [*] percent

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 17 of 56

<PAGE>

([*]%) royalty for Know-How not relating to manufacturing (whether or not such
Know-How continues as a valid intellectual property right or is in the public
domain) on Vanda's, its Affiliates' and any Sublicensees' annual Net Sales of
the Product in the Non-Patent Countries for a period of five (5) years from the
date of the first commercial sale of the Product in each such country by Vanda,
its Affiliates or Sublicensees. After the end of such five (5) year period, no
further royalties arising from the sales of the Product in such country shall be
due. However, with respect to Section 3.5(a) or (b), if at any time during or
after such five (5) year period a Patent for Compound or Product is issued in
such country, subject to Section 3.4, Vanda shall pay to Novartis, from the date
the Patent was issued, the same royalties as provided for in Sections 3.3(a) and
(b) above. Upon expiration of Vanda's obligation to pay a royalty under such
Patent, notwithstanding Section 3.4, a [*] percent ([*]%) royalty for Know-How
not relating to manufacturing (whether or not such Know-How continues as a valid
intellectual property right or is in the public domain), on Net Sales of the
Product in such country, shall be paid by Vanda and/or any of its Sublicensees
directly to HMRI for a period of five (5) years after which Vanda shall be
entitled to continue to use the Know-How on a fully-paid, irrevocable basis in
accordance with Section 10.3.

4. COMPULSORY LICENSES AND THIRD PARTY LICENSES

4.1. (a) in the event that during the term of this Sublicense Agreement a
governmental agency in the Territory grants or compels HMRI and/or Titan and/or
Novartis to grant a license to any Third Party for the Compound or Product in a
country(ies), it is the intent of the parties that Vanda not be placed at a
competitive disadvantage as a result of a lower royalty rate being granted to a
Third Party compulsory licensee. Therefore, in the event that Novartis, Titan or
HMRI is compelled to grant a license to a Third Party, Novartis, Titan and HMRI
will meet to discuss in good faith equitable arrangements, which could include
adjustments to Vanda's original royalty rates in Section 3.3 of this Sublicense
Agreement which are to be paid on Net Sales of Product in such country, to
accomplish the intent of Novartis and Vanda set forth above. In such
discussions, consideration will be given to Novartis' obligations to HMRI and
Titan under Section 4.l (d) of the Titan Agreement.

(b) If a governmental authority in a country in the Territory imposes a maximum
royalty rate, such that lower royalty rates than would otherwise apply under
this Sublicense Agreement are mandated in such country, then the royalty rates
provided for herein shall be reduced to

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 18 of 56

<PAGE>

equal such lower rates for sales of the Product in such country for the period
such lower royalty rate is required by any governmental authority and shall
cease when Vanda's royalty payment obligations cease under this Sublicense
Agreement.

4.2 If, during the term of this Sublicense Agreement, HMRI and Vanda agree that
patent(s) of a Third Party exists in the Territory covering the manufacture, use
or sale of the Compound or Product, and if it should prove, in the reasonable
judgment of Vanda and HMRI, impractical or impossible for Vanda or its
Affiliates or Sublicensees to continue the activity or activities sublicensed
hereunder in the Field without obtaining a royalty-bearing license from such
Third Party under such patent(s) or if Vanda and HMRI otherwise agree it is
desirable for HMRI to acquire any Third Party patent or license in connection
with the development or manufacture of Compound or Product covered by Patents in
the Territory, then in either case the provisions of Section 8.8(c) shall apply.

4.3 If, after attempting in good faith to resolve the issue relating to
licensing Third Party patents in Section 4.2 between themselves, Vanda and HMRI
are unable to agree within ninety (90) days as to whether it is impracticable or
impossible for Vanda, its Affiliates or Sublicensees to continue the activity or
activities sublicensed hereunder without obtaining a royalty-bearing license
from a Third Party, the issue shall be submitted to a disinterested, competent
and experienced patent attorney reasonably acceptable to both Vanda and HMRI for
resolution. If Vanda and HMRI cannot agree on the selection of such patent
attorney, then each party shall select a patent attorney and the selected patent
attorneys shall select a mutually acceptable patent attorney who will determine
whether such Third Party rights materially inhibit Vanda's ability to
manufacture, distribute or sell the Compound or Product. The compensation to,
and expense of such patent attorney shall be borne by the party whose position
is not upheld by such patent attorney (that is, for example, if the patent
attorney determines that such Third Party rights do not materially inhibit
Vanda's ability to manufacture, distribute or sell the Compound or Product, then
the costs of such patent attorney shall be borne by Vanda).

5. DEVELOPMENT

5.1 Upon the signing of this Sublicense Agreement, Vanda shall have full legal
and financial responsibility for all costs that are incurred and all activities
that are undertaken after the

                                  Page 19 of 56

<PAGE>

signing of this Sublicense Agreement, which are related to development, safety
and required periodic reporting to the FDA and equivalent ex-U.S. regulatory
agencies, marketing, regulatory approvals, price registrations, and other
activities required by Vanda or its Sublicensee(s) (or their respective agents
or distributors) to obtain appropriate government approvals for, and to
commercialize, the Compound and Product in the Territory. Other than as
expressly provided for in Section 5.4, Vanda shall not assume, nor shall Vande
be liable for, any costs or activities (whether scientific, financial or
otherwise) relating to the Compound or Product that were incurred or undertaken
prior to the signing of this Sublicense Agreement (including without limitation
any costs, expenses, damages, losses, fines, penalties or the like that may be
awarded or assessed after the signing of this Sublicense Agreement, but which
arise out of events and activities that occurred prior to the signing of this
Sublicense Agreement).

5.2 Provided that the Affiliates, Sublicensees and other Third Parties agree to
substantially the same terms of confidentiality in Section 6.4 hereof, Vanda may
appoint such Affiliates, Sublicensees(s) and other Third Parties to perform any
and all development activities necessary to obtain government approvals for the
Product in the Territory. The appointment of any Sublicensee shall require
HMRI's prior written consent, which consent shall not be unreasonably withheld.

5.3 Vanda shall, in a manner consistent with the effort Vanda devotes to its own
products having the same or similar potential value as Product, exercise its
Commercially Reasonable Efforts and diligence in conducting clinical trials and
commercializing the Product alone or in collaboration with a Third Party, and in
undertaking those investigations and actions required to obtain appropriate
governmental approvals to manufacture the Compound and market the Product in the
Territory. All such activity shall be undertaken at Vanda's expense. Novartis
shall arrange with HMRI to provide assistance or consultation at Vanda's expense
in support of the development of the Compound or Product, but HMRI in its
discretion may limit such assistance and consultation.

5.4 The parties further agree that:

(a) Novartis will be informed by Vanda on a timely and regular basis of the
development, registration and commercialisation of the Compound and Product in
the Territory, and will

                                  Page 20 of 56

<PAGE>

have an opportunity to regularly meet with Vanda and provide input into the
development and registration process, and

(b) all of Novartis' contractual obligations to Third Parties involved in the
development and registration process for the Compound and Product (including
Contract Research Organizations (CROs) existing as of the date of this
Sublicense Agreement, which CROs are identified in APPENDIX E), will be
considered by Vanda to the extent they are not inconsistent with Vanda's
Standard Operating Procedures.

(c) Vanda shall be solely responsible for the negotiation of contracts with any
CROs and other organisations it desires to work on development activities
relating to the Compound and/or Product and Vanda shall bear all legal and
financial responsibility under such contracts.

5.5 Any inventions or discoveries or improvements which arise from Vanda's, its
Affiliates' or Sublicensees work relating to the development and/or manufacture
of the Compound and/or Product shall be owned by Vanda, but shall be licensed to
HMRI, Titan and Novartis at their option on a worldwide, non-exclusive,
perpetual basis, at a license fee and/or royalty to be negotiated at such time.
In the case of any inventions or discoveries or improvements arising in areas
outside of the original field, which was defined in the HMRI Agreement and the
Titan Agreement, shall be owned by Vanda, but shall only be licensed to HMRI, at
HMRI's option on a worldwide, non-exclusive, perpetual basis, at a license fee
and/or royalty to be negotiated at such time. Notwithstanding anything to the
contrary in this Sublicense Agreement, in the event that this Sublicense
Agreement between Novartis Pharma AG and Vanda Pharmaceuticals, Inc. expires or
terminates, in its entirety or with respect to any country, (except as a result
of material breach of the Agreement by Novartis), any inventions or discoveries
or improvements which arise from Vanda's, its Affiliates' or Sublicensees' work
relating to development and/or manufacture of the Compound and/or Product (the
"Vanda IP") shall be disclosed to HMRI and be owned by and become the property
of HMRI (or assignees or successors, as the case may be), but shall be licensed
to Titan under Section 2.1(a) of the HMRI- Agreement and subsequently to
Novartis under the Titan Agreement. Vanda shall promptly undertake any and all
actions necessary to effectuate such ownership in and assignment to HMRI. If the
Vanda Sublicense Agreement expires or terminates with

                                  Page 21 of 56

<PAGE>

respect to a particular country, then the requirements of this Section 5.5 and
Aventis' rights to the Vanda IP shall be limited to such country.

5.6 deleted.

5.7 In addition to that which is required under Section 5.4(a), Vanda shall
provide to Novartis regular written reports at least every six (6) months
setting forth significant developments and improvements, including the status
and progress of the development and/or registration activities, that affect the
Compound or Product.

5.8 Vanda, or its Sublicensees, shall promptly advise Novartis in writing upon
the submission and filing for government regulatory approval to manufacture and
market the Product, and upon the receipt of government regulatory approval to
market the Product, in each case in each country in the Territory, and shall
commence marketing the Product in such country in accordance with Section 5.3.

5.9 Subject to applicable laws and regulations, labeling on all Product sold by
or on behalf of Vanda pursuant to this Sublicense Agreement, and all
advertising, marketing and promotional materials used in connection therewith,
will identify Novartis as the licensor of the Product.

5.10 If at any time during the term hereof a product is developed by Vanda or
any of its Affiliates or Sublicensees, which product contains the Compound and
one or more other pharmaceutically active ingredients for use in the Field (a
"Combination Product"), Novartis shall negotiate in good faith with Titan an
amendment to the Titan Agreement, which amendment will provide, inter alia for
how royalties to be paid by Novartis to Titan for Net Sales of such Combination
Product will be calculated and for how long such royalties shall be paid. After
such amendment to the Titan Agreement has been executed by Novartis and Titan,
this Sublicense Agreement shall be similarly amended by Novartis and Vanda to
provide for such Combination Product.

6. EXCHANGE OF INFORMATION AND CONFIDENTIALITY.

6.1 Upon the signing of this Sublicense Agreement, Novartis shall deliver to
Vanda, all available Know-How, documents, information and data which is owned
or controlled by Novartis and its Affiliates, which may be reasonably expected
to assist Vanda in developing, registering, manufacturing and marketing the
Compound and Product in the Territory. After the execution of this Sublicense
Agreement, there shall be a sixty (60) day transition period

                                  Page 22 of 56

<PAGE>

during which Novartis shall provide, at its own cost, reasonable resources,
expertise, and documents to effectively transfer the Know-How and development
activity to Vanda. Banked DNA samples and or animal tissues treated with the
compound will only be made available to Vanda for further studies in accordance
with the protocols and informed consents set forth at the time of sample
acquisition provided however that no human tissue samples with identifiable
patient data will be transferred to Vanda. All raw data and individual clinical
and genetic data will be transferred to Vanda under a mutually agreed coding
schema, in order to protect patient confidentiality. All original identifiable
patient data will, however be provided to the FDA as part of the submission
package. If Vanda requires additional genotyping on existing samples, Novartis
will contract this work out, in accordance with the informed consents, on
Vanda's behalf and at Vanda's cost. If further DNA samples from past study
patients are desired, Vanda will revisit the sites and try to consent or
reconsent these patients for additional DNA sampling. Upon Novartis' receipt of
the up front license fee referred to in Section 3.1(a) hereof, Vanda and
Novartis each shall promptly provide written notification to the FDA that
Novartis assigns and that Vanda assumes sponsorship of the U.S. IND No. 36,827
(as specified in 21 CFR 314.72). Within ten (10) days after the date of such
written notification, Novartis shall transfer the U.S. IND for the Compound or
Product to Vanda. Until such transfer is made, Vanda shall have the right to
make reference to such Compound or Product owned or controlled by Novartis or
its Affiliates. Furthermore, upon Novartis' receipt of the upfront license fee
referred to in Section 3.1(a), Novartis shall arrange for the transfer to Vanda
of Canadian IND Control No. 27740.

6.2 Vanda shall have Exclusive use, subject to the terms of this Sublicense
Agreement and in particular Section 2.3, of all Know-How, documents,
information, data and material for the development, registration, manufacture
and marketing of the Compound and the Product for use in the Field in the
Territory. Novartis and its respective Affiliates shall keep confidential all
Know-How, documents, information and data in their possession or received from
or generated by or on behalf of Vanda that is not already in the public domain
relating to the Compound and Product regarding the use in the Field with the
same level of care that Novartis and its respective Affiliates use for their own
confidential information. Upon Novartis' request during the term of this
Sublicense Agreement, Vanda shall deliver to Novartis a copy of all such
information and data in a form to be mutually agreed upon, within thirty (30)
days after Novartis' request, it being understood and agreed that any and all
such information and data will be made available by Novartis to Titan, upon
Titan's request.

6.3 Subject to the confidentiality obligations of this Article 6, Vanda shall
make available and HMRI, Titan and Novartis shall be able to freely use Know-How
and documents, information and data relating to the Compound and/or Product
disclosed or generated by Vanda, its Affiliates and Sublicensees and
applications for government approvals (United States or

                                  Page 23 of 56

<PAGE>

European Union or Japan), reports on the status and progress of the development
of the Compound or the Product and the like in any country(ies) deleted from the
Territory and to which this Sublicense Agreement has been terminated pursuant to
the terms hereof.

6.4 During the period of time during which Vanda is obligated to pay royalties
hereunder, irrespective of any termination with respect to a particular country
or countries in the Territory, Vanda shall not reveal or disclose to a Third
Party or use for any purpose other than to perform its obligations herein any
Confidential Information (as defined below) without first obtaining the written
consent of Novartis, except as may be otherwise provided herein, or for securing
essential or desirable authorizations, privileges, licenses, registration or
rights from governmental agencies, or is required to be disclosed to a
governmental agency or is necessary to file or prosecute Patent applications
concerning the Compound or Product or to carry out any litigation concerning the
Compound or Product provided, however, that Vanda notifies Novartis in writing
in a reasonably sufficient time frame prior to making such disclosure that Vanda
intends to make such disclosures and the details thereof, and Vanda seeks
confidential treatment where available of such Confidential Information from
such governmental agencies. This confidentiality obligation shall not apply to
such information which is or becomes a matter or public knowledge through no
fault of Novartis, or is already in the possession of Novartis as evidenced by
written records, or is disclosed to Vanda by a Third Party having the right to
do so, or is subsequently and independently developed by employees of Novartis
or its Affiliates who had no knowledge of the Confidential Information. Vanda
shall take reasonable measures to assure that no unauthorised use or disclosure
is made by others to whore access to such information is granted. As used
herein, "Confidential Information" means, any confidential or proprietary
information of HMRI, Titan or Novartis or their Affiliates, including any
present or future formulas, research project, work in process, inventions,
procedures, development, scientific, engineering, manufacturing, marketing,
business or financial plan or records, products, sales, suppliers, customers, or
investors, whether such confidential or proprietary information is in oral,
written, graphic or electronic form (including all copies in whole or in part of
any of the foregoing) and which derives value from being known to the disclosure
or owner.

6.5 After transfer of the United States and Canadian INDs to Vanda under Section
6.1, Novartis and Vanda shall co-operate with respect to the exchange of adverse
event and safety information associated with Compound and Product, and such
information shall be coordinated by Vanda central clinical, safety and
epidemiology organisation. Details of the obligations of the parties with
respect to reporting such information to each other, and processing of this data
shall be covered in an addendum following execution of this Sublicense
Agreement.

                                  Page 24 of 56

<PAGE>

6.6 Nothing herein shall be construed as preventing Vanda from disclosing any
information received from Novartis to an Affiliate, Sublicensee, distributor,
contractor, agent, consultant, legal counselor other Third Party involved in the
development, manufacture, marketing, promotion or sale of the Compound or
Product, provided that such Affiliate or Sublicensee or other Third Party has
undertaken a similar obligation of confidentiality with respect to the
Confidential Information.

6.7 In the event that a court or other legal or administrative tribunal,
directly or through an appointed master, trustee or receiver, assumes partial or
complete control over the assets of Vanda based on the insolvency or bankruptcy
of Vanda, Vanda shall promptly notify the court or other tribunal (i) that
Confidential Information received from Novartis remains the property of HMRI,
Titan or Novartis, or their respective Affiliates, as the case may be, and (ii)
of the confidentiality obligations under this Sublicense Agreement. In addition,
Vanda shall, to the extent permitted by law, take all steps reasonably necessary
or desirable to maintain the confidentiality of the Confidential Information of
HMRI, Titan or Novartis, as the case may be, and to ensure that the court, other
tribunal or appointee maintains such information in confidence in accordance
with the terms of this Sublicense Agreement.

6.8 No public announcement or other disclosure to a Third Party concerning the
existence of or terms of this Sublicense Agreement shall be made, either
directly or indirectly by either party to this Sublicense Agreement, except as
may be legally required, without first obtaining the approval of the other
party, which approval shall not be unreasonably withheld, and shall be given
within a reasonable time. The party desiring to make any such public
announcement or other disclosure shall provide the other party with a written
copy of the proposed announcement or disclosure in sufficient time prior to the
proposed public release, to allow such other party to comment upon the nature,
content and timing of such announcement or disclosure, prior to the proposed
public release. Notwithstanding the foregoing, Vanda shall be permitted to refer
to this Sublicense Agreement in presentation to prospective investors.

6.9 Neither party shall submit for written or oral publication any manuscript,
abstract or the like which includes Know-How, data or other information
generated and/or provided by Novartis or Vanda pursuant to this Sublicense
Agreement without first obtaining the prior written consent of the party
generating or providing such information, which consent shall not be
unreasonably withheld. The contribution of each party shall be noted in all
publications or presentations by acknowledgment or co-authorship, whichever is
appropriate.

7. NOVARTIS SUPPLY OF COMPOUND AND PRODUCT TO VANDA.

7.1 Novartis shall supply Compound and Product to Vanda under the following
conditions:

                                  Page 25 of 56

<PAGE>

(a) Within sixty (60) days after the Effective Date of this Sublicense Agreement
as agreed to by the parties in good faith, Novartis will, at Vanda's cost,
arrange for the transfer to Vanda, to a single site to be designated by Vanda,
all quantities of milled Compound available to it as of the Effective Date of
this Sublicense Agreement.

(b) Title to, and risk of loss with respect to, all Compound and the Product
supplied by Novartis to Vanda under this Section 7.1 shall pass to Vanda upon
the receipt of such Compound and Product by Vanda or its designee at its point
of delivery. Novartis shall not be liable for any loss of such Compound and/or
Product except where such loss is the result of Novartis negligence or willful
misconduct.

(c) Novartis shall provide to Vanda the most recent certificate of analysis for
any shipment of Compound or Product.

(d) Novartis makes no representation or warranty that Compound and Product
supplied by it to Vanda for clinical trials will conform to the IND
specifications therefore as well as all laws and regulatory requirements,
including current Good Manufacturing Practices applicable to the Compound and
Product when used in clinical trials in accordance with the IND.

7.2 Novartis shall provide information and assistance to Vanda with respect to
the Compound and Product as follows:

(a) Within sixty (60) days after the full execution and delivery of this
Sublicense Agreement, Novartis shall deliver to Vanda any and all Know-How,
documentation, data and other information owned or controlled by Novartis and
its Affiliates, that Vanda may reasonably require for the manufacture of the
Compound and Product. Such information shall include without limitation the
specifications for the Compound and Product and methods of analysis for testing
the Compound and Product, as currently described within the IND regulatory
documentation, including Chemistry-Manufacturing/Controls (CMC) information
amendments and the technology transfer file.

(b) Novartis shall make reasonable commercial efforts to arrange for HMRI to
provide to Vanda or its designated Third Party assistance for the transfer of
manufacturing technology, through documentation, consultation and face-to-face
meetings, to enable Vanda or such Third Party to proceed with development of
commercial-scale manufacturing. If requested by Vanda or such Third Party,
Novartis shall visit the designated commercial manufacturing facility, with the
limitation of three (3) visits, not to exceed a total of ten (10) business days,

                                  Page 26 of 56

<PAGE>

for which Vanda shall bear all the costs of reasonable travel and other
out-of-pocket expenses.

7.3 Novartis represents and warrants that the specifications for the Compound
and Product are consistent with those set out in the INDs sponsored by Novartis.

7.4 Upon expiration or termination of this agreement, Vanda shall return to
Novartis, all unused Compound or Product supplied by Novartis hereunder.

8. PATENT PROSECUTION; MAINTENANCE AND EXTENSION; INFRINGEMENT

8.1 HMRI shall be responsible for the filing, prosecution (including
oppositions) and maintenance of the Patents excluding Novartis Patents
(hereinafter "HMRI-Patents") at HMRI's expense. For so long as the-license
grants set forth in Article 2 remain in effect, HMRI agrees to file and
prosecute and maintain the HMRI-Patents in the Territory, provided that the
foregoing is subject to HMRI's reasonable business judgment. Novartis shall keep
Vanda informed, to the same extent HMRI and/or Titan keep Novartis informed, of
important issues relating to the preparation, filing, prosecution and
maintenance of such HMRI-Patent applications and HMRI-Patents. Vanda, through
Novartis, shall have the right to comment on HMRI's preparation, filing,
prosecution and maintenance of HMRI-Patent applications and HMRI-Patents, and
HMRI shall give due consideration to Vanda's comments, but HMRI shall make all
decisions regarding the same.

8.2 If HMRI elects not to seek patent protection in countries listed in APPENDIX
F or to maintain patent protection on HMRI-Patents listed in APPENDIX A in any
country in the Territory to the extent that HMRI-Patents claim the Compound or
the Product (or formulations, use or manufacture thereof), Vanda shall have the
right, at its option and at HMRI's expense, which expense must be approved in
advance by HMRI (approval which shall not be unreasonably withheld), to file,
prosecute (including oppositions) and maintain any such HMRI-Patent applications
and HMRI-Patents in HMRI's name, and any HMRI-Patent issued therefrom shall be
owned by HMRI. Novartis shall advise Vanda of HMRI's decision) not to seek or
maintain patent protection in a reasonably timely manner. In the event that a
HMRI-Patent is issued covering the Compound or Product in any country in
Territory under the conditions of this Section 8.2, Vanda shall pay directly to
HMRI a [*] percent ([*]%) royalty on Net Sales of Product in such country, for a
period of five (5) years from the date of such patent issuance in such country,
in recognition of HMRI's Know-How and manufacturing rights and the right to make
and sell the Compound or Product in such

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 27 of 56

<PAGE>

country. Legal fees and expenses, as confirmed by HMRI, incurred by Vanda shall
be deducted from the royalty paid to HMRI.

8.3 Vanda shall be responsible for the filing, prosecution (including
oppositions) and maintenance of the Patents owned by Novartis (hereinafter
"Novartis-Patents") at Vanda's expense. Vanda agrees to file and prosecute and
maintain the Novartis-Patents in the Territory, provided that the foregoing is
subject to Vanda's reasonable business judgment. Novartis, shall have the right
to comment on Vanda's preparation, filing, prosecution and maintenance
of Novartis-Patent applications and Novartis-Patents, and Vanda shall give due
consideration to Novartis' comments. If Vanda elects not to maintain patent
protection on Novartis-Patents in any country, Novartis shall have the right, at
its option, to file, prosecute and maintain any such Novartis-Patent. Vanda
shall have the right but not the obligation to enforce Novartis-Patents against
Third Parties at its cost, and if Vanda does not act, Novartis may in its sole
discretion take such enforcement action as Novartis deems necessary.

8.4 Each of HMRI, Titan, Novartis and Vanda shall make available to the other,
its employees, agents, subcontractors or consultants (including its authorized
attorneys) to the extent reasonably necessary or appropriate to enable the
appropriate party to file, prosecute and maintain patent applications and
resulting patents subject to this Sublicense Agreement to the extent that
Patents claim the Compound or Product (or formulations, use or manufacture
thereof). Where appropriate, each of HMRI, Titan, Novartis and Vanda shall sign
or cause to have signed all documents relating to said patent applications or
patents at no charge to the other.

8.5 Novartis shall obtain all assignments or licenses, as applicable from the
patent holder of the Patents, to the same extent as Novartis is entitled to
receive such assignments or licenses from HMRI and Titan under the HMRI
Agreement as applicable, to provide Vanda with the same degree of exclusivity in
the Territory under the Patents as Novartis is granted by HMRI and Titan under
the Titan Agreement.

8.6 Promptly after it is notified by HMRI and Titan, Novartis shall notify
Vanda in writing of (a) the issuance of each HMRI-Patent, giving the date of
issue and patent number for each patent, and (b) each notice pertaining to any
HMRI-Patent which HMRI receives as patent owner pursuant to the Drug Price
Competition and Patent Term Restoration Act of 1984, or other similar laws now
or hereafter in effect which extend the Patent life, or pursuant to comparable
laws or regulations in other countries in the Territory. At HMRI's expense,
HMRI, Titan, Novartis and Vanda shall co-operate with each other in applying for
patent term extensions (including Supplementary Protection Certificates in
European Union member states) where applicable in any country of the Territory.
HMRI shall have full

                                  Page 28 of 56

<PAGE>

responsibility and authority in the decisions regarding filing for the foregoing
HMRI-Patent extensions at its own expense although Vanda, through Novartis,
shall be consulted and its opinions given due consideration in such
decision-making process. If HMRI elects not to pursue extension of any
HMRI-Patents, Vanda shall have the right (but not the obligation) to apply for
such extension in HMRI's name and at Vanda's expense, and HMRI shall reasonably
co-operate in the filing and procurement thereof.

8.7 Except as otherwise expressly provided in this Sublicense Agreement, under
no circumstances shall a party hereto, as a result of this Sublicense Agreement,
obtain any ownership interest in or other right to any technology, Know-How,
Patents, pending Patent applications, products, or biological material of the
other party, Titan or HMRI, including items owned, controlled, discovered,
invented or developed by the other party, Titan or HMRI, or transferred by the
other party, Titan or HMRI to that party, at anytime pursuant to this Sublicense
Agreement which is not a direct result of the study, Know-How and
experimentation of the Compound and Product.

8.8 Each of Vanda, Novartis, Titan and HMRI shall promptly, but in any event no
later than ten (10) business days after receipt of notice of such action, notify
the other in writing of any Patent nullity actions, any declaratory judgment
actions or any alleged or threatened infringement of Patents or misappropriation
of intellectual property comprising Patents, or if Vanda, HMRI, Titan or
Novartis, or any of their respective Affiliates or Sublicensees, shall be
individually named as a defendant in a legal proceeding by a Third Party
alleging infringement of a patent or other intellectual property right of such
Third Party as a result of the manufacture, production, use, development,
marketing, selling or distribution of the Compound or Product, or of any
information or notification regarding the Patents.

8.9 HMRI shall have the first right to respond to, defend or prosecute any
actions, challenges, infringements, misappropriations or proceedings by a Third
Party alleging infringement described in Section 8.8. In the event HMRI elects
to do so, Vanda will co-operate with HMRI and its legal counsel, join in such
suits as may be brought by HMRI, and be available at HMRI's reasonable request
to be an expert witness or otherwise to assist in such proceedings and at
HMRI's expense. HMRI will co-operate with Vanda and its legal counsel and keep
Vanda and its counsel reasonably informed at all times as to the status of
HMRI's response or defense.

8.10 In the event that HMRI elects to respond to, defend or prosecute any
actions, challenges, infringements, misappropriations or proceedings by a Third
Party claiming infringement described in Section 8.8 hereof, then: (a) legal
fees and other costs and expenses of HMRI associated with such response or
defense shall be paid by HMRI; (b) legal fees and other

                                  Page 29 of 56

<PAGE>

costs and expenses associated with such response or defense incurred by Vanda at
HMRI's request, shall be paid by HMRI; (c) the costs of acquiring Third Party
patents or licenses and any settlement, court award, judgment or other damages
shall be paid by HMRI to such Third Parties out of royalties projected to be
received from Vanda (through Titan or Novartis); provided, however, HMRI shall
not be obligated to pay for any patents or licenses for uses of the Compound or
Products not disclosed in the Patents as of the date of the execution of the
HMRI Agreement; and (d) any amounts recovered from Third Parties in connection
with such response or defense shall be applied [*] percent ([*]%) to Vanda
(through Titan and Novartis), and [*] percent ([*]%) to HMRI, subject first to
reimbursement of expenses of HMRI, Novartis, Vanda and Titan.

8.11 In the event that HMRI elects not to respond to, defend or prosecute any
actions, challenges, infringements, misappropriations or proceedings by a Third
Party alleging infringement described in Section. 8.8 hereof or HMRI abandons
any such action, Novartis shall notify Vanda promptly after receiving
notification from HMRI or Titan of such actions, challenges, infringements,
misappropriations, proceeding or HMRI's decision to abandon any such action. In
such event, Vanda shall have the option to respond, defend or prosecute such
action at Vanda' sole cost, provided that HMRI shall co-operate with and provide
assistance to Vanda at HMRI's expense. All amounts recovered from any Third
Party shall be applied [*] percent ([*]%) to Vanda and [*] percent ([*]%) to
HMRI, subject first to reimbursement of expenses of HMRI, Vanda, Novartis and
Titan.

8.12 In the event that HMRI and Vanda mutually agree that it is desirable for
HMRI to acquire any Third Party patent or license in connection with the
development or manufacture of the Compound or Product covered by the
HMRI-Patents in the Territory then the costs of acquiring such Third Party
patent or license shall be paid by HMRI to such Third Parties out of royalties
received from Vanda (either directly or through Titan and Novartis).

8.13 Vanda recognises that HMRI has reserved certain rights in the HMRI-Patents
set forth in APPENDIX A and that there may be a legitimate dispute between the
parties whether a legal action should be brought against a Third Party which
could affect HMRI's reserved rights under those HMRI-Patents and Vanda's
sublicense rights under this Sublicense Agreement. In the event that there is a
dispute between Vanda and HMRI regarding whether there is an infringement of
HMRI-Patents by a Third Party and therefore whether a legal action should be
initiated, Vanda and HMRI shall submit the issue to a disinterested, competent
and experienced patent attorney reasonably acceptable to Vanda and HMRI to
determine whether or not there is an infringement and legal actions should be
taken. If Vanda and HMRI cannot agree on the selection of such a patent
attorney, then Vanda and HMRI shall each select a patent attorney and those
selected patent attorneys shall select a mutually acceptable patent

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 30 of 56

<PAGE>

attorney. That selected patent attorney shall determine whether or not there is
an infringement and legal action should be taken and then Vanda and HMRI may
decide whether or not to initiate a legal action as described by this Article 8.
The compensation to, and expenses of, such patent attorney shall be borne by the
losing party.

9. STATEMENTS AND REMITTANCES.

9.1 Vanda shall keep, and require its Affiliates and Sublicensees to keep
complete and accurate records of all Net Sales of the Product under the
sublicenses granted herein. HMRI and Novartis shall have the right, at their
expense, through a certified public accountant or like independent person
reasonably acceptable to Vanda, and following reasonable notice, to examine such
records under conditions of confidentiality during regular business hours during
the period of time during which royalties are due and payable hereunder and for
[*] thereafter; provided, however, that such examination shall not take place
more often than once a year and shall not cover such records for more than the
preceding [*]; and provided further, that such accountant shall report to
Novartis only as to the accuracy of the Net Sales computation and royalty
statements and payments. It is agreed that if this Sublicense Agreement is
terminated with respect to a particular country(ies), then Novartis' examination
rights shall continue with respect to sales of the Product in such country(ies)
only for a period of [*] after the termination of sublicense rights in that
country. Copies of all such accountant's reports shall be supplied to Vanda.

9.2 Within forty-five (45) days after the close of each calendar quarter, Vanda
shall deliver to Novartis a true accounting of all Product sold by Vanda, its
Affiliates and Sublicensees during such quarter and shall at the same time pay
all earned royalties due. Such accounting shall show Net Sales of Product on a
country-by-country and product-by-product basis and such other particulars as
are reasonably necessary for accounting of the royalties payable hereunder.

9.3 Any tax paid or required to be withheld by Vanda on account of royalties
payable by Vanda under this Sublicense Agreement shall be indicated on the
accounting described in Section 9.2 hereof and deducted from the amount of
royalties otherwise due. Vanda shall secure and send to Novartis or HMRI, as the
case may be, proof of any such taxes withheld and paid by Vanda. Any withholding
or other tax arising on or following permitted assignment of this Sublicense
Agreement by Vanda or a Sublicensee shall be for the account of and paid by
Vanda.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 31 of 56

<PAGE>

9.4 Unless otherwise indicated herein, and subject to foreign exchange
regulations then prevailing, to the extent free conversion from local currency
to United States dollars is permitted, all payments and royalties payable under
this Sublicense Agreement shall be paid in cash in U.S. dollars by wire transfer
in accordance with Section 3.2 hereof. If governmental regulations prevent
remittances from a foreign country with respect to sales made in that country,
the obligation of Vanda to pay royalties on sales in that country shall be
suspended until such remittances are possible, but such royalties shall accrue
as accounts payable by Vanda to Novartis or HMRI, as the case may be. Novartis
or HMRI, as the case may be, shall have the right, upon giving written notice to
Vanda, to receive payment in that country in local currency.

9.5 Royalty payments and Net Sales shall be calculated on the basis of Vanda's
quarterly standard account of internal sales which represents the conversion of
all local currency sales for a calendar quarter into Swiss francs at the average
exchange rate: (as routinely derived via Vanda's' standard methodology) for such
calendar quarter in which the sales are recorded. The exchange rate between the
Swiss franc and the U.S. dollar for the quarterly royalty payments to Novartis
or HMRI (as the case may be) shall be the exchange rates published in the
Foreign Exchange column of The Wall Street Journal, New York edition, or other
qualified source mutually acceptable to the parties on the last business day of
the calendar quarter for which the royalties are being paid. Notwithstanding the
foregoing, if there is a difference between any amount that Vanda pays to
Novartis or HMRI (as the case may be) under Sections 3.3, 3.4 or 3.5, and the
amount that Novartis is required to pay to Titan under the Titan Agreement
(which difference arises as a result of using the method for calculating
royalties that are due and payable under this Section 9.5, and the method for
calculating such royalties under Section 9.5 of the Titan Agreement), the
shortfall or excess (as the case may be) in royalty payments made by Vanda under
this Section 9.5 shall be paid by Vanda to HMRI or Novartis (as the case may be)
in the case of a shortfall, and by Novartis to Vanda in the case of an excess
payment by Vanda to Novartis under Section 3.3 or 3.5.

10. TERM AND TERMINATION

10.1 (a) Vanda will have the right to terminate the sublicense for the Territory
or on a country-by-country basis for major problems associated with the Product
as reasonably determined by Vanda. For this purpose "major problems" are ones
which would substantially negatively impact the Product's chances for successful
development, registration and/or commercialization in the Territory or such
country, as applicable; and would include, but not be limited to, major safety
issues, lack of efficacy, unacceptable pharmaceutical properties or
extraordinary unforeseen competitive developments which, in each case, would
have the substantial negative impact referred to above.

                                  Page 32 of 56

<PAGE>

(b) In the event of termination in the entire Territory by Vanda pursuant to
this Section 10.1, Vanda shall, within thirty (30) days of such termination,
return to Novartis any and all information and data (including new information
and data) relating to the Compound and Product, whether generated by or on
behalf of Titan, Novartis, HMRI or Vanda, and make no further use thereof.
Additionally, in such event, this Sublicense Agreement shall terminate in its
entirety and the sublicense granted hereunder shall revert back to Novartis.
Novartis shall retain all up front license fees and milestone payments it had
received up to the date of termination if, and only if, termination was not due
to any fraud, misrepresentations, omissions or falsifications of information
with respect to such Know-How, information or data owned or controlled by HMRI,
Titan, Novartis or their Affiliates as of the date hereof in which case, to the
extent that Novartis has for its own part perpetrated a fraud,
misrepresentation, omission or falsification of information with respect to such
Know-How, information or data owned or controlled by it, Novartis shall repay to
Vanda, within ninety-five (95) days of such termination, that portion of the up
front license fee and milestone payments Novartis had received from Vanda up to
the date of such termination. In no event shall Novartis be liable to Vanda for
any misrepresentation, omission or falsification of information owned or
controlled by HMRI or Titan or their Affiliates.

(c) Novartis may terminate this Sublicense Agreement by giving Vanda three
months prior written notice in the event that the time period elapsing between
patient dosing in clinical trials is greater than eighteen (18) months or more
than twelve (12) months elapses between the grant of first marketing
authorization in the United States or a Major Market Country and the commercial
launch of the Product in that country.

10.2 In the event the development of the Compound and Product is terminated
altogether by Vanda on or before January 1, 2006, for reasons other than those
described in Section 10.1, then this Sublicense Agreement shall terminate in its
entirety and the sublicense granted hereunder shall revert back to Novartis.
Novartis shall retain all up front license fees it had received up to the date
of termination and Vanda shall also pay a [*] penalty payment to Novartis if,
and only if, termination was not due to any fraud, misrepresentations, omissions
or falsifications (of information owned or controlled by HMRI, Titan, Novartis
or their Affiliates with respect to Know-How, information or data).

10.3 Unless otherwise terminated, this Sublicense Agreement shall expire on a
country-by-country basis upon the expiration of Vanda's obligation to pay
royalties under this Sublicense Agreement in each such country. Expiration of
this Sublicense Agreement under this provision shall not preclude Vanda, its
Affiliates and Sublicensees from continuing directly

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 33 of 56

<PAGE>

or indirectly to manufacture the Compound and market and sell Product and to use
Know-How without further royalty payments.

10.4 In the event there is a change in the control of Vanda, Vanda shall give
Novartis thirty (30) days written notice of such event and that the development
and commercialisation of COMPOUND and PRODUCT will continue per the terms of
this Sublicense Agreement.

10.5 (a) If either party materially defaults in its performance of this
Sublicense Agreement and if such default is not corrected or if the party in
default is not exercising reasonably diligent efforts to cure such default
within ninety (90) days after receiving written notice from the other party with
respect to such default, or if such default is not correctable within ninety
(90) days then such other party shall have the right to terminate this
Sublicense Agreement at the end of such period in its entirety by giving written
notice to the party in default. In the event Vanda. materially defaults in its
performance under this Sublicense Agreement with respect to a particular
country, then, subject to Section 11.4 hereof, Novartis' right to terminate
shall be limited to termination of the sublicense granted hereunder in such
country only.

(b) if Novartis materially defaults in its performance of the Sublicense
Agreement, then Vanda shall have the right but not the obligation to correct or
cure such default in the place of Novartis at Vanda's' own cost and expense
within the ninety (90) day period provided for in Section 10.5 of the Titan
Agreement without prejudice to any other rights Vanda may have under this
Sublicense Agreement (including the right to recover amounts paid to Novartis),
provided that (i) Vanda notifies Novartis in writing of Vanda's election to do
so, and (ii) Vanda's correction or cure of such default does not increase
Novartis' liability under the Sublicense Agreement.

(c) It is agreed that a material default by Novartis under the Titan Agreement
shall be a material default by Novartis under this Sublicense Agreement.

10.6 Subject to applicable bankruptcy laws; either party may terminate this
Sublicense Agreement if, at any time, the other party shall file in any court
pursuant to any statute of the United States or of any individual state or
foreign country, a voluntary petition in bankruptcy or insolvency or for
reorganisation in bankruptcy or for an arrangement or the appointment of a
receiver or trustee of the party or of its assets, or if the other party shall
be served with an involuntary petition against it, filed in any insolvency
proceeding, and such petition shall not be dismissed within ninety (90) days
after the filing thereof, or if the other party shall propose or be a party to
any dissolution, or if the other party shall make an assignment for the benefit
of creditors.

                                  Page 34 of 56

<PAGE>

(a) Without limitation, Vanda's rights under this Sublicense Agreement shall
include those rights afforded by 11 U.S.C. Section 365(n) of the United States
Bankruptcy Code and any successor thereto (the "Code"). If the bankruptcy
trustee of Novartis as a debtor or debtor-in-possession rejects this Sublicense
Agreement under 11 U.S.C. Section 365(n) of the Code, Vanda may elect to retain
its rights sublicensed from Novartis hereunder (and any other supplementary
agreements hereto) for the duration of this Sublicense Agreement and avail
itself of all rights and remedies to the full extent contemplated by this
Sublicense Agreement and 11 U.S.C. Section 365(n) of the Code, and any other
relevant sections of the Code and other relevant non-bankruptcy law.

11. RIGHTS AND DUTIES UPON TERMINATION.

11.1 Upon termination of this Sublicense Agreement (other than for Novartis'
breach), Novartis shall have the right to retain any suns already paid by Vanda
hereunder, and Vanda shall pay all sums accrued hereunder which are then due
except as otherwise defined in this Sublicense Agreement.

11.2 Upon early termination of this Sublicense Agreement in its entirety or with
respect to any country, under Sections 10.1 or 11.6 or due to a breach hereof by
Vanda, Vanda shall notify Novartis of the amount of Product that Vanda, its
Affiliates and Sublicensees then have on hand for sale in each country, the sale
of which would, but for the termination, be subject to royalty, and Vanda, its
Affiliates and Sublicensees shall thereupon be permitted to sell that amount of
Product, provided that Vanda shall pay the royalty thereon to Novartis, or HMRI,
as the case may be, at the time provided for.

11.3 Expiration or termination of this Sublicense Agreement or termination on a
country-by-country basis shall terminate all outstanding obligations and
liabilities between the parties arising from this Sublicense Agreement except
those described in Sections 6.2 (with sole respect to Novartis confidentiality)
6.3, 6.4, 6.5, 6.6, 6.8, 9.1, 9.2, 10.1, 10.2, 10.3, 11.1, 11.2, 11.4, 11.5,
11.6, 12.5, 12.6, 12.7, 14.1 and 14.2, which sections shall survive such
termination. In addition, any other provision required to interpret and enforce
the parties' rights and obligations under this Sublicense Agreement shall also
survive, but only to the extent required for the full observation and
performance of the surviving obligations under this Sublicense Agreement.

11.4 Except as otherwise specifically provided for herein, termination, in whole
or in part, of the Sublicense Agreement in accordance with the provisions hereof
shall not limit remedies to the parties which may be otherwise available in law
or equity, including consequential,

                                  Page 35 of 56

<PAGE>

incidental or indirect damages (such as loss of sales, profits, or goodwill)
arising out of a party's performance or nonperformance under this Sublicense
Agreement.

11.5 Subject to Section 11.2 and other express provisions hereof, upon early
termination of this Sublicense Agreement in its entirety due to breach hereof by
Vanda or pursuant to Sections 10.1, 10.2 or 11.6, Vanda's rights in the Compound
and Product shall cease, Vanda, its Affiliates and Sublicensees shall cease
manufacture, development, marketing and sale of the Compound and Product in the
Territory, and all originals and copies of Know-How, data, results and other
information collected and/or generated by Vanda, its Affiliates and Sublicensees
relating to the Compound or Product prior to termination shall be delivered to
Novartis within thirty (30) days thereafter, except for one copy thereof which
may be retained in Vanda's legal or other appropriately restricted files solely
for the purpose of establishing the extent of its obligations hereunder. Any IND
or other regulatory filing effected prior to termination shall be assigned by
Vanda to Novartis (or its designee(s), which designee may be HMRI or Titan), at
Novartis' request and expense, if not already assigned to Novartis. Vanda shall
provide to Novartis, within thirty (30) days of Novartis' request, copies of all
regulatory correspondence, including, but not limited to, IND Information
Amendments, IND Reports, IND Safety Reports, NDA submission, NDA Postmarketing
Reports, and reports of written/phone contacts to and from regulatory agencies,
as well as the safety database for the Product.

11.6 If (a) Vanda is precluded from selling the Product in a particular country
in the Territory by virtue of infringement of Third Party patent rights, or (b)
there is a holding of invalidity or unenforceability of any Patent, from which
no further appeal can be taken, that materially affects Vanda's ability to
commercialise the Product in a particular country in the Territory, Vanda shall
have the right but not the obligation to terminate this Sublicense Agreement in
such country. At Vanda's option, this Sublicense Agreement may be terminated in
its entirety if the events described in subsection (a) or (b) of this Section
11.6 occur in either the United States or two of the Major Market Countries.
Within ninety-five (95) days of any such termination, subject to the following
sentence, Novartis shall repay to Vanda if the Sublicense Agreement has been
terminated in its entirety, that portion of the up front license fee and
milestone payments it has received from Vanda up to the date of termination. In
the event that the Sublicense Agreement is terminated pursuant to Section 11.6
of the Sublicense Agreement, Novartis shall be obligated to make the foregoing
repayments to Vanda, but only to the extent that it has been repaid its own
up-front license fee and milestone payments due to Novartis under Section 11.6
of the Titan Agreement. If this Sublicense Agreement has been terminated only
with respect to certain country(ies), the parties shall negotiate in good faith
a smaller portion of the upfront license fee and milestone payments Novartis has
received from Vanda up to such date which shall be repaid to Vanda; provided,
however, if

                                  Page 36 of 56

<PAGE>

the Titan Agreement has been terminated only with respect to such certain
countries under Section 11.6 of the Titan Agreement, Novartis shall be obligated
to make such repayments to Vanda but only to the extent Novartis has been repaid
the corresponding portion of the up front license fee and milestone payments
owed to it pursuant to Section 11.6 of the Titan Agreement. If the parties are
unable to agree on such smaller portions within ninety (90) days, the issue
shall be submitted for determination by arbitration in accordance with Section
14.2.

12. WARRANTIES INDEMNIFICATIONS AND REPRESENTATIONS

12.1 Novartis represents and warrants that to the best of its knowledge at the
date of this Sublicense Agreement:

(a) all currently issued or pending patents and patent applications owned or
controlled by HMRI or its Affiliates or its Sublicensees claiming the Compound
or Product, are listed in APPENDIX A;

(b) HMRI or its Affiliates or its Sublicensees own or control the entire right,
title and interest in Patents and Know-How. If Novartis becomes aware of any
patents or patent applications owned or controlled by HMRI or its Affiliates or
Sublicensees claiming the Compound or Product or manufacture, formulation or
use thereof, not listed in Appendix A-and is within the rights granted to Vanda
in this Sublicense Agreement, such patents and patent applications shall be
added to APPENDIX A at no cost to Vanda. Novartis further represents and
warrants that to the best of its knowledge as of the date of this Sublicense
Agreement;

(c) the Titan Agreement is in full force and effect and neither HMRI nor Titan
nor Novartis is in default of any of their obligations thereunder;

(d) subject to obtaining HMRI's and Titan's prior written consent, each of
which has been obtained, Novartis has the legal power, right and authority to
enter into this Sublicense Agreement; and

(e) Novartis has not previously assigned, transferred, conveyed or otherwise
encumbered its right, title and interest in the Patents or Know-How.

Vanda represents and warrants that it has the legal power, right and authority
to enter into this Sublicense Agreement.

12.2 Nothing in this Sublicense Agreement shall be construed as a warranty that
the Patents are valid or enforceable or that their exercise does not infringe
any patent rights of Third Parties. Novartis hereby represents and warrants that
it has no present knowledge (except as disclosed to Vanda or as available to
Vanda from public information) that (i) the Patents are invalid or
unenforceable, (ii) the exercise of Patents infringes any patent rights of Third
Parties, and (iii) Third Party licenses are necessary for the development,
manufacture or commercialization of the Compound or Product. A holding of
invalidity or unenforceability

                                  Page 37 of 56

<PAGE>

of any Patent, from which no further appeal is or can be taken, shall not affect
any obligation already accrued hereunder, but shall only eliminate future
royalties otherwise due under such Patent from the date such holding becomes
final.

12.3 Each party represents and warrants to the other that it is not currently
debarred, suspended or otherwise excluded by any U.S. Government agencies from
receiving federal contracts.

12.4 Vanda represents and warrants that during the term of this Sublicense
Agreement, neither it, an Affiliate or a Sublicensee shall license, develop,
have developed, manufacture, have manufactured, sell or have sold any of the
following compounds or products classified as an atypical antipsychotic [*].

In the event that Vanda or a Sublicensee undertakes any of the foregoing actions
within the EEA, then Novartis may not terminate this Sublicense Agreement or
seek damages or equitable remedies for such actions, but may at its option by
notice to Vanda (i) terminate the Exclusive nature of the licenses granted
pursuant to Article 2 hereof in the EEA, so that all use of Patents and Know-How
in the EEA will thereafter be on a non-exclusive basis at a reduced royalty rate
to be negotiated at time of change in exclusivity; (ii) cease providing
improvements to Vanda pursuant to Section 2.3; and/or (iii) require Vanda to
prove to Novartis' reasonable satisfaction that the Know-How is not being used
for such activities. Notwithstanding the foregoing, Novartis and Vanda agree
that in the event Vanda acquires rights to one or more of the [*] compounds or
products listed in the first paragraph of this Section 12.4 (the "Acquired
Compounds or Products") as part of a corporate transaction Novartis shall use
its good faith efforts to cause HMRI and Titan to waive any rights that it may
have against Vanda or Novartis under this Section 12.4 and Section 12.4 of the
Titan Agreement. To assist Novartis in obtaining such waiver from HMRI, Vanda
will provide Novartis with arguments supporting how Vanda intends to prevent the
Products from being negatively impacted by the Acquired Compounds or Products.
In the event that HMRI or Titan will not waive such rights and Vanda does not
agree to divest the Acquired Compounds or Products or, alternatively, sublicense
the Product to a mutually acceptable Third Party (which third party must also be
acceptable to HMRI and Titan), Novartis agrees that its sole and exclusive
remedy against Vanda shall be to terminate the Exclusive nature of the
Sublicense Agreement in the EEA as provided for in this Section 12.4, and to
terminate this Sublicense Agreement elsewhere in the Territory.

12.5 Vanda shall indemnify, defend and hold Novartis, HMRI, Titan and their
respective Affiliates harmless from and against any and all liabilities, claims,
demands, damages, costs,

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 38 of 56

<PAGE>

expenses, fines, penalties or money judgments including without limitation court
costs and reasonable attorney's fees (hereinafter referred to as "Liabilities"),
during the term of this Sublicense Agreement and after its expiration or
termination, incurred by or rendered against Novartis, Titan, HMRI and their
respective Affiliates which arise out of the clinical testing, use or labeling,
or the manufacture, processing, packaging, sale or distribution of the Compound
or Product (as the case may be) by Vanda, its Affiliates and Sublicensees, or
the breach of this Sublicense Agreement by Vanda (including without limitation
any breach of Vanda's' representations and warranties under this Sublicense
Agreement) or any negligence or misconduct of Vanda, except to the extent that
such Liabilities are directly attributable to the breach of this Sublicense
Agreement by Novartis or breach of the Titan Agreement by HMRI or Titan
(including without limitation any breach of Novartis' representations or
warranties under this Sublicense Agreement or any breach of HMRI's or Titan's
representations or Warranties under the Titan Agreement) or any negligence or
misconduct by Novartis, Titan or HMRI. Vanda shall also indemnify, defend and
hold Novartis, Titan, HMRI and their respective Affiliates harmless from and
against any and all Liabilities incurred by or rendered against Novartis, Titan,
HMRI and their respective Affiliates which arise out of the Compound or Product
supplied by Vanda to HMRI, Titan and/or Novartis and for use pursuant to Section
2.3, or which arise out of any contracts or arrangements with Third Parties
(including CROs) relating to, the development and/or registration process for
the Compound or Product from and after the Effective Date of this Sublicense
Agreement, whether such contracts or arrangements with Third Parties were
entered into prior to or following the Effective Date of this Sublicense
Agreement, except to the extent that such Liabilities are directly attributable
to the breach of this Sublicense Agreement by Novartis or breach of the Titan
Agreement by HMRI or Titan (including without limitation any breach of Novartis'
representations or Warranties under this Sublicense Agreement or any breach of
HMRI's or Titan's representations or warranties under the Titan Agreement) or
any negligence or misconduct by Novartis, Titan or HMRI.

12.6 Novartis shall indemnify, defend and hold Vanda, its Affiliates and
Sublicensees harmless from and against any and all Liabilities (as defined in
Section 12.5 hereof), incurred by or rendered against Vanda, its Affiliates and
Sublicensees; which arise out of the breach of this Sublicense Agreement by
Novartis (including any breach of Novartis' representations or warranties under
this Sublicense Agreement), or any negligence or misconduct by Novartis, except
to the extent that such Liabilities are directly attributable to the breach of
this Sublicense Agreement by a third party (including without limitation any
breach of Novartis' representations and warranties under this Sublicense
Agreement), or any negligence or misconduct by Vanda, HMRI or Titan. Novartis
shall also indemnify, defend and hold Vanda, its Affiliates and Sublicensees
harmless from and against any and all Liabilities incurred by or rendered
against Vanda, and its Affiliates and Sublicensees which arise out of

                                  Page 39 of 56

<PAGE>

the manufacture, use or sale of the Compound and Product that has been
manufactured or sold by or on behalf of Novartis and its Affiliates or
Sublicensees in those countries where Vanda's sublicense rights hereunder have
been terminated (including the clinical testing, use and labeling of the Product
and the manufacture, processing, packaging, sale or distribution of the Product
by Novartis and its Affiliates and Sublicensees) or subject to Section 5.4(b),
which arise out of the activities of any CRO which occurred prior to the
execution of this Sublicense Agreement and that were undertaken pursuant to a
written contract between Novartis and such CRO relating to the Compound or
Product.

12.7 Each party shall give the other prompt notice in writing of any claim or
demand referred to in Sections 12.5 or 12.6. In addition, the obligations of any
indemnifying party shall be subject to the indemnified party fulfilling the
following obligations:

(a) With respect to third parry claims, indemnified party shall fully cooperate
with the indemnifying party in the defense of such claim or demand which defense
shall be controlled by the indemnifying party; and

(b) With respect to third party claims, indemnified party shall not, except at
its own cost, voluntarily make any payment or incur any expense with respect to
any claim, demand or suit (including without limitation retaining its own
counsel) without the prior written consent of the indemnifying party, which such
party shall not be required to give.

13. FORCE MAJEURE.

13.1 If the performance of any part of this Sublicense Agreement by either
party, or if any obligation under this Sublicense Agreement, is prevented,
restricted, interfered with or delayed by reason of any cause beyond the
reasonable control of the party required to perform, the party so affected, upon
giving written notice and written evidence of such force majeure to the other
party, shall be excused from such performance to the extent of such prevention,
restriction, interference or delay, provided that the affected party shall use
its reasonable commercial efforts to avoid or remove such causes of
non-performance and shall continue performance with the utmost dispatch whenever
the force majeure is removed. In the event of a force majeure, the parties shall
also discuss whether modification of the terms of this Sublicense Agreement are
necessary to alleviate the hardship or loss caused by the force majeure.

14. GOVERNING LAW AND ARBITRATION.

14.1 This Sublicense Agreement shall be deemed to have been made in the State of
New York and its form, execution, validity, construction and effect shall be
determined in

                                  Page 40 of 56

<PAGE>

accordance with the laws of the State of New York (without regard to New York's
or any other jurisdiction's choice of law principles).

14.2 In the event of any controversy or claim arising out of or relating to any
provision of this Sublicense Agreement, the parties shall try to settle their
differences amicably between themselves. Any unresolved disputes arising between
the parties relating to, arising out of or in any way connected with this
Sublicense Agreement or any term or condition hereof, or the performance by
either party of its obligations hereunder, whether before or after termination
of this Sublicense Agreement, shall be resolved by final and binding
arbitration. Whenever a party shall decide to institute arbitration proceedings,
it shall give written notice to that effect to the other party. Except in the
case of a determination to be made where payments are to be made to by one party
to the other, the party giving such notice shall refrain from instituting the
arbitration proceedings for a period of sixty (60) days following such notice to
allow the parties time to further attempt to come to an amicable resolution of
the dispute. Arbitration shall be held in New York City, New York according to
the commercial rules of the American Arbitration Association ("AAA"). The
arbitration will be conducted by a panel of three arbitrators appointed in
accordance with AAA rules; provided, however, that each party shall within
thirty (30) days after the institution of the arbitration proceedings appoint a
party arbitrator, and the party-arbitrators shall select a neutral arbitrator,
to be chairman of the arbitration panel, within thirty (30) days thereafter. If
the party-arbitrators are unable to select a neutral within such period, the
neutral shall be appointed in accordance with AAA rules. All arbitrator(s)
eligible to conduct the arbitration must agree to render their opinion(s) within
thirty (30) days of the final arbitration hearing. No arbitrator (nor the panel
of arbitrators) shall have the power to award punitive damages under this
Sublicense Agreement and such award is expressly prohibited. Decisions of the
arbitrator(s) shall be final and binding on all of the parties. Judgment on the
award so rendered may be entered in a court having jurisdiction thereof. In any
arbitration pursuant to this Sublicense Agreement, the arbitrators shall
interpret the express terms hereof and apply the laws of the State of New York.
The losing party to the arbitration as determined by the arbitrators shall pay
the costs of arbitration. Notwithstanding the provisions of this clause, either
party may seek preliminary or injunctive measures or relief in. any competent
court having jurisdiction.

15. SEPARABILITY

15.1. In the event any portion of this Sublicense Agreement not material to the
remaining portions shall be held illegal, void or ineffective, the remaining
portions hereof shall remain in full force and effect.

                                  Page 41 of 56

<PAGE>

15.2 If any of the terms or provisions of this Sublicense Agreement are in
conflict with any applicable statute or rule of law, then such terms or
provisions shall be deemed inoperative to the extent that they may conflict
therewith and shall be deemed to be modified to conform with such statute or
rule of law.

15.3 In the event that the terms and conditions of this Sublicense Agreement are
materially altered as a result of Sections 15.1 or 15.2, the parties shall
renegotiate the terms and conditions of this Sublicense Agreement so as to
accomplish as nearly as possible the original intentions of the parties.

16. ENTIRE AGREEMENT

16.1 This Sublicense Agreement and the Appendices attached hereto, entered into
as of the date written above, constitutes the entire agreement between the
parties relating to the subject matter hereof and supersedes all previous
writings and understandings, including the Confidentiality Agreement between the
parties dated June 16, 2003 (it being understood and agreed that all
Confidential Information of HMRI, Titan and Novartis disclosed to Vanda prior to
the Effective Date of this Sublicense Agreement shall be subject to Sections
6.4, 6.6, 6.7 and 6.9 of this Sublicense Agreement). No terms or provisions of
this Sublicense Agreement shall be varied or modified by any prior or subsequent
statement, conduct or act of either of the parties, except that the parties may
amend this Sublicense Agreement by written instruments specifically referring to
and executed in the same manner as this Sublicense Agreement. Any amendments to
this agreement require the prior written approval of Titan and HMRI, which
approval will not be unreasonably withheld.

17. NOTICES

17.1 Any notice required or permitted under this Sublicense Agreement shall be
in writing and in English and shall be sent by airmail, postage prepaid, or
facsimile or courier to the following address of each party or to such other
address as may be designated in writing by the respective parties:

If to NOVARTIS:
Novartis Pharma AG
Legal Services
P.O. Box
4002 Basel
Switzerland
Facsimile: +41 61 324 68 59

                                  Page 42 of 56

<PAGE>

Attention: General Counsel Pharma Legal

With a copy to:
Business Development and Licensing
Novartis Pharma AG
P.O. Box
4002 Basel
Switzerland
Attention: Head of Global Partnering

If to Vanda:
Vanda Pharmaceuticals Inc.
47 Hulfish Street, Suite 310
Princeton, NJ 08542
Attn: Patricia Nasshom

17.2 Any notice required or permitted to be given concerning the Sublicense
Agreement or HMRI Agreement shall be effective upon receipt by the party to whom
it is addressed.

If to TITAN:
Titan Pharmaceuticals, Inc.
400 Oyster Point Blvd., Suite 505
South San Francisco, CA 94080
Attention: Louis R. Bucalo, M.D.
President & CEO
Telephone: (650) 244-4990
Facsimile: (650) 244-4956

With a copy to:
Titan Pharmaceuticals, Inc.
400 Oyster Point Blvd., Suite 505
South San Francisco, CA 94080
Attention: Sunil R. Bhonsle
Executive V.P & COO
Telephone: (650) 244-4990
Facsimile: (650) 244-4956
and
Loeb & Loeb LLP

                                  Page 43 of 56

<PAGE>

345 Park Avenue
New York, New York 10154
Attn: Fran Stoller
Phone: 212-407-4935
Facsimilie: 212-407-4990
e-mail: fstoller@loeb.com

If to HMRI:
Aventis Inc.
200 Crossing Boulevard
Mail Stop BX2 800D
Bridgewater, NJ 08807-0890
Facsimile: 908-231-3619
Attn: Senior Vice President, Corporate Development

With copies to:
Aventis Inc.
200 Crossing Boulevard
Mail Stop BX2 700A
Bridgewater, NJ 08807-0890
Facsimile: 908-231-4480
Attn: Vice President, Legal Corporate Development

For safety and Adverse Event Reporting:
AVENTIS Inc.
Global Pharmacovigilance & Epidemiology
Suraj Patel
License Partner Coordinator
200 Crossing Boulevard
PO Box 6890, BX4-400G
Bridgewater, NJ 08807-0890
USA
Fax: +1 908 231 4229 Phone: +1 908 541 5431
Email: suraj.patel@aventis.com

With copies to:
AVENTIS Inc.
US Regulatory Liaison
Kerry Rothschild

                                  Page 44 of 56

<PAGE>

License Partner Coordinator
200 Crossing Boulevard
PO Box 6890, BX2-209G
Bridgewater, NJ 08807-0890
USA
Phone: +1 908 231 2848
Email: kerry.rothschild@aventis.com
And,
AVENTIS Inc.
US Regulatory Coordination
Steve Caffe
License Partner Coordinator
200 Crossing Boulevard
PO Box 6890, BX2-209G
Bridgewater, NJ 08807-0890
USA
Fax: +1 908 541 5293
Phone: +1 908 231 5683
Email: steve.caffe@aventis.com

18. ASSIGNMENT

18.1 This Sublicense Agreement or any portions thereof and the sublicenses
herein shall be binding upon and inure to the benefit of the successors in
interest and assignees of the respective parties.

18.2 Vanda may assign this Sublicense Agreement to an Affiliate without the
prior written consent of Novartis, and in such event Vanda will continue to
guarantee the obligations of such Affiliate hereunder. Subject to the foregoing,
Vanda shall not have the right to assign this Sublicense Agreement to any Third
Party without the prior written consent of Novartis, Titan and HMRI, such
consent not to be unreasonably withheld; provided, however, that no such consent
shall be required in connection with an assignment in connection with any event
referred to in Section 18.3 below.

18.3 In the event of a consolidation, merger, acquisition which involves a
change in control of Vanda, this Sublicense Agreement shall remain in full force
and effect, and Vanda agrees to notify Novartis, Titan and HMRI. Consolidation,
mergers and/or acquisitions to which

                                  Page 45 of 56

<PAGE>

Vanda is a party which do not involve a change in control of Vanda shall not
require such notice.

18.4 In order for any assignment by Vanda of this Sublicense Agreement (which is
permitted by this Sublicense Agreement) to be valid, the assignee of such
assignment shall assume and agree to be bound by the provisions hereof.

19. FAILURE TO ENFORCE

19.1 The failure of either party to enforce at any time any provisions hereof
shall not be construed to be a waiver of such provision nor of the right of such
party thereafter to enforce each and every such provision.

20. AGENCY

20.1 Except as expressly set forth in this Sublicense Agreement, nothing in this
Sublicense Agreement authorizes either party to act as agent for the other or,
as to any third party, to indicate or imply the existence of any such agency
relationship. The relationship between the parties is that of independent
contractors.

21. FURTHER ASSURANCES

21.1 Each party hereto agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate
in order to carry out the purposes and intent of this Sublicense Agreement.

22. CAPTIONS

22.1 Captions are inserted for convenience only and in no way are to be
construed to define, limit or affect the construction or interpretation hereof.

23. MISCELLANEOUS

23.1 Both parties agree to discuss matters arising during the term of this
Sublicense Agreement in the spirit of co-operation and good faith and endeavour
to resolve any differences by mutual agreement whenever possible. If the parties
fail to reach agreement, either party may submit the matter for resolution
pursuant to Section 14.2.

                                  Page 46 of 56

<PAGE>

23.2 HMRI and its Affiliates shall be third party beneficiaries under this
Sublicense Agreement to the extent that this Sublicense Agreement inures to the
benefit of HMRI, with respect to Sections 2.1(a), 2.4, 2.5, 2.7, 2.9(a), 2.9(d),
2.10, 3.4(a), 3.5, 4.1(a), 4.2, 4.3, 5.2, 5.3, 5.5, 6.3, 6.4, 6.7, 8.1, 8.2,
8.4, 8.5, 8.6, 8.7, 8.9, 8.10, 8.11, 8.12, 8.13, 9.1, 9.3, 9.4, 9.5, 10.1(b),
11.5, 12.5, 17.2, 18.2, 18.3, 18.4, 23.2 and 23.3 with all rights and remedies
associated therewith.

23.3 Vanda covenants to Novartis that during the term of this Sublicense
Agreement, Vanda, its Affiliates and Sublicensees shall not violate the Federal
Foreign Corrupt Practices Act in the performance of its negotiations or
obligations hereunder.

   ***[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK - SIGNATURE PAGE FOLLOWS]***

                                  Page 47 of 56

<PAGE>

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their duly authorized representatives as of the Effective Date.

                                        VANDA PHARMACEUTICALS, INC.

                                        By: /s/ Mihael Polymeropoulos
                                            ------------------------------------
                                            Mihael Polymeropoulos
                                            Chief Executive Officer

                                        NOVARTIS PHARMA AG

                                        By: /s/ Herve Girsault
                                            ------------------------------------
                                        Name: Herve Girsault
                                        Title: Head, Global Partnering
                                               Business Development & Licensing

                                        By: /s/ Tom Chakraborti
                                            ------------------------------------
                                        Name: Tom Chakraborti
                                        Title: Senior Legal Counsel

                                  Page 48 of 56

<PAGE>

                               List of Appendices

<TABLE>
<S>                               <C>
Patents and Patent Applications   Appendix A
blank                             Appendix B
blank                             Appendix C
blank                             Appendix D
blank                             Appendix E
blank                             Appendix F
Titan Agreement                   Appendix G
</TABLE>

                                  Page 49 of 56

<PAGE>

                                                                      APPENDIX A

HMRI PATENTS AND PATENT APPLICATIONS

                                      [*]

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 50 of 56

<PAGE>

                                                                      APPENDIX B

BLANK

                                  Page 51 of 56

<PAGE>

                                                                      APPENDIX C

BLANK

                                  Page 52 of 56

<PAGE>

                                                                      APPENDIX D

BLANK

                                  Page 53 of 56

<PAGE>

                                                                      APPENDIX E

CRO CONTRACTS

NONE

                                  Page 54 of 56

<PAGE>

                                                                      APPENDIX F

SPECIAL COUNTRIES

                                  Page 55 of 56

<PAGE>

                                                                      APPENDIX G

TITAN AGREEMENT

                                      [*]

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 56 of 56

<PAGE>

                        ADDENDUM TO SUBLICENSE AGREEMENT

                                     between

                               NOVARTIS PHARMA AG

                                       and

                           VANDA PHARMACEUTICALS, INC.

This Addendum is part of the SUBLICENSE AGREEMENT that became effective on the
4th day of June, 2004, between Vanda Pharmaceuticals, Inc., a corporation
organized and existing under the laws of the State of Delaware and having its
principal office at 47 Hullfish Street, Suite 310, Princeton, NJ 08542
("Vanda"), and Novartis Pharma AG, a corporation organized under the laws of
Switzerland and having its principal office at Lichtstrasse 35, CH-4056, Basel,
Switzerland ("Novartis").

EXCHANGE OF INFORMATION AND CONFIDENTIALITY

The parties agree to be bound to the following terms, and hereby incorporate
them into the Sublicense Agreement.

     1.0 Privacy and Security of Pharmacogenetic samples and data

Vanda agrees that all pharmacogenetic information that it receives in connection
with this agreement, including any DNA samples and/or animal tissues treated
with the compound that may be provided for further studies in accordance with
the Sublicense Agreement terms, as well as any raw data and individual clinical
genetic data and information, will be maintained in a confidential and secure
manner, in full compliance with applicable United States (federal and state),
European Union, and other country specific regulations for privacy and security
of genetic data and samples and personally identifiable health information, and
will only be used and/or disclosed in accordance with those regulations. Vanda
also agrees to ensure that any of its affiliates, agents, vendors or other
business partners who receive any identifiable genetic information or data from
Vanda relating to the compound, shall adhere to the same standards of privacy
and security mandated by this Addendum and the Sublicense Agreement.

                                   Page 1 of 3

<PAGE>

     2.0 Privacy and Security of Adverse Event information.

Vanda agrees that all personally identifiable adverse event information that it
receives in connection with this agreement, including spontaneous adverse event
report forms from Novartis, will be maintained in a confidential and secure
manner, in full compliance with applicable United States (federal and state),
European Union, and country specific regulations for privacy and security of
personally identifiable health information, including any specific requirements
that may apply to adverse event reporting information, and will only be used or
disclosed in accordance with those regulations. Vanda also agrees to ensure that
any of its affiliates, agents, vendors or other business partners (excluding
health authorities) who receive any identifiable adverse event information from
Vanda relating to the compound, shall adhere to the same standards of privacy
and security mandated by this Addendum and the Sublicense Agreement.

     3.0 Compliance with Informed Consents.

Vanda will assume all obligations of Novartis contained in the informed consents
with the individual participants in the studies transferred to Vanda. In case
only the genetic information or study data of such studies is transferred to
Vanda, Vanda will comply with any request by Novartis pursuant to a disclosure,
deletion or destruction request received by Novartis from an individual
participant of such study.

     4.0 Indemnification

Vanda agrees to indemnify and hold harmless Novartis for damages and legal fees
that may result from any breach by vanda of paragraphs 1.0 and 3.0 of this
Addendum. Vanda shall also provide written notification to Novartis of any claim
against Vanda relating to a privacy or security breach involving data or
information provided to Vanda under this Addendum or the Sublicense Agreement,
within three (3) business days of receipt of such claim, lawsuit or
notification. Vanda agrees that Novartis shall be permitted to select counsel of
its own choosing in the event that a claim or lawsuit is filed that impacts
Novartis' interests.

  *** Remainder of page intentionally left blank, signature page to follow ***

                                   Page 2 of 3

<PAGE>

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their duly authorized representatives as of the Effective Date.

                                        VANDA PHARMACEUTICALS, INC.

                                        By: /s/ Chip Clark
                                            ------------------------------------
                                        Name: Chip Clark
                                        Title: Chief Business Officer

                                        NOVARTIS PHARMA AG

                                        By: /s/ Herve Girsault
                                            ------------------------------------
                                        Name: Herve Girsault
                                        Title: Head, Global Partnering
                                               Business Development & Licensing

                                        By: /s/ Kimberly J. Urdahl
                                            ------------------------------------
                                        Name: Kimberly J. Urdahl
                                        Title: Head of Legal, Primary Care

                                   Page 3 of 3

<PAGE>

                   ADDENDUM NO. 2 TO THE SUBLICENSE AGREEMENT

                                     between

                               NOVARTIS PHARMA AG

                                       and

                           VANDA PHARMACEUTICALS, INC.

                                   Page 1 of 5

<PAGE>

This Addendum No.2 ("ADDENDUM") is part of the SUBLICENSE AGREEMENT that became
effective on the 4th day of June, 2004 ("AGREEMENT"), between Vanda
Pharmaceuticals, Inc., a corporation organized and existing under the laws of
the State of Delaware and having its principal office at 9605 Medical Center
Drive, Rockville, MD 20850 USA ("VANDA"), and Novartis Pharma AG, a corporation
organized under the laws of Switzerland and having its principal office at
Lichtstrasse 35, CH-4056, Basel, Switzerland ("NOVARTIS").

Save as expressly stated otherwise, defined terms (to be identified by their
first letter in capitals) shall have the same meaning in this Addendum as such
term is defined in the Agreement.

A. ADDITION TO APPENDIX A OF THE AGREEMENT

Novartis has filed a patent application covering additional Compound metabolites
as identified hereto in ANNEX 2, which hereby shall be deemed incorporated into
Appendix A of the Agreement.

B. NON-EXCLUSIVE PATENT LICENSE

Novartis hereby grants to Vanda under the patent covering a biomarker as
identified hereto in ANNEX 1 a license under the same terms as with respect to
the Novartis Patents under the Agreement however such license shall be: a)
non-exclusive and b) limited as far as such patent identified in ANNEX 1 covers
any aspects of Iloperidone;

Contrary to Section 8.3 of the Agreement relating to the other Novartis Patents,
Novartis will retain all financial, filing, maintenance and prosecution
(including oppositions) responsibility for the patent identified in ANNEX 1
hereto.

C. LEGAL EFFECT

Other than amended by this Addendum the Agreement shall remain in full force and
effect.

   *** Remainder of page intentionally left blank signature page to follow ***

                                   Page 2 of 5

<PAGE>

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed in duplicates by their duly authorized representatives as of the date
of the last signature set hereto.

Rockville, February 16, 2006            VANDA PHARMACEUTICALS, INC.

                                        By: /s/ Chip Clark
                                            ------------------------------------
                                        Name: Chip Clark
                                        Title: CBO

Basel, February 20, 2006                NOVARTIS PHARMA AG

                                        By: /s/ CHRISTINA ACKERMANN
                                            ------------------------------------
                                        Name: CHRISTINA ACKERMANN
                                        Title: Head Legal Pharma,
                                               General Medicine

                                        By: /s/ Peter De Weerd
                                            ------------------------------------
                                        Name: Peter De Weerd
                                        Title: Authorised Signatory

                                   Page 3 of 5

<PAGE>

                                                                         ANNEX 1

[*]

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                   Page 4 of 5

<PAGE>

                                                                         ANNEX 2

[*]

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                   Page 5 of 5<PAGE>

                                                                    Exhibit 10.3

================================================================================

                 AMENDED AND RESTATED LICENSE, DEVELOPMENT AND
                           COMMERCIALIZATION AGREEMENT

                                 BY AND BETWEEN

                          BRISTOL-MYERS SQUIBB COMPANY
                            (A DELAWARE CORPORATION)

                                       AND

                           VANDA PHARMACEUTICALS, INC.
                            (A DELAWARE CORPORATION)

================================================================================

----------
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            PAGE
                                                                            ----
<S>                                                                         <C>
ARTICLE 1  DEFINITIONS ..................................................     1
ARTICLE 2  LICENSE GRANT ................................................     8
   2.1  Exclusive License Grant .........................................     8
   2.2  Non Exclusive License Grant .....................................     8
   2.3  Sublicense ......................................................     8
   2.4  No Trademark License ............................................     8
   2.5  No Implied Licenses .............................................     8
   2.6  Marketing Arrangements ..........................................     9
   2.7  Retained Rights .................................................     9
ARTICLE 3  OPTION GRANTS ................................................     9
   3.1  Vanda's Option: Third Party Development Partners ................     9
   3.2  BMS Option Exercisable Upon Completion of Phase III
        Clinical Studies: Commercialization .............................    10
   3.3  Right of First Negotiation to Act as a Co-Promotion Partner in
        Commercialization of a Product By Either Party ..................    11
   3.4  Responsibilities Regulatory Affairs .............................    12
ARTICLE 4  TRANSFER OF BMS KNOW-HOW; ....................................    13
   4.1  Transfer of BMS Compound Know-How ...............................    13
   4.2  Non-Solicitation ................................................    14
ARTICLE 5  DEVELOPMENT ..................................................    14
   5.1  Program Liaison .................................................    14
   5.2  Development .....................................................    14
   5.3  Development Reports .............................................    15
   5.4  Records .........................................................    15
   5.5  Development Responsibilities and Costs ..........................    15
   5.6  Regulatory Responsibilities and Costs ...........................    15
ARTICLE 6  COMMERCIALIZATION ............................................    18
   6.1  Commercializing Party's Responsibilities ........................    18
ARTICLE 7  MANUFACTURE AND SUPPLY .......................................    19
</TABLE>

                                        i

<PAGE>

                               TABLE OF CONTENTS
                                   (continued)

<TABLE>
<CAPTION>
                                                                            PAGE
                                                                            ----
<S>                                                                         <C>
   7.1  Responsibility ..................................................    19
   7.2  Provision of Compound ...........................................    19
   7.3  Right to Manufacture Commercial Supply ..........................    19
ARTICLE 8  PAYMENTS .....................................................    20
   8.1  Technology Access Fee ...........................................    20
   8.2  Milestone Payments ..............................................    20
   8.3  Timing ..........................................................    21
   8.4  Development Costs ...............................................    21
   8.5  Royalty Payment .................................................    21
   8.6  Third Party Royalty Payments ....................................    22
   8.7  Royalty Offset for Third Party Royalty Payments .................    22
   8.8  Term for Royalty Payments .......................................    22
   8.9  Sales Reports ...................................................    23
   8.10 Currency Exchange ...............................................    24
   8.11 Tax Withholding .................................................    24
   8.12 Interest Due ....................................................    24
ARTICLE 9  REPRESENTATIONS AND WARRANTIES; DISCLAIMER; LIMITATION OF
        LIABILITY .......................................................    24
   9.1  Mutual Warranties ...............................................    24
   9.2  BMS Warranties and Covenants ....................................    25
   9.3  Vanda Warranties and Covenants ..................................    25
   9.4  DISCLAIMER ......................................................    25
   9.5  Limitation of Liability .........................................    26
ARTICLE 10 PATENT MAINTENANCE; INFRINGEMENT; CONFIDENTIALITY ............    26
   10.1 Inventions ......................................................    26
   10.2 Patent Maintenance; Abandonment .................................    26
   10.3 Enforcement of BMS Patent Rights Against Infringers .............    27
   10.4 Defense of Third Party Claims ...................................    28
ARTICLE 11 NONDISCLOSURE OF CONFIDENTIAL INFORMATION ....................    29
</TABLE>

                                       ii

<PAGE>

                                TABLE OF CONTENTS
                                   (continued)

<TABLE>
<CAPTION>
                                                                            PAGE
                                                                            ----
<S>                                                                         <C>
   11.1  Nondisclosure ..................................................    29
   11.2  Authorized Disclosure ..........................................    29
   11.3  Terms of this Agreement ........................................    30
   11.4  Exception for Disclosure of Tax Treatment ......................    30
ARTICLE 12 INDEMNITY ....................................................    31
   12.1  Vanda Indemnity ................................................    31
   12.2  BMS Indemnity ..................................................    31
   12.3  Indemnification Procedures .....................................    32
   12.4  Insurance ......................................................    32
ARTICLE 13 TERM AND TERMINATION .........................................    33
   13.1  Term ...........................................................    33
   13.2  Termination By BMS .............................................    33
   13.3  Termination by Vanda ...........................................    34
   13.4  Effect of Termination ..........................................    34
   13.5  Survival .......................................................    37
   13.6  Bankruptcy .....................................................    37
ARTICLE 14 MISCELLANEOUS ................................................    38
   14.1  Provisions Contrary to Law .....................................    38
   14.2  Third Party Rights .............................................    38
   14.3  Notices ........................................................    39
   14.4  Force Majeure ..................................................    39
   14.5  Use of Names ...................................................    39
   14.6  Assignment .....................................................    40
   14.7  Further Assurances .............................................    40
   14.8  Waivers and Modifications ......................................    40
   14.9  Choice of Law and Jurisdiction .................................    41
   14.10 Publicity ......................................................    41
   14.11 Entire Agreement ...............................................    42
   14.12 Counterparts ...................................................    42
</TABLE>

                                       iii

<PAGE>

                                TABLE OF CONTENTS
                                   (continued)

<TABLE>
<CAPTION>
                                                                            PAGE
                                                                            ----
<S>                                                                         <C>
   14.13 Relationship of the Parties ....................................    42
   14.14 Headings .......................................................    42
   14.14 Dispute Resolution .............................................    42
</TABLE>

                                       iv

<PAGE>

                  AMENDED AND RESTATED LICENSE, DEVELOPMENT AND
                           COMMERCIALIZATION AGREEMENT

     THIS AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION
AGREEMENT (this "Agreement"), effective as of the Effective Date (defined
below), is made and entered into by and between BRISTOL-MYERS SQUIBB COMPANY, a
Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154
USA ("BMS") and VANDA PHARMACEUTICALS, INC., a Delaware corporation having its
principal place of business at 47 Hulfish Street, Suite 310, Princeton, NJ 08542
("Vanda"). Each of BMS and Vanda is referred to herein as a "Party" and BMS and
Vanda are collectively referred to herein as the "Parties."

                                    ARTICLE 1
                                   DEFINITIONS

For the purposes of this Agreement, the following definitions shall apply, and
the terms defined herein in plural shall include the singular and vice-versa:

     1.1 "AFFILIATE" means any corporation, company, partnership, joint venture
and/or firm which controls, is controlled by, or is under common control with a
specified person or entity. For purposes of this Section 1.1, "control" means
the power, direct or indirect, to direct the management and policies of an
entity, and shall be presumed to exist if one of the following conditions is
met: (a) in the case of corporate entities, direct or indirect ownership of at
least fifty percent (50%) of the stock or shares having the right to vote for
the election of directors, and (b) in the case of non-corporate entities, direct
or indirect ownership of at least fifty percent (50%) of the equity interest
with the power to direct the management and policies of such non-corporate
entities. The Parties acknowledge that in the case of certain entities organized
under the laws of certain countries outside of the United States, the maximum
percentage ownership permitted by law for a foreign investor may be less than
fifty percent (50%), and that in such cases such lower percentage shall be
substituted in the preceding sentence, provided that such foreign investor has
the power to direct the management and policies of such entity. Care Capital LLC
shall not be considered an Affiliate of Vanda and shall be considered a Third
Party if and only if Care Capital LLC (a) is not involved in the Development,
manufacture or Commercialization of a Product and (b) does not Control any
know-how or patent relating to any composition, formulation, method of use or
manufacture of a Compound or a Product that is not Controlled by Vanda and
Vanda's Affiliates (i.e., Care Capital does not Control any know-how or patent
that would be subject to Section 13.4.1(g) if Care Capital LLC was considered an
Affiliate of Vanda).

     1.2 "APPROVAL" means Marketing Authorizations with pricing, labeling, and
reimbursement approvals and any other similar final approvals from the FDA or an

                                       -1-

<PAGE>

equivalent Regulatory Authority of another country necessary to manufacture
and/or Commercialize a Product.

     1.3 "BMS COMPOUND PATENT RIGHTS" means (a) all U.S. patents and patent
applications and their foreign counterparts Controlled by BMS as of the
Effective Date covering the composition or utility of a Compound; (b) any
continuation, continuation-in-part (but only to the extent that such application
includes new data in support of claims previously submitted in a prior
originally filed application), divisional, and continued-prosecution
applications of any such patent applications in (a), and (c) any patents granted
on or issuing from any aforesaid applications in (a) and (b), including any
renewals, extensions, patents of addition, revivals, re-examinations, and
reissues thereof. Such Patent Rights are listed on Schedule 1.3.

     1.4 "BMS COMPOUND KNOW-HOW" means all technical information and know-how
known to and Controlled by BMS as of the Effective Date (including, without
limitation, all biological, chemical, pharmacological, toxicological, clinical,
assay, and related know-how and trade secrets) identified by BMS as directly
relating to, and are reasonably useful for, the Development and/or
Commercialization of a Compound or Product in the manner that the Compound or
Product has been Developed and Commercialized by BMS heretofore.

     1.5 "BMS KNOW-HOW" means the BMS Compound Know-How and the BMS
Manufacturing Know-How.

     1.6 "BMS MANUFACTURING KNOW-HOW" means all technical information and
know-how known to and Controlled by BMS as of the Effective Date (including,
without limitation, all manufacturing data, the percentages and specifications
of ingredients, the manufacturing processes, specifications, technology, assays,
quality control and testing procedures, and related know-how and trade secrets)
identified by BMS as directly relating to, and are reasonably useful for, the
manufacture of a Compound or Product in the manner that the Compound or Product
has been manufactured by BMS heretofore.

     1.7 "BMS MANUFACTURING PATENT RIGHTS" means those U.S. or foreign patents,
if any, Controlled by BMS as of the Effective Date, including any renewals,
extensions, patents of addition, revivals, re-examinations, and reissues
thereof, for which any claim covers the manufacture of a Compound in the same
manner that such Compound has heretofore been manufactured by BMS. Such patent
rights are listed on Schedule 1.7.

     1.8 "BMS PATENT RIGHTS" means the BMS Compound Patent Rights and the BMS
Manufacturing Patent Rights.

     1.9 "BUSINESS DAY" means a day other than Saturday, Sunday or any day on
which commercial banks located in New York are authorized or obligated by law to
close.

     1.10 "COMBINATION PRODUCT" means a Product including at least one
additional active ingredient other than a Compound. For clarity, drug delivery
vehicles, adjuvants,

                                       -2-

<PAGE>

and excipients shall not be deemed to be "active ingredients" the presence of
which in a Product would be deemed to create a Combination Product.

     1.11 "COMMERCIALIZING PARTY" has the meaning set forth in Section 6.1.1.

     1.12 "COMPOUNDS" means the compounds identified as BMS-214778 and
BMS-330446 each as specifically described in Schedule 1.3 and including without
limitation metabolites or prodrugs thereof, and any hydrates, conjugates, salts,
esters, isomers, polymorphs or analogues of any of the foregoing.

     1.13 "COMMERCIALLY REASONABLE EFFORTS" means, with respect to a Product,
the carrying out of obligations in a diligent and sustained manner (using
efforts not less than the efforts a Party devotes to a product of similar market
potential, profit potential or strategic value resulting from its own research
efforts), based on conditions then prevailing. Commercially Reasonable Efforts
requires that each Party: (a) promptly assign responsibility for such
obligations to specific employee(s) who are held accountable for progress and
monitor such progress on an on-going basis, (b) set and consistently seek to
achieve specific and meaningful objectives for carrying out such obligations,
(c) consistently make and implement decisions and allocate resources designed to
advance progress with respect to such objectives, and (d) employ compensation
systems for its employees reasonably calculated to intent such employees to
achieve such objectives.

     1.14 "COMMERCIALIZATION" or "COMMERCIALIZE" means activities directed to
obtaining pricing and reimbursement approvals, marketing, promoting,
distributing, importing or selling a product.

     1.15 "CONFIDENTIAL INFORMATION" means all trade secrets, processes,
formulae, data, know-how, improvements, inventions, chemical or biological
materials, techniques, marketing plans, strategies, customer lists, or other
information that has been created, discovered, or developed by a Party, or has
otherwise become known to a Party, or which proper rights have been assigned to
a Party, as well as any other information and materials that are deemed
confidential or proprietary to or by a Party (including, without limitation, all
information and materials of a Party's customers and any other third party and
their consultants), regardless of whether any of the foregoing are marked
"confidential" or "proprietary" or communicated to the other by the disclosing
Party in oral, written, graphic, or electronic form. In the case of BMS,
"Confidential Information" shall include, without limitation, the BMS Know-How.

     1.16 "CONTROLLED" or "CONTROLS", when used in reference to intellectual
property, shall mean the legal authority or right of a Party hereto (or any of
its Affiliates) to grant a license or sublicense of intellectual property rights
to another Party, or to otherwise disclose proprietary or trade secret
information to such other Party, without breaching the terms of any agreement
with a Third Party, infringing upon the intellectual property rights of a Third
Party, or misappropriating the proprietary or trade secret information of a
Third Party.

                                       -3-

<PAGE>

     1.17 "DEVELOPMENT" means non-clinical and clinical drug development
activities reasonably related to the development and submission of information
to a Regulatory Authority, including without limitation toxicology, pharmacology
and other discovery efforts, test method development and stability testing,
process development, formulation development, delivery system development,
quality assurance and quality control development, statistical analysis,
clinical studies (including pre-and post-approval studies and specifically
excluding regulatory activities directed to obtaining pricing and reimbursement
approvals). When used as a verb, "Develop" means to engage in Development.

     1.18 "DEVELOPMENT COSTS" means costs incurred by each Party that were
reasonably necessary for, and that reasonably relate to, the Development of a
Product in accordance with this Agreement and the Development Plan for that
Product, including, without limitation, (a) all reasonable and documented
out-of-pocket costs and expenses incurred, (b) the costs of internal scientific,
medical, technical or managerial personnel directly related to implementing the
Development Plan for that Product, to be determined based on the applicable FTE
Rate, with appropriate allocation in the case of any such personnel devoting
less than full time to such activities, unless another basis is otherwise agreed
by the Parties in writing, (c) the Manufacturing Costs of clinical supplies for
such efforts, (d) direct costs and expenses incurred in connection with
manufacturing process development and validation, manufacturing scale-up and
improvements, stability testing and quality assurance/quality control
development, and qualification and validation of Third Party contract
manufacturers, and (e) any other costs explicitly included in the budgets
included in the Development Plan for that Product.

     1.19 "DEVELOPMENT PLAN" means the drug development plan for a Product
mutually agreed to in writing by the Parties, and as it may be amended by mutual
written agreement from time to time. It shall include, among other things,
budgets for Development of the Product that are planned to be conducted to
achieve each step towards preparation of an NDA for use of the Product in the
Field. The preliminary Development Plan for a Product containing the Compound
identified as BMS-214778 is attached hereto as Schedule 1.19.

     1.20 "DOLLAR" means the lawful currency of the United States of America.

     1.21 "EFFECTIVE DATE" means February 25, 2004.

     1.22 "FDA" means the U.S. Food and Drug Administration or its successor
agency.

     1.23 "FIELD" means the application to any human disease, disorder or
condition, including without limitation sleep disorders such as insomnia and
disorders of circadian rhythm.

     1.24 "FIRST COMMERCIAL SALE" means, with respect to any Product, the first
sale for use or consumption by the general public of such Product in any country
in the

                                       -4-

<PAGE>

Territory after Marketing Authorization has been granted, or otherwise
permitted, by the governing health authority of such country.

     1.25 "FTE RATE" means the rates set forth in Schedule 1.25, such rate to be
annually increased on the anniversary of the Effective Date to reflect
adjustment in the CPI, using January 1, 2004 as the base year.

     1.26 "IND" means an Investigational New Drug Application, as defined in the
United States Federal Food, Drug and Cosmetic Act filed with the FDA or its
foreign counterparts.

     1.27 "INDEMNIFICATION CLAIM" has the meaning set forth in Section 12.1.

     1.28 "JOINT INVENTIONS" has the meaning set forth in Section 10.1.

     1.29 "LOSSES AND CLAIMS" has the meaning set forth in Section 12.1.

     1.30 "MAJOR MARKET COUNTRY" means the United States, Japan, Germany, the
United Kingdom, France, Spain and Italy.

     1.31 "MANUFACTURING COST" means (i) where and to the extent a Compound or
Product (or any component thereof) is manufactured, finished or packaged by a
Party, the direct costs and a reasonable allocation of indirect costs (such as
materials, labor and charges in the nature of depreciation, and variable and
fixed overhead) that are necessary for the normal operation of a production
facility that are incurred by such Party and its Affiliates in connection with
the manufacturing, finishing and packaging of the Compound or Product at any
facility of such Party where the Product (or such component) is so manufactured,
finished and packaged, as determined in accordance with U.S. GAAP, consistently
applied from period to period, plus (ii) where and to the extent the Compound or
Product (or any component thereof) is manufactured, finished or packaged by a
Third Party, the actual cost charged to such Party by such Third Party.
Manufacturing overhead (including any idle capacity charges) required to operate
the facility will be allocated based on the amount of capacity that such Party
is reasonably required to reserve to meet expected demand for the Product.
Annual adjustments to variable overhead charges will be based on actual costs,
while fixed overhead will be adjusted annually based on changes from the
previous year to the Producer Price Index-Commodities Index for Drugs and
Pharmaceuticals, as published by U.S. Department of Labor, Bureau of Statistics
(or successor governmental authority). As an example of idle capacity charges,
if a Parry reserves a capacity of five million capsules and actual demand is
three million capsules, then the idle plant for the balance of two million
capsules will be included in the Manufacturing Cost; however, if a Party needs
five million capsule capacity and BMS were to build a new plant for ten million
capsule capacity, then the extra five million capsule idle plant will not be
part of the Manufacturing Cost.

     1.32 "MARKETING AUTHORIZATION" means, with respect to a country, the
regulatory authorization required to market and sell a Product in such country.

                                       -5-

<PAGE>

     1.33 "MGH LICENSE AGREEMENT" means the agreement between The General
Hospital Corporation d/b/a Massachusetts General Hospital ("MGH") and
Bristol-Myers Squibb Company that is currently being negotiated and that will be
entered into after the Effective Date, and as it may be modified or supplemented
after being entered into, under which BMS will be obligated to pay MGH a royalty
on the sales of Products.

     1.34 "NDA" means a New Drug Application, as defined in the United States
Federal Food, Drug and Cosmetic Act and applicable regulations promulgated
thereunder as amended from time to time.

     1.35 "NET SALES" means the gross amounts invoiced by the Royalty Paying
Party, its Affiliates or sublicensees for sales of Product in finished package
form (ready for use by the ultimate consumer) in the Territory to a Third Party,
including, but not limited to, sales to wholesalers or other customers typical
in each country in bona fide, arm's length transactions. In determining Net
Sales, certain deductions may be taken against the gross amount invoiced to the
extent not reimbursed by a Third Party. These allowable deductions are:

          1.35.1 (a) discounts, including cash discounts, discounts to managed
care or similar organizations or government organizations, administrative fees
paid to pharmacy benefits managers, (b) rebates paid or credited, including
government rebates such as Medicaid chargebacks or rebates, and (c) retroactive
price reductions or allowances actually allowed or granted from the billed
amount;

          1.35.2 credits or allowances actually granted upon claims, rejections
or returns of such sales of Products;

          1.35.3 taxes, duties or other governmental charges levied on or
measured by the billing amount when included in billing, as adjusted for
rebates, charge-backs and refunds;

          1.35.4 freight, postage, shipping and insurance charges to the extent
included on the same invoice by the Royalty Paying Party or its sublicensee for
delivery of such Products; and

          1.35.5 the actual amount of any write-offs for bad debt.

A "sale" of a Product is deemed to occur upon the invoicing, or if no invoice is
issued, upon the earlier of shipment or transfer of title in the Product to a
Third Party.

With respect to a Combination Product, Net Sales for such Combination Product
sold by the Royalty Paying Party shall be determined by the Parties to this
Agreement in good faith based on the relative value of the Compound and the
additional active ingredients that are included in the Combination Product.

     1.36 "PHASE II CLINICAL STUDY" means a clinical study of a Product in human
subjects for the purpose of identifying a dose or doses at which there is
evidence of

                                       -6-

<PAGE>

efficacy and acceptable safety and tolerability, which shall be deemed commenced
upon the dosing of the first subject in such study.

     1.37 "PHASE III CLINICAL STUDY" means a clinical study of a Product in
human subjects the results of which could be used to establish safety and
efficacy of the Product as a basis for Marketing Authorization of the Product
which shall be deemed commenced upon the dosing of the first subject in such
study.

     1.38 "PRODUCT" means any product or pharmaceutical formulation containing a
Compound as one of its active ingredients (or as the sole active ingredient), in
all dosage forms, formulations, presentations, line extensions, and package
configurations.

     1.39 "REGULATORY AUTHORITY" means any regulatory agency or other
governmental instrumentality that has regulatory authority, anywhere or at any
governmental level, in the Territory over the Development or Commercialization
of the Products.

     1.40 "ROYALTY PAYING PARTY" has the meaning set forth in Section 8.5.

     1.41 "ROYALTY RECEIVING PARTY" has the meaning set forth in Section 8.5.

     1.42 "BMS OPTION" has the meaning set forth in Section 3.2.1.

     1.43 "BMS OPTION PERIOD" has the meaning set forth in Section 3.2.1.

     1.44 "SOLE INVENTIONS" has the meaning set forth in Section 10.1.

     1.45 "SUPPLY AGREEMENT" has the meaning set forth in Section 7.3.

     1.46 "TERRITORY" means any country in the world.

     1.47 "THIRD PARTY" means any business entity other than Vanda, BMS and
their respective Affiliates.

     1.48 "VALID CLAIM" means a claim of an issued and unexpired patent, or a
claim of a pending patent application or a supplementary protection certificate,
which claim has not been held invalid or unenforceable by a court or other
government agency of competent jurisdiction from which no appeal can be or has
been taken and has not been held or admitted to be invalid or unenforceable
through re-examination or disclaimer, opposition procedure, nullity suit or
otherwise, which claim, but for the licenses granted herein, would be infringed
by the sale of a Product; provided, however, that if a claim of a pending patent
application shall not have issued within five (5) years after the filing date
from which such claim takes priority, such claim shall not constitute a Valid
Claim for the purposes of this Agreement unless and until such claim shall
issue.

     1.49 "VANDA THIRD PARTY DEVELOPMENT OPTION" has the meaning set forth in
Section 3.1.1.

                                       -7-

<PAGE>

     1.50 "VANDA THIRD PARTY DEVELOPMENT OPTION PERIOD" has the meaning set
forth in Section 3.1.1.

                                   ARTICLE 2
                                 LICENSE GRANT

     2.1 EXCLUSIVE LICENSE GRANT. Subject to all of the terms and conditions in
this Agreement, BMS hereby grants to Vanda a non-transferable, exclusive
license, with the limited right to sublicense pursuant to Section 2.3, under the
BMS Compound Patent Rights solely to the extent necessary to Develop, make, have
made, use, import, offer to sell, and Commercialize the Products in the Field in
the Territory.

     2.2 NON EXCLUSIVE LICENSE GRANT. Subject to all of the terms and conditions
in this Agreement, BMS hereby grants to Vanda a non-transferable, nonexclusive
license, with the limited right to sublicense pursuant to Section 2.3, (a) under
the BMS Know How solely to the extent necessary to Develop, make, have made,
use, import, offer to sell, and Commercialize the Products in the Field in the
Territory, and (b) in the event Vanda enters into a Supply Agreement with a
Third Party in accordance with Article 7, under the BMS Manufacturing Patents
solely to the extent necessary to have made the Products or Compounds in the
Field in the Territory for sale to Vanda.

     2.3 SUBLICENSE. The rights licensed to Vanda under Sections 2.1, 2.2(a) and
2.2(b) shall be sublicensable only as part of a license of rights to a Product
in the Field and only for use with such Product, and only where (i) the
sublicensee has agreed first in writing to be bound by the terms and conditions
of this Agreement in the same manner as Vanda, (ii) BMS is made an express third
party beneficiary of the sublicensee's obligations under such sublicense that
relate to compliance with the terms and conditions of this Agreement, and (iii)
a copy of the proposed sublicense shall have been provided to BMS for review
(financial terms not relating to this Agreement may be redacted). A copy of the
sublicense shall be provided to BMS promptly after execution. Vanda shall remain
jointly and severally liable with any such sublicensee for any failure by such
sublicensee to perform or observe the terms and conditions of this Agreement.
Each sublicense granted by Vanda to any right licensed to it hereunder shall
terminate immediately upon the termination of the license from BMS to Vanda with
respect to such right.

     2.4 NO TRADEMARK LICENSE. No right or license, express or implied, is
granted to Vanda to use any trademarks, tradenames or trade dress owned or
Controlled by BMS and its Affiliates.

     2.5 NO IMPLIED LICENSES. Only licenses and rights granted expressly herein
shall be of legal force and effect. No license or other right shall be created
hereunder by implication, estoppel or otherwise. Vanda represents, covenants and
warrants that it will use the rights licensed to it hereunder solely in
accordance with the terms and conditions contained in this Agreement.

                                       -8-

<PAGE>

     2.6 MARKETING ARRANGEMENTS. In connection with arrangements with Third
Parties whereby such Third Parties would distribute or otherwise Commercialize
Products, Vanda agrees to comply and to cause such Third Parties to comply with
all terms and conditions of this Agreement.

     2.7 RETAINED RIGHTS. All rights not expressly granted hereunder are
reserved by BMS and may be used by BMS for any purpose.

                                    ARTICLE 3
                                  OPTION GRANTS

     3.1 VANDA'S OPTION: THIRD PARTY DEVELOPMENT PARTNERS.

          3.1.1 Vanda Development Option Period. Vanda will have the right,
anytime prior to filing an NDA for a Product ("Vanda Third Party Development
Option Period"), to negotiate an agreement to sublicense Vanda's rights' to
Develop and Commercialize a Product (a "Development and Commercialization
Agreement") with a Third Party in at least one Major Market Country ("Vanda
Third Party Development Option"); provided, however, that with respect to each
Product, upon Vanda locking the database for Vanda's first Phase III Clinical
Study for the Product, Vanda shall have a limited time in which to exercise the
Vanda Third Party Development Option for the Product before the right to
exercise such option is suspended. Vanda shall have 120 days from the date Vanda
locks the database for Vanda's first phase III Clinical Study for the Product to
exercise such option. If Vanda exercises such option during such 120 day period,
BMS shall have a right of first negotiation to enter into a Development and
Commercialization Agreement for the Product with Vanda. BMS shall have a thirty
(30) day review period, from the receipt of Vanda's written notice to seek a
Third Party partner, to elect to enter into negotiations with Vanda. During the
thirty (30) day review period, Vanda shall timely provide BMS with copies of any
reports, data, results or information, material to the Development of the
Product that are or may become available, including but not limited to those
relating to the first phase III Clinical Study for the Product. Thereafter, BMS
will have a ninety (90) day period of exclusivity in which to negotiate and
execute a Development and Commercialization Agreement, and Vanda shall negotiate
in good faith during such ninety (90) day period. During such thirty (30) day
review period and such ninety (90) day period of exclusivity, Vanda shall not
approach any Third Party concerning a Development and Commercialization
Agreement or disclose any of the Phase III Clinical Study data, results or
conclusions to any Third Party that may potentially enter into a Development and
Commercialization Agreement for the Product. If, during the thirty (30) day
review period BMS does not formally notify Vanda in writing of its intention to
enter into a Development and Commercialization Agreement or informs Vanda that
it is not interested in entering into such an agreement or if BMS does notify
Vanda of its intention to enter into such an agreement but does not enter into a
such an agreement for the Product during such ninety (90) day period of
exclusivity, then Vanda shall have 120 days from the end of the thirty (30) day
review period if BMS does not provide Vanda with notice of its intention to

                                       -9-

<PAGE>

negotiate during such thirty (30) day period, or 120 days from the date BMS
notifies Vanda that it is not interested in entering into a Development and
Commercialization Agreement for the Product or 120 days from the end of the
ninety (90) day period of exclusivity if BMS does notify Vanda of its intention
to enter into such an agreement but the parties do not enter into a such an
agreement during such ninety (90) day period, as the case may be, to negotiate
and enter into a Development and Commercialization Agreement with a Third Party
for the Product. If Vanda does not enter into such an agreement with a Third
Party during such 120 day period, then the Vanda Third Party Development Option
shall be suspended from the end of such 120 day period (the Option Suspension
Date) until the end of the BMS Option Period for the Product. The Vanda Third
Party Development Option is exercisable by written notice from Vanda to BMS of
Vanda's intention to seek a Third Party partner. Such option shall be
exercisable on a Product-by-Product and on a Major Market Country by Major
Market Country basis. For the avoidance of doubt, rights to Develop and
Commericalize a Product in non-Major Market Countries may be included in the
Development and Commercialization Agreement for a Major Market Country. With
respect to a Product, the Major Market Countries together with all other
countries that are not included in a Development and Commercialization Agreement
for the Product shall be referred to as the "Remaining Countries."

          3.1.2 Option Exercise. Except as provided in Section 3.1.1 for the
period following the locking of the database after the first Phase III Clinical
Study for a Product, in the event that Vanda exercises its Vanda Third Party
Development Option for a Product in a particular Major Market Country in the
Vanda Third Party Development Option Period, BMS shall have a right of first
negotiation to enter into a Development and Commercialization Agreement for that
Product in that Major Market Country. BMS shall have a thirty (30) day review
period, from the receipt of Vanda's written notice to seek a Third Party
partner, to elect to enter into negotiations with Vanda. During the thirty (30)
day review period, Vanda shall timely provide BMS with copies of any reports,
data, results or information, material to the Development of a Product that are
or may become available. Thereafter, BMS will have a sixty (60) day period of
exclusivity in which to negotiate and execute a Development and
Commercialization Agreement for the Product, and Vanda shall negotiate in good
faith during such sixty (60) day period. If during the thirty (30) day review
period BMS does not formally notify Vanda in writing of its intention to enter
into such an agreement or informs Vanda that it is not interested in entering
into such an agreement or if BMS does not enter into such an agreement during
the sixty (60) day period of exclusivity, then Vanda may enter into a
Development and Commercialization Agreement for the Product with a Third Party.
The Parties will use reasonable efforts to make decisions earlier than the final
day of each period allowed by this section 3.1.2 to the extent practicable. In
the event that Vanda enters into one or more Development and Commercialization
Agreements for a Product pursuant to the provisions of Section 3.1.1 and/or this
Section 3.1.2 prior to the Option Suspension Date, then BMS will surrender the
BMS Option with respect to the Product in those countries that are included in
such Development and Commercialization Agreements but retain the BMS Option with
respect to the Remaining Countries.

                                      -10-

<PAGE>

          3.1.3 Vanda Third Party Development Option Not Exercised. In the event
Vanda does not exercise its Vanda Third Party Development Option for a Product
or enter into any Development and Commercialization Agreements for the Product
prior to the Option Suspension Date for the Product, then BMS will have an
opportunity to exercise its BMS Option for the Product in all countries on the
terms and conditions described in Section 3.2.

     3.2 BMS OPTION EXERCISABLE UPON COMPLETION OF PHASE III CLINICAL STUDIES:
COMMERCIALIZATION.

          3.2.1 BMS Option Period. The BMS Option Period for a Product will
commence for the Remaining Countries (providing Vanda has not entered into one
or more Development and Commercialization Agreements for the Product which when
taken together include all of the Major Market Countries prior to the Option
Suspension Date for the Product) on the date that (1) Vanda provides BMS with a
full written report of the Phase III Clinical Studies, including the results and
conclusions thereof, on which Vanda intends to rely for filing for Marketing
Authorization for the Product in the first Major Market Country and (2) both
Parties agree in writing is the commencement date for the BMS Option Period. The
BMS Option Period shall terminate ninety (90) days later ("BMS Option Period").
At any time during the BMS Option Period, BMS may provide Vanda with written
notice that either: (a) it does not wish to Develop or Commercialize the Product
in the Remaining Countries; or (b) it wishes to reacquire all rights to the
Product in the Remaining Countries ((b) shall be referred to as the "BMS
Option"). Such option shall be exercisable on a Product-by-Product basis. For
the avoidance of doubt, if BMS does not exercise the BMS Option for the
Remaining Countries within the BMS Option Period, then upon completion of the
BMS Option Period, the Vanda Third Party Development Option shall be exercisable
for the Remaining Countries for the remainder of the Vanda Third Party
Development Option Period.

          3.2.2 BMS Option Diligence Materials. Vanda shall provide to BMS on or
prior to the commencement of the BMS Option Period, any additional data
(including without limitation, copies of all case report forms, if requested by
BMS) or information relating to the Development of the Product that is in
Vanda's possession which BMS reasonably believes to be necessary or useful for
its review of the opportunity. At 30-day intervals during the BMS Option Period,
Vanda will promptly provide any reports, data, results or information, material
to the Development of a Product that may become available.

          3.2.3 Option Exercised. In the event BMS exercises its BMS Option for
a Product, then, among other things,

               (a) LICENSE GRANT. The licenses granted to Vanda pursuant to
Section 2.1 and 2.2 will immediately terminate with respect to the Product in
the Remaining Countries without further action on the part of either Party, and
Vanda shall cease all use of the BMS Patent Rights, and BMS Know-How with
respect to the Product in the Remaining Countries;

                                      -11-

<PAGE>

               (b) TRANSFER OF DATA, INFORMATION AND REGULATORY FILINGS. Vanda
shall promptly assign to BMS all rights, title and interests in any INDs,
Marketing Authorizations, and Approvals that it shall have filed in the
Remaining Countries with respect to the Product and the Compound contained in
the Product and all data generated by it with respect to the Product and the
Compound contained in the Product in the Remaining Countries, and will promptly
transfer to BMS originals or copies of all pertinent documents relating to same
as requested by BMS. In the event that Vanda fails to effectuate the transfer of
the foregoing within thirty (30) days after the date that BMS exercises its BMS
Option, then, in addition to any other recourse or remedy that BMS may be
entitled to at law or in equity, BMS shall be entitled to specific performance
of the foregoing obligation and the Parties acknowledge and agree that BMS may
obtain an order for same from any court of competent jurisdiction without
posting of bond. BMS will reimburse Vanda for any out-of-pocket expenses
incurred in connection with such assignment. Within ninety (90) days following
any such assignment to BMS, the Parties will finalize and enter into a Data
Safety Exchange covering such matters as adverse event reporting, data safety
exchange and response to physician inquiries so that BMS may fulfill its
reporting responsibilities on a timely basis to Regulatory Authorities;

               (c) DEVELOPMENT BMS will thereafter be solely responsible for any
further Development activities needed to achieve Approvals in the Remaining
Countries for the Product, and will use Commercially Reasonable Efforts to
achieve same;

               (d) COMMERCIALIZATION. Provided the United States is included in
the Remaining Countries, as soon as reasonably necessary, and in no event later
than six months prior to the anticipated First Commercial Sale of the Product in
the United States, BMS will advise Vanda in writing whether it intends to seek a
co-promotion partner in the United States for the Product. In the event that BMS
seeks a co-promotion partner in the United States, and provided that Vanda is
able to meet the requirements established by BMS at that time for a co-promotion
partner, the Parties will have ninety days in which to negotiate a mutually
acceptable co-promotion agreement in accordance with Section 3.3; and

               (e) OTHER TERMS. The provisions of Section 13.4.1(e), (g), (h)
and (i) shall also apply as though set forth herein. It is understood and agreed
that BMS shall be entitled to specific performance as a remedy to enforce the
provisions of this Section 3.3.4(e), in addition to any other remedy to which it
may be entitled by applicable law.

          3.2.4 BMS Option Not Exercised. In the event that BMS does not
exercise its BMS Option for a Product with respect to the Remaining Countries,
Vanda will, subject to Section 3.3, Develop and Commercialize the Product in the
Remaining Countries pursuant to the terms and conditions set forth in this
Agreement.

     3.3 RIGHT OF FIRST NEGOTIATION TO ACT AS A CO-PROMOTION PARTNER IN
COMMERCIALIZATION OF A PRODUCT BY EITHER PARTY.

                                      -12-

<PAGE>

          3.3.1 Vanda's Right to Co-Promote. If BMS is Developing and/or
Commercializing a Product in the U.S. pursuant to this Agreement and decides to
co-promote the Product with a Third Party marketing partner in the U.S., BMS
shall promptly notify Vanda in writing of its intention to co-promote the
Product with such Third Party marketing partner in the U.S. Vanda will have
sixty (60) days from the date BMS notifies Vanda of its intention to co-promote
the Product with such Third Party marketing partner to provide written notice of
its intent to exercise its option to co-promote the Product with BMS in the U.S.
and demonstrate that it has, or is reasonably likely to have at the time
required, the capabilities to undertake such co-promotion effort, including
without limitation, sufficient numbers of Vanda employees with sufficient
experience as sales representatives and sales and marketing managers and
executives to allow it to fulfill the obligations established by BMS for the
co-promotion partner (including without limitation minimum number of details,
minimum primary detail equivalents, sales force size and training, advertising
and promotional spend requirements, etc.). Vanda may not delegate or subcontract
such co-promotion responsibilities to a Third Party, unless such Third Party (a)
has been an alliance partner of Vanda's for at least twenty-four (24) months
prior to the date Vanda receives notice under this Section 3.2.1 from BMS of
BMS' intention to co-promote the Product with a Third Party marketing partner,
and (b) has the capabilities to undertake such co-promotion effort, including
without limitation, sufficient numbers of employees with sufficient experience
as sales representatives and sales and marketing managers and executives to
allow it to fulfill the obligations established by BMS for the co-promotion
partner (including without limitation minimum number of details, minimum primary
detail equivalents, sales force size and training, advertising and promotional
spend requirements, etc.). If Vanda exercises its option and demonstrates to
BMS' satisfaction that it can meet, or is reasonably likely to be able to meet
at the necessary time, such capabilities and fulfill such obligations by itself
or with such an alliance partner, the Parties will, for a period not longer than
ninety (90) days after Vanda's exercise of the option, exclusively negotiate
with each other in good faith a Co-Promotion Agreement on commercially
reasonable terms and conditions reflective of those used in the contract sales
organization industry. If after such ninety (90) day period, the Parties have
not entered into a co-promotion agreement, BMS would be free to enter into an
arrangement with a Third Party marketing partner.

          3.3.2 BMS' Right to Co-Promote. If Vanda is Commercializing a Product
pursuant to this Agreement and decides to co-promote the Product with a Third
Party marketing partner, Vanda shall promptly notify BMS in writing of its
intention to co-promote the Products with such Third Party marketing partner.
BMS will have sixty (60) days from the date Vanda notifies BMS of its intention
to co-promote the Product with such Third Party marketing partner to provide
written notice of its intent to exercise its option to co-promote the Product
with Vanda. If BMS exercises its option, the Parties will, for a period not
longer than sixty (60) days after BMS' exercise of the option, negotiate
exclusively with each other in good faith a co-promotion agreement on
commercially reasonable terms and conditions reflective of those used in
pharmaceutical partnerships. If after such sixty (60) day period, the Parties
have not entered into a co-promotion agreement, Vanda would be free to enter
into an arrangement with a Third Party marketing partner.

                                      -13-

<PAGE>

     3.4 RESPONSIBILITIES REGULATORY AFFAIRS. Following the date that the IND,
Marketing Authorization or Approval in a given country for a Product has been
assigned to BMS, BMS shall have sole responsibility for preparing, all
regulatory filings and related submissions with respect to the Product and the
Compound contained in the Product in such country and making all final decisions
relating thereto. BMS shall be the primary interface with and otherwise handle
all interactions with Regulatory Authorities concerning the Product and the
Compound contained in the Product. Pursuant to Section 14.7, Vanda shall be
obliged to render whatever assistance BMS may reasonably request to allow BMS to
fulfill its obligations under this Section 3.4. To the extent not prohibited by
law or regulation, in the event that BMS is Developing and Commercializing a
Product in the United States, Vanda shall have the right to have one
representative participate in all material meetings pertaining to Development of
the Product between representatives of BMS and the FDA. BMS will provide Vanda,
at least five (5) business days before any such meeting, with copies of all
documents, correspondence and other materials in its possession which are
relevant to the matters to be addressed at any such meeting. BMS will provide
Vanda with draft and final copies (which may be wholly or partly in electronic
form) of all material correspondence with the Regulatory Authorities in each of
the Major Market Countries relating to the Product, including any draft
Marketing Authorizations and Approvals, for Vanda's review and comment within a
reasonable time prior to filing with the appropriate Regulatory Authority. BMS
shall give due consideration to Vanda's comments, however, BMS shall not be
bound thereby.

                                    ARTICLE 4
                            TRANSFER OF BMS KNOW-HOW;

     4.1 TRANSFER OF BMS COMPOUND KNOW-HOW.

          4.1.1 TRANSFER. During the three (3) month period following the
Effective Date, BMS shall provide Vanda with the assistance of certain BMS
employees having knowledge relevant to the Compounds to provide Vanda with a
reasonable level of technical assistance and consultation in connection with the
transfer of BMS Know-How (provided that BMS shall only be required to make a
good faith effort to provide the BMS Know How but shall not be in default
hereunder for inadvertent failure to disclose all or non-material information).
Vanda shall be responsible for ensuring that its personnel who receive such
assistance are appropriately qualified and experienced for such purpose.

          4.1.2 COPIES OF DOCUMENTS. BMS shall provide Vanda with one copy of
all documents, data or other information Controlled by BMS to the extent that
such documents, data and information are the subject of the BMS Know-How
licenses and are, in BMS' good faith judgment, reasonably necessary for the
Development, manufacture or Commercialization of the Compounds and are
reasonably available to BMS without undue searching; provided however, the
foregoing shall in no event require BMS to provide copies of laboratory
notebooks or manufacturing run records required to be maintained by FDA. The BMS
Know-How provided by BMS shall not be used by Vanda for any purpose other than
Development, manufacture or Commercialization of

                                      -14-

<PAGE>

the Compounds and Products and is Confidential Information of BMS. Vanda shall
assume full responsibility and liability to BMS for any unauthorized use or
disclosure of Confidential Information of BMS. BMS shall be responsible for the
cost of providing one set of copies only, and in addition to paper and other
tangible copies, BMS shall, upon Vanda's request and where already available to
BMS, also provide to Vanda electronic copies of such documents, data and other
information, provided, that BMS shall have no obligation to reformat or
otherwise alter or modify any such materials in order to provide them to Vanda.

          4.1.3 ON-SITE CONSULTING. BMS shall not be obligated to provide more
than forty (40) hours of consulting advice or on-site consulting advice
(including travel time) over the term of this Agreement, as may be requested by
Vanda, with respect to the transfer of any BMS Know-How. BMS will be reimbursed
by Vanda for its fully-burdened costs (including out-of-pocket costs) incurred
to provide such advice or services. In the event that Vanda requires
consultation with BMS over and above the forty (40) hours provided here, Vanda
will submit its request for consultation to BMS, in writing, stating in
sufficient detail the subject matter, and the number of hours required. BMS will
consider each such request in good faith, and will inform Vanda in a timely
manner if BMS will be able to provide the consulting time requested, with the
understanding that BMS shall not obligated to provide more than forty (40) hours
of consulting advice or on-site consulting advice (including travel time) over
the term of this Agreement.

          4.1.4 IND. As soon as reasonable practicable after the Effective Date,
BMS will promptly effectuate the assignment of IND 54,776 (the active IND for
the Compound currently identified as BMS-214778) to Vanda. Vanda will reimburse
BMS for any personnel and other expenses incurred in connection with such
assignment.

     4.2 NON-SOLICITATION. During the term of this Agreement, and for [*] years
thereafter, each Party and its Affiliates shall not solicit, directly or
indirectly, any employee of the other Party or of an Affiliate of the other
Party, wherever located, who is or was involved in the performance of this
Agreement; provided, that the foregoing restriction on solicitation shall not
apply to advertisements run in trade journals or other publications or on the
Internet that are targeted to qualified individuals generally for the position
in question.

                                    ARTICLE 5

                                   DEVELOPMENT

     5.1 PROGRAM LIAISON. As soon as practicable after the Effective Date, each
Party will provide the other, in writing, with the name of its "Program
Liaison." The Program Liaison will act as the primary liaison in coordinating
the activities under this Agreement. The Program Liaisons will review and agree
on the suitability of the Development Plan set forth in Schedule 1.19. Before
Vanda begins Development of a Product under a Development Plan other than the
Development Plan in Schedule 1.19, the Program Liaisons will prepare such
Development Plan, and the Parties must agree in

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -15-

<PAGE>

writing upon such Development Plan before Vanda commences Development of the
Product under such Development Plan.

     5.2 DEVELOPMENT

          5.2.1 Vanda shall use good faith Commercially Reasonable Efforts to
Develop the Compounds and Products.

          5.2.2 As soon as reasonably practicable after the Effective Date,
Vanda shall commence Phase II Clinical Studies for the Product in accordance
with the Development Plan set forth in Schedule 1.19 and this Agreement. In any
event, Vanda (a) shall initiate Phase II Clinical Studies for-the first Product
no later than six (6) months after the Effective Date, (b) complete (at least)
one-Phase II Clinical Study for the first Product no later than twelve (12)
months after commencement of the first Phase II Clinical Study (i.e., the date
when the first patient in the study is dosed), (c) shall initiate Phase III
Clinical Studies for the first Product no later than twenty-four (24) months
after completing the first Phase II Clinical Study, and (d) shall file an NDA
for the first Product no later than six (6) years after the Effective Date. In
the event that any of such milestones are missed, it shall be deemed a material
breach of this Agreement for the purposes of Article 13. BMS' ability to
terminate this Agreement pursuant to Section 13.2 shall apply without regard to
whether any circumstances falling within Section 14.4 might otherwise excuse (in
whole or in part) any inability or failure to meet any such milestones. If Vanda
misses any of the above milestone dates, Vanda may request that BMS grant a
reasonable extension to allow it to meet such milestone, and BMS agrees that it
will not unreasonably withhold its assent to any such reasonable revision where
supported by clear evidence that Vanda has been making good faith and diligent
efforts to achieve the milestones but has failed as a result of technical
difficulties or delays that the parties could not have reasonably avoided in the
achievement of such milestones; and provided, that BMS may also need to seek
approval of MGH in such event, and any approval by BMS shall further be
conditioned on receipt of approval of MGH.

     5.3 DEVELOPMENT REPORTS. Vanda shall provide quarterly written reports to
BMS, within thirty (30) days following the end of each calendar quarter,
presenting a meaningful summary of the Development activities accomplished by
Vanda and results obtained through the end of such quarter. Such reports shall
include all material results, information and data generated in the course of
Development of Products. Vanda will make Development plans, clinical protocols,
investigator brochures and regulatory submissions available to BMS at BMS'
written request. In addition, on reasonable request by BMS, Vanda will meet with
BMS to make presentations of the Development activities taken relating to the
Products.

     5.4 RECORDS. Vanda shall maintain complete and accurate records of all work
conducted in furtherance of the Development and Commercialization of the
Compounds and Products and all results, data and developments made in
furtherance thereof. Such records shall be complete and accurate and shall fully
and properly reflect all work done and results achieved in sufficient detail and
in good scientific manner appropriate for patent and regulatory purposes.

                                      -16-

<PAGE>

     5.5 DEVELOPMENT RESPONSIBILITIES AND COSTS. Except in the case where BMS
enters into a Development and Commercialization Agreement or exercises its BMS
Option, Vanda shall have sole responsibility for, and shall bear the cost of
conducting, Development with respect to Products and Compounds. Vanda shall
Develop the Compounds and Products in compliance with all applicable legal and
regulatory requirements, including without limitation all legal and regulatory
requirements pertaining to the design and conduct of clinical studies.

     5.6 REGULATORY RESPONSIBILITIES AND COSTS.

          5.6.1 Regulatory Interactions. Only in the case where Vanda does not
enter into any Development and Commercialization Agreements and BMS does not
exercise the BMS Option, Vanda shall have sole responsibility for, and shall
bear the cost of preparing, all regulatory filings and related submissions with
respect to Compounds or Products. Vanda shall be the primary interface with and
otherwise handle all interactions with Regulatory Authorities concerning
Compounds or Products. To the extent not prohibited by law or regulation, BMS
shall have the right to have one representative participate in all material
meetings pertaining to Development of a Product between representatives of Vanda
and Regulatory Authorities of the Major Market Countries and the FDA. Vanda will
provide BMS, at least five (5) business days before any such meeting, with
copies of all documents, correspondence and other materials in its possession
which are relevant to the matters to be addressed at any such meeting. Vanda
will provide BMS with draft and final copies (which may be wholly or partly in
electronic form) of all material correspondence with Regulatory Authorities
relating to the Product, including any draft Marketing Authorizations, for BMS'
review and comment within a reasonable time prior to filing with the Regulatory
Authorities. Vanda will be responsible for meeting the requirements of all
pre-approval inspections required by any Regulatory Authorities.

          5.6.2 Ownership of Regulatory Filings. Vanda shall own all INDs,
Marketing Authorizations, Approvals and submissions in connection therewith and
Approvals shall be obtained by and in the name of Vanda, unless and until BMS
(a) has entered into a Development and Commercialization Agreement with Vanda
pursuant to Section 3.1, or (b) has exercised the BMS Option.

                                    ARTICLE 6
                                COMMERCIALIZATION

     6.1 COMMERCIALIZING PARTY'S RESPONSIBILITIES.

          6.1.1 Introduction. The Party Commercializing a Product in a country
(the "Commercializing Party") shall use Commercially Reasonable Efforts to
Commercialize the Product and, at a minimum, effect introduction of the Product
into such country as soon as reasonably practicable.

                                      -17-

<PAGE>

          6.1.2 Continued Availability. Following the First Commercial Sale of a
Product in a country in the Territory and until the expiration or termination of
this Agreement, the Commercializing Party shall use Commercially Reasonable
Efforts to supply and keep the Product reasonably available to the public in
such country.

          6.1.3 Marking. Each Product Commercialized by Vanda under this
Agreement shall be marked (to the extent not prohibited by law): (a) with a
notice that such Product is sold under a license from BMS and (b) with all
patent and other intellectual property notices relating to the BMS Patent Rights
in such a manner as may be required by applicable law.

                                    ARTICLE 7

                             MANUFACTURE AND SUPPLY

     7.1 RESPONSIBILITY. Subject to Section 7.2, the Commercializing Party for a
Product shall be solely responsible at its expense for all of its requirements
in the Territory for any purpose of the Product and the Compound contained in
the Product and shall use Commercially Reasonable Efforts to supply all
requirements of its customers. The Commercializing Party shall manufacture, or
cause to have manufactured, the Product and the Compound contained in the
Product in compliance with all applicable legal and regulatory requirements and
with its internal policies and procedures.

     7.2 PROVISION OF COMPOUNDS. As soon as possible after the Effective Date,
(and no later than thirty (30) days) BMS will transfer to Vanda [*] active
pharmaceutical ingredient that has been requalified by BMS to be within
specification as well as the most recent reference standard that has been
submitted.

     7.3 RIGHT TO MANUFACTURE COMMERCIAL SUPPLY. In the event that BMS has
entered into a Development and Commercialization Agreement or exercised its BMS
Option for a particular Product, BMS will have the first right to manufacture
and supply such Product or the Compound contained in such Product at any time
thereafter for clinical and commercial use, as applicable. In the event that BMS
does not enter into a Development and Commercialization Agreement or exercise
its BMS Option for a particular Product, and Vanda enters into negotiations with
a Third Party to manufacture a clinical or commercial supply of such Product or
the Compound contained in such Product (the "Supply Agreement"), it will
promptly notify BMS and provide a reasonably detailed summary of the material
financial terms of such Supply Agreement as well as a reasonably detailed
summary of data pertinent to evaluating such opportunity. BMS will have thirty
(30) days from receipt of the data summary to notify Vanda that it will enter
into the agreement on the same material financial terms and conditions. The
Parties will then negotiate a Supply Agreement in good faith for thirty (30)
days or such longer period as agreed between the Parties. In the event the
Parties do not enter into a Supply Agreement within such thirty (30) day period,
or the agreed extension thereof, Vanda is free to enter into an agreement with
any other entity with respect to such clinical or commercial supply.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -18-

<PAGE>

                                    ARTICLE 8

                                    PAYMENTS

     8.1 TECHNOLOGY ACCESS FEE. On the Effective Date, Vanda will pay to BMS the
sum of five hundred thousand Dollars ($500,000) as partial reimbursement for
BMS' previously incurred research and development expenses for the Compounds.

     8.2 MILESTONE PAYMENTS.

          8.2.1 Milestone Payments By Vanda. In the event that Vanda is
Developing or Commercializing a Product in any country and/or has entered into a
Development and Commercialization Agreement for the Product with a Third Party,
then Vanda will pay BMS, as partial reimbursement for research and development
expenses for the Compounds, upon Vanda or such Third Party achieving the
following milestones for that Product:

<TABLE>
<CAPTION>
MILESTONE   DOLLARS
---------   -------
<S>         <C>
[*]           [*]
[*]           [*]
[*]           [*]
[*]           [*]
</TABLE>

          8.2.2 "BMS Option" Milestone Payments by BMS. In the event that BMS
exercises its BMS Option for a particular Product, then BMS will pay Vanda, as
partial reimbursement for research and development expenses for the Compounds,
upon BMS achieving the following milestones for that Product:

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -19-

<PAGE>

<TABLE>
<CAPTION>
MILESTONE   DOLLARS
---------   -------
<S>         <C>
   [*]        [*]

   [*]        [*]

   [*]        [*]
</TABLE>

          8.2.3 No Milestone under any of Sections 8.2.1 and 8.2.2 shall be paid
more than one time on a Product, regardless of the number of indications
obtained for the Product or number of formulations, dosages or presentations of
the particular active Compound in such Product.

     8.3 TIMING. Payment shall be made on or before the thirtieth (30th)
Business Day following the occurrence of an event giving rise to a payment
obligation hereunder. All payments to BMS shall be made by wire transfer in
Dollars to the credit of the bank account indicated below or to such other
account as may be designated, from time to time, by BMS in writing. All Payments
to Vanda shall be made by wire transfer in Dollars to the credit of such bank
account as may be designated, from time to time, by Vanda in writing.

Bank:              [*]

ABA No.:           [*]

Account No.:       [*]

Account Name:      [*]

Company Details:   [*]

     8.4 DEVELOPMENT COSTS.

          8.4.1 Vanda Development Costs. Vanda will be responsible for all
Development Costs, unless BMS enters into a Development and Commercialization
Agreement prior to the BMS Option Period, in which the terms may involve sharing
in Development Costs for that Product.

          8.5 ROYALTY PAYMENT.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -20-

<PAGE>

          8.5.1 Vanda Royalty to BMS. In the event that Vanda Commercializes a
Product and/or enters into a Development and Commercialization Agreement with a
Third Party for the Product, then Vanda will pay BMS a [*] percent ([*]%)
royalty on annual Net Sales of that Product by Vanda, its Affiliates, and
sublicensees, including but not limited to such Third Party, in he Territory, In
the event that Vanda enters into one or more Development and Commercialization
Agreements for a particular Product, Vanda will also pay BMS [*] percent ([*]%)
of any and all sublicense fees, upfront payments and milestone payments (other
than running royalties) that are received by Vanda in consideration of each such
Development and Commercialization Agreement. Vanda agrees that it shall also pay
MGH, on behalf of BMS, all financial obligations of BMS under the MGH License
Agreement arising from the Development, manufacture and Commercialization of
Products by Vanda, its Affiliates and sublicensees, including but not limited to
any royalty obligation under the MGH License Agreement arising from the sale of
any Product by Vanda, its Affiliates or sublicensees in the Territory, and shall
comply with and fulfill all applicable terms and conditions of the MGH License
Agreement. Without limiting the foregoing, with respect to each Product, Vanda
shall comply with and fulfill all of the applicable terms and conditions of the
MGH License Agreement relating to the Development, manufacture and
Commercialization of Products by Vanda, its Affiliates and sublicensees, which
shall include making the royalty payments in accordance with the terms and
conditions of the MGH License Agreement, beeping books of accounting and making
them available for inspection by MGH in accordance with the terms and conditions
of the MGH License Agreement, providing any information and reports to MGH
required by the terms and conditions of the MGH License Agreement in connection
with the sale of any Product, and obtaining and maintaining the type and amounts
of insurance required of BMS under the MGH License Agreement. Vanda shall
provide BMS with a copy of each document provided to MGH in accordance with the
terms and conditions of the MGH License Agreement, including but not limited to
a copy of each royalty report and a copy of any other document providing
information to MGH.

          8.5.2 BMS Royalty to Vanda. In the event that BMS exercises its BMS
Option for a particular Product, BMS will pay directly to Vanda a [*] percent
([*]%) royalty on annual Net Sales of that Product by BMS, its Affiliates and
sublicensees in the Remaining Countries. If, however, BMS entered into a
Development, and Commercialization Agreement, BMS would pay [*].

          Each of the foregoing shall be collectively and individually referred
to as "Royalties." The Party paying Royalties shall be referred to as the
"Royalty Paying Party". The Party receiving Royalty payments shall be referred
to as the "Royalty Receiving Party".

     8.6 THIRD PARTY ROYALTY PAYMENTS. The Royalty Paying Party shall be
responsible for making any Third Party license payments, whether existing as of
or arising after the Effective Date and reasonably necessary to Develop or
Commercialize the Product.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -21-

<PAGE>

     8.7 ROYALTY OFFSET FOR THIRD PARTY ROYALTY PAYMENTS. Other than any
royalties due to a Third Party under the MGH License Agreement or under
agreements existing as of the Effective Date with respect to the manufacture,
use or sale of a Product, the Royalty Paying Party, its Affiliate and
sublicensees shall, except where Section 8.8.2 applies, be entitled to offset up
to [*] percent ([*]%) of any royalties due to the Royalty Receiving Party by the
amount of any royalties and license fees paid to a Third Party reasonably
necessary to enable the Royalty Paying Party to sell the Product in a country in
the Territory; provided, that the royalty payable to the Royalty Receiving Party
shall not be reduced below [*] of what it would otherwise have received in the
absence of this Section 8.7.

     8.8 TERM FOR ROYALTY PAYMENTS.

          8.8.1 Term. Royalties shall be payable on a country by country basis
from the First Commercial Sale until the later of (a) ten (10) years from the
First Commercial Sale and (b) the expiration of the last to expire patent owned
or Controlled by the Royalty Receiving Party (including extensions thereof) with
a Valid Claim directed to the Product, including, without limitation, a method
of use thereof.

          8.8.2 Countries With No Valid Claim Covering Product. If at any time
during the royalty period set forth in 8.8.1 there is in a country no patent
owned or Controlled by the Royalty Receiving Party with a Valid Claim directed
to the Product or a method of use thereof, then the royalties shall be reduced
by [*] percent ([*]%) with respect to the Net Sales of the Product in such
country.

     8.9 SALES REPORTS

          8.9.1 Substance of Reports. After the First Commercial Sale of Product
and during the term of this Agreement, the Royalty Paying Party shall furnish or
cause to be furnished to the Royalty Receiving Party a written report, within 30
days after the end of each calendar quarter, showing the amount of royalty due
calculated for such calendar quarter, with the royalty due paid to the Royalty
Receiving Party at the time such report is provided. With each quarterly
payment, the Royalty Paying Party shall deliver to the Royalty Receiving Party a
full and accurate accounting to include at least the following information:

               (a) Quantity of each Product sold or leased (by country) by the
Royalty Paying Party, and its Affiliates or sublicensees;

               (b) Total billings for each Product (by country);

               (c) Quantities of each Product used by the Royalty Paying Party
and its Affiliates or sublicensees or sold to the U.S. Government;

               (d) Names and Addresses of all sublicensees of the Royalty Paying
Party; and

               (e) Total royalties payable to the Royalty Receiving Party.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -22-

<PAGE>

          8.9.2 Sales Record Audit. The Royalty Paying Party shall keep, and
shall cause each of its Affiliates and sublicensees, if any, to keep full and
accurate books of accounting containing all particulars that may be necessary
for the purpose of calculating all royalties payable to the Royalty Receiving
Party. Such books of accounting shall be kept at their principal place of
business and, with all necessary supporting data, shall during all reasonable
times for the [*] next following the end of the calendar year to which each
shall pertain, be open for inspection at reasonable times by an independent
certified accountant selected by the Royalty Receiving Party, and as to which
the Royalty Paying Party has no reasonable objection, at the Royalty Receiving
Party's expense, for the purpose of verifying royalty statements for compliance
with this Agreement. Such accountant must have agreed in writing to maintain all
information learned in confidence, except as necessary to disclose to the
Royalty Receiving Party such compliance or noncompliance by the Royalty Paying
Party. The results of each inspection, if any, shall be binding on both Parties.
The Royalty Receiving Party shall pay for such inspections, except that in the
event there is any upward adjustment in aggregate royalties payable for any year
shown by such inspection of more than [*] percent ([*]%) of the amount paid, the
Royalty Paying Party shall pay for such inspection. Any overpayments shall be
fully creditable against amounts payable in subsequent payment periods.

     8.10 CURRENCY EXCHANGE. With respect to Net Sales invoiced in Dollars, the
Net Sales and the amounts due to the Royalty Receiving Party hereunder shall be
expressed in Dollars. With respect to Net Sales invoiced in a currency other
than Dollars, the Net Sales shall be expressed in the domestic currency of the
entity making the sale, together with the Dollar equivalent, calculated using
the arithmetic average of the spot rates on the close of business on last
Business Day of each month of the calendar quarter in which the Net Sales were
made. The "closing mid-point rates" found in the "dollar spot forward against
the dollar" table published by The Financial Times or any other publication as
agreed to by the Parties shall be used as the source of spot rates to calculate
the average as defined in the preceding sentence. All payments shall be made in
Dollars. If at any time legal restrictions in any country in the Territory
prevent the prompt remittance of any payments with respect to sales in that
country, the Royalty Paying Party shall have the right and option to make such
payments by depositing the amount thereof in local currency to the Royalty
Receiving Party's account in a bank or depository in such country.

     8.11 TAX WITHHOLDING. The withholding tax, duties, and other levies (if
any) applied by a government of any country of the Territory on payments made by
the Royalty Paying Party, to the Royalty Receiving Party hereunder shall be
borne by the Royalty Receiving Party. The Royalty Paying Party, its Affiliates
and sublicensees shall cooperate with the Royalty Receiving Party to enable the
Royalty Receiving Party to claim exemption therefrom under any double taxation
or similar agreement in force and shall provide to the Royalty Receiving Party
proper evidence of payments of withholding tax and assist the Royalty Receiving
Party by obtaining or providing in as far as possible the required documentation
for the purpose of the Royalty Receiving Party' tax returns.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -23-

<PAGE>

     8.12 INTEREST DUE. In case of any delay in payment by the Royalty Paying
Party to the Royalty Receiving Party not occasioned by Force Majeure, interest
on the overdue payment shall accrue [*], as determined for each month on the
last business day of that month, assessed from the day payment was initially
due. The foregoing interest shall be due from the Royalty Paying Party without
any special notice.

                                    ARTICLE 9

       REPRESENTATIONS AND WARRANTIES; DISCLAIMER; LIMITATION OF LIABILITY

     9.1 MUTUAL WARRANTIES. Each Party represents and warrants to the other
Party that (a) it (and in the case of Vanda, its general partner as well) has
all requisite corporate power and authority to enter into this Agreement, to
grant the licenses granted by it hereunder, and to perform its other obligations
under this Agreement, (b) execution of this Agreement and the performance by the
warranting Party (and in the case of Vanda, by its general partner as well) of
its obligations hereunder, including, without limitation, the licenses granted
by that Party hereunder, have been duly authorized, (c) this Agreement is fully
binding and enforceable on each Party (and in the case of Vanda, on its general
partner as well) in accordance with its terms, and (d) the performance of this
Agreement by it does not create a breach or default under any other agreement to
which it (and in the case of Vanda, to which its general partner as well) is a
Party.

     9.2 BMS WARRANTIES AND COVENANTS. As of the Effective Date, BMS represents
and warrants to Vanda that, to the actual knowledge of its in-house patent
counsel (based on such counsels' good faith understanding of the facts and
information in their possession without any duty to conduct any investigation
with respect to such facts and information), (a) there is no pending litigation
which alleges, or any written communication alleging, that BMS' activities with
respect to the BMS Patent Rights or the Compounds have infringed or
misappropriated any of the intellectual property rights of any Third Party, (b)
all fees required to be paid by BMS in order to maintain the patents licensed to
Vanda hereunder have been paid to date as of the Effective Date such that the
claims included in any such issued patents are in full force and effect as of
the Effective Date, (c) the BMS Patent Rights exist and are not invalid or
unenforceable, in whole or in part, (d) it has the full right, power and
authority to enter into this Agreement and to grant the licenses granted under
Article II hereof, (e) it has not previously assigned, transferred, conveyed or
otherwise encumbered its right, title and interest in the BMS Patent Rights or
the BMS Know-How, and (f) it is the sole and exclusive owner of the BMS Patent
Rights and the BMS Know-How.

     9.3 VANDA WARRANTIES AND COVENANTS.

          9.3.1 Vanda warrants, represents and covenants that all of its
activities related to its use of the BMS Patent Rights and BMS Know-How, and
the Development and Commercialization of the Compounds and Products, pursuant to
this Agreement shall comply in all material respects with all applicable legal
and regulatory requirements.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -24-

<PAGE>

Vanda further warrants and covenants that it shall not engage in any activities
that use the BMS Patent Rights and BMS Know-How in a manner that is outside the
scope of the license rights granted to it hereunder.

          9.3.2 Vanda warrants, represents and covenants that it has available
to it funds necessary to consummate the transaction contemplated by this
Agreement to Develop and Commercialize the Compounds and Products in accordance
with the terms of this Agreement.

     9.4 DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, BMS MAKES
NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE BMS PATENT RIGHTS OR BMS
KNOW-HOW OR ANY LICENSE GRANTED BY BMS HEREUNDER, OR WITH RESPECT TO ANY
COMPOUNDS OR PRODUCTS. FURTHERMORE, NOTHING IN THIS AGREEMENT SMALL BE CONSTRUED
AS A WARRANTY THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE BMS
PATENT RIGHTS ARE VALID OR ENFORCEABLE OR THAT VANDA'S USE OF THE BMS PATENT
RIGHTS AND BMS KNOW-HOW CONTEMPLATED HEREUNDER DOES NOT INFRINGE ANY PATENT
RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY.

     9.5 LIMITATION OF LIABILITY. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR
OTHERWISE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER WITH RESPECT TO ANY
SUBJECT MATTER OF THIS AGREEMENT, WHETHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT
LIABILITY, OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY INCIDENTAL, INDIRECT,
SPECIAL, EXEMPLARY, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT
NOT LIMITED TO, LOST PROFITS, LOSS OF USE, DAMAGE TO GOODWILL, OR LOSS OF
BUSINESS) AND, IN ANY CASE, BMS SHALL NOT BE LIABLE IN AN AMOUNT GREATER THAN
THE AMOUNTS PAID BY VANDA TO BMS UNDER SECTIONS 8.1, 8.2 AND 8.5 OF THIS
AGREEMENT; PROVIDED, THAT THE FOREGOING SHALL NOT APPLY TO ANY BREACH BY VANDA
OF THE RIGHTS LICENSED TO IT UNDER ARTICLE 2 HEREOF OR TO ANY BREACH BY A PARTY
OF ARTICLE 11 HEREOF.

                                   ARTICLE 10
                PATENT MAINTENANCE; INFRINGEMENT; CONFIDENTIALITY

     10.1 INVENTIONS. Each Party shall own the entire right, title and interest
in and to any and all inventions conceived solely by its employees and agents
after the Effective Date ("Sole Inventions"), and any patents covering such Sole
Inventions. BMS and Vanda shall each own an undivided one-half interest in and
to any and all inventions conceived jointly after the Effective Date by (a)
employees and agents of BMS and (b) employees and agents of Vanda, and in and to
any patents and other intellectual property

                                      -25-

<PAGE>

rights claiming or covering such joint Inventions ("Joint Inventions"). BMS and
Vanda as joint owners each shall have the right to exploit and to grant licenses
under such Joint Inventions (without an accounting or obligation to, or consent
required from, the other Party), unless otherwise specified in this Agreement.

     10.2 PATENT MAINTENANCE; ABANDONMENT.

          10.2.1 BMS PATENT RIGHTS. BMS shall be responsible for, and shall
control, the prosecution (including any interferences, reissue proceedings and
reexaminations) and maintenance of all BMS Patent Rights. BMS shall provide
Vanda with copies of all correspondence from any and all patent offices
concerning the BMS Patent Rights and an opportunity to comment on any proposed
responses, voluntary amendments and submissions of any kind to be made to any
and all such patent offices (other than routine filings and correspondence to
maintain the patents). BMS shall have the right to select the in-house or
outside counsel who will perform the aforementioned prosecution and
maintenance-associated activities, and Vanda shall reimburse BMS for its
fully-burdened costs (including any fees payable to the applicable patent
office) incurred in connection therewith. In the event that BMS exercises the
BMS Option and the Parties are co-Developing or co-promoting the Product, Vanda
will only reimburse BMS for fifty percent (50%) of the patent costs incurred
from the commencement of the Phase III Clinical Studies (i.e., the date when the
first patient in the Phase III Clinical Studies is dosed) or the effective date
of the co-promotion agreement, as applicable. If Vanda elects not to pay any
expenses with respect to a BMS Patent Right in a given country, Vanda shall
inform BMS in writing not less than two months before any relevant deadline (or,
in the event of a shorter period in which to respond to a patent office, as soon
as reasonably practicable). In the event Vanda makes such election, or if Vanda
fails to reimburse BMS for its fully-burdened costs incurred for prosecuting and
maintaining a BMS Patent Right in a given country, BMS may retain or abandon
such BMS Patent Right at its sole discretion and Vanda's license under such BMS
Patent Right shall be extinguished. Except as provided in the previous sentence,
BMS may not abandon a BMS Patent Right without the prior written consent of
Vanda.

          10.2.2 SOLE INVENTIONS. Each Party shall direct and control at its
expense the filing, prosecution (including any interferences, reissue
proceedings and reexaminations) and maintenance of all patents covering its Sole
Inventions.

          10.2.3 JOINT INVENTIONS. The Parties shall supervise, and shall
assign, on a Joint Invention-by-Joint Invention basis, one Party to be
responsible for, the filing, prosecution (including any interferences, reissue
proceedings and reexaminations) and maintenance of all patents covering such
Joint Invention consistent with such strategy. The designated controlling Party
shall provide the other Party with (a) drafts of any new patent application that
covers a Joint Invention prior to filing that application, allowing adequate
time for review and comment by the Party if possible; provided, however, the
designated controlling Party shall not be obligated to delay the filing of any
patent application; and (b) copies of all correspondence from any and all patent
offices concerning patent applications covering Joint Inventions and an
opportunity to comment on any proposed responses, voluntary amendments and
submissions of any kind to be

                                      -26-

<PAGE>

made to any and all such patent offices. The Parties shall mutually agree on the
in-house or outside counsel who will perform the filing, prosecution and
maintenance of Joint Inventions and the allocation of out-of-pocket costs
incurred in connection therewith.

     10.3 ENFORCEMENT OF BMS PATENT RIGHTS AGAINST INFRINGERS.

          10.3.1 Enforcement by BMS. In the event that BMS or in-house counsel
of Vanda becomes aware of a suspected infringement of any BMS Patent Right, such
Party shall notify the other Party promptly, and following such notification,
the Parties shall confer. BMS shall have the right, but shall not be obligated,
to bring an infringement action at its own expense, in its own name and entirely
under its own direction and control. Vanda will reasonably assist BMS (at BMS'
expense) in any action or proceeding being prosecuted if so requested, and will
lend its name to such actions or proceedings if requested by BMS or required by
law, and BMS will indemnify and hold Vanda harmless from any liability incurred
by Vanda arising out of any such actions or proceedings. Vanda shall have the
right to participate and be represented in any such suit by its own counsel at
its own expense. No settlement of any such action or defense which restricts the
scope, or adversely affects the enforceability, of a BMS Patent Right may be
entered into by BMS without the prior written consent of Vanda, which consent
shall not be unreasonably withheld.

          10.3.2 Enforcement by Vanda. If BMS elects not to bring any action for
infringement described in Section 10.3.1 and so notifies Vanda, then Vanda may
bring such action at its own expense, in its own name and entirely under its own
direction and control. BMS will reasonably assist Vanda (at Vanda' expense) in
any action or proceeding being prosecuted if so requested, and will lend its
name to such actions or proceedings if requested by Vanda or required by law,
and Vanda will indemnify and hold BMS harmless from any liability incurred by
BMS arising out of any such actions or proceedings. BMS shall have the right to
participate and be represented in any such suit by its own counsel at its own
expense. No settlement of any such action or defense which restricts the scope,
or adversely affects the enforceability, of a BMS Patent Right may be entered
into by Vanda without the prior written consent of BMS, which consent shall not
be unreasonably withheld.

          10.3.3 Withdrawal. If either Party brings such an action or defends
such a proceeding under this Section 10.3 and subsequently ceases to pursue or
withdraws from such action or proceeding, it shall promptly notify the other
Party and the other Party may substitute itself for the withdrawing Party under
the terms of this Section 10.3.

          10.3.4 Damages. In the event either Party exercises the rights
conferred in this Section 10.3 and recovers any damages or other sums in such
action, suit or proceeding or in settlement thereof, such damages or other sums
recovered shall first be applied to all out-of-pocket costs and expenses
incurred by the Parties in connection therewith, including attorneys fees. If
such recovery is insufficient to cover all such costs and expenses of both
Parties, it shall be shared in proportion to the total such costs and expenses
incurred by each Party. If after such reimbursement any funds shall remain from
such damages or other sums recovered, such funds shall be retained by the Party

                                      -27-

<PAGE>

that controlled the action or proceeding under this Section 10.3; provided, that
the Royalty Receiving Party shall receive out of any such remaining recovery
received by the Royalty Paying Party an amount equal to the lost royalties or
other license payments that would have been paid to it on the Net Sales to which
such recovery pertains.

     10.4 DEFENSE OF THIRD PARTY CLAIMS. If a claim is brought by a Third Party
against either Party that any activity related to the Development, manufacture,
Commercialization, use, sale, import or export of a Compound or Product
infringes the intellectual property rights of such Third Party, each Party will
give prompt written notice to the other Party of such claim. The Royalty Paying
Party shall control and bear the expense of its own defense, and shall be solely
responsible for, and shall defend, indemnify and hold harmless the Royalty
Receiving Party and its Affiliates from and against, any such claims, damages,
losses, liabilities, costs (including without limitation reasonable legal
expenses, costs of litigation, and reasonable attorney's fees) or judgments,
whether for money or equitable relief.

                                   ARTICLE 11

                   NONDISCLOSURE OF CONFIDENTIAL INFORMATION.

     11.1 NONDISCLOSURE. Each Party agrees that for a period of [*] after
receipt of Confidential Information from the other Party, a Party receiving
Confidential Information of the other Party will (a) use commercially reasonable
efforts to maintain in confidence such Confidential Information (but not less
than those efforts as such Party uses to maintain in confidence its own
proprietary industrial information of similar kind and value) and not to
disclose such Confidential Information to any Third Party without prior written
consent of the other Party, except for disclosures made in confidence to any
Third Party under terms consistent with this Agreement and made in furtherance
of this Agreement or of rights granted to a Party hereunder, and (b) not use
such other Party's Confidential Information for any purpose except those
permitted by this Agreement (it being understood that this subsection (b) shall
not create or imply any rights or licenses not expressly granted under Article 2
hereof).

          11.1.1 EXCEPTIONS. The obligations in Section 11.1 shall not apply
with respect to any portion of the Confidential Information that the receiving
Party can show by competent proof:

               (a) Is publicly disclosed by the disclosing Party, either before
or after it is disclosed to the receiving Party hereunder; or

               (b) Was known to the receiving Party or any of its Affiliates,
without obligation to keep it confidential, prior to disclosure by the
disclosing Party; or

               (c) Is subsequently disclosed to the receiving Party or any of
its Affiliates by a Third Party lawfully in possession thereof and without
obligation to keep it confidential; or

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -28-

<PAGE>

               (d) Is published by a Third Party or otherwise becomes publicly
available or enters the public domain, either before or after it is disclosed to
the receiving Party; or

               (e) Has been independently developed by employees or contractors
of the receiving Party or any of its Affiliates without the aid, application or
use of Confidential Information.

     11.2 AUTHORIZED DISCLOSURE. A Party may disclose the Confidential
Information belonging to the other Party to the extent such disclosure is
reasonably necessary in the following instances:

          11.2.1 Filing or prosecuting patents;

          11.2.2 Regulatory filings;

          11.2.3 Prosecuting or defending litigation;

          11.2.4 Complying with applicable governmental laws and regulations and
with judicial process;

          11.2.5 Disclosure, in connection with the performance of this
Agreement, to Affiliates, potential collaborators, partners, and counterparties
(including potential co-marketing and co-promotion contractors), research
collaborators, potential investment bankers, investors, lenders, and investors,
employees, consultants, or agents, each of whom prior to disclosure must be
bound by similar obligations of confidentiality and non-use at least equivalent
in scope to those set forth in this Section 11.2; and

          11.2.6 For purposes of raising capital, provided that prior to
disclosure, each Third Party to whom Confidential Information is disclosed must
be bound by similar obligations of confidentiality and non-use at least
equivalent in scope to those set forth in this Section 11.2.

     11.3 TERMS OF THIS AGREEMENT. The Parties acknowledge that the terms of
this Agreement shall be treated as Confidential Information of both Parties.
Such terms may be disclosed by a Party to individuals or entities covered by
Sections 11.2.5 and 11.2.6 above, each of whom prior to disclosure must be bound
by similar obligations of confidentiality and non-use at least equivalent in
scope to those set forth in this Section 11.3. In addition, a copy of this
Agreement may be filed by either Party with the Securities and Exchange
Commission in connection with any public offering of such Party's securities.
In connection with any such filing, such Party shall endeavor to obtain
confidential treatment of economic and trade secret information. In any event,
the Parties agree to take all reasonable action to avoid disclosure of
Confidential Information except as permitted hereunder.

     11.4 EXCEPTION FOR DISCLOSURE OF TAX TREATMENT. Notwithstanding anything
else in this Agreement to the contrary, each Party hereto (and each employee,
representative, or other agent of any Party) may disclose to any and all
persons, without

                                      -29-

<PAGE>

limitation of any kind, the Federal income tax treatment and Federal income tax
structure of any and all transaction(s) contemplated herein and all materials of
any kind (including opinions or other tax analyses) that are or have been
provided to any Party (or to any employee, representative, or other agent of any
Party) relating to such tax treatment or tax structure, provided, however, that
this authorization of disclosure shall not apply to restrictions reasonably
necessary to comply with securities laws. This authorization of disclosure is
retroactively effective immediately upon commencement of the first discussions
regarding the transactions contemplated herein, and the Parties aver and affirm
that this tax disclosure authorization has been given on a date which is no
later than thirty (30) days from the first day that any Party hereto (or any
employee, representative, or other agent of any Party hereto) first made or
provided a statement as to the potential tax consequences that may result from
the transactions contemplated hereby.

                                   ARTICLE 12

                                    INDEMNITY

     12.1 VANDA INDEMNITY. Vanda shall indemnify, defend and hold harmless BMS
and its Affiliates and the officers, directors, employees, agents, licensors
(including without limitation MGH and its officers, medical and professional
staff, employees, trustees, and agents and their respective successors, heirs
and assigns) and representatives of BMS and its Affiliates from and against any
and all claims, threatened claims, damages, losses, suits, proceedings,
liabilities, costs (including without limitation reasonable legal expenses,
costs of litigation, and reasonable attorney's fees) or judgments, whether for
money or equitable relief, of any kind ("Losses and Claims") arising out of or
relating to, directly or indirectly, (i) the research, Development, manufacture,
use, sale or other disposition, promotion, advertising, Commercialization,
offering for sale, importation, handling, storage, transfer, or exportation of
any Compound or Product by Vanda and its Affiliates, sublicensees and
contractors or to Vanda's (or its Affiliates' and sublicensees') use and
practice otherwise of the BMS Patent Rights and BMS Compound Know-How,
including without limitation, Claims based on (a) product liability, bodily
injury, death or property damage, and (b) infringement or misappropriation of
Third Party patents, copyrights, trademarks, or other intellectual property
rights, or the failure to comply with applicable Laws related to the research,
development, Commercialization, promotion, distribution and sale of the Products
and/or to the manufacture and labeling of the Products; except for Losses and
Claims to the extent reasonably attributable to (i) breach by BMS of Article 11,
or (ii) BMS having committed an act or acts of gross negligence, recklessness,
or willful misconduct. A claim to which indemnification applies under this
Section 12.1 or Section 12.2 shall be referred to herein as an "Indemnification
Claim".

     12.2 BMS INDEMNITY. Only in the event that BMS exercises the BMS Option
with respect to a Product shall BMS indemnify, defend and hold harmless Vanda
and its Affiliates and the officers, directors, employees, agents, licensors and
representatives of Vanda and its Affiliates from Losses and Claims arising out
of or relating to, directly or

                                      -30-

<PAGE>

indirectly, (i) the research, Development, manufacture, use, sale or other
disposition, promotion, advertising, Commercialization, offering for sale,
importation, handling, storage, transfer, or exportation of that Product by BMS
and its Affiliates, sublicensees and contractors or to BMS' (or its Affiliates'
and sublicensees') use and practice of the BMS Patent Rights and BMS Compound
Know-How in the Development and Commercialization of that Product, including
without limitation, Claims based on (a) product liability, bodily injury, death
or property damage, and (b) infringement or misappropriation of Third Party
patents, copyrights, trademarks, or other intellectual property rights, or the
failure to comply with applicable Laws related to the research, development,
Commercialization, promotion, distribution and sale of that Product and/or to
the manufacture and labeling of that Product; except for Losses and Claims to
the extent reasonably attributable to (i) breach by Vanda of Article 11, or (ii)
Vanda having committed an act or acts of gross negligence, recklessness, or
willful misconduct.

     12.3 INDEMNIFICATION PROCEDURES. If a party or any its Affiliates or their
respective officers, directors, employees, agents, licensors and representatives
(collectively, the "Indemnitee") intends to claim indemnification under this
Article 12, the Indemnitee shall notify the other party (the "Indemnitor") in
writing promptly upon becoming aware of any Claim that may be an Indemnification
Claim The Indemnitor shall have the right to assume and control the defense of
the Indemnification Claim at its own expense. If the right to assume and have
sole control of the defense is exercised by the Indemnitor, the Indemnitee shall
have the right to participate in, but not control, such defense at its own
expense and the Indemnitor's indemnity obligations shall not include any
attorneys, fees and litigation expenses incurred by the Indemnitee after the
assumption of the defense by the Indemnitor. If the Indemnitor does not assume
the defense of the Indemnification Claim, the Indemnitee may defend the
Indemnification Claim but shall have no obligation to do so. The Indemnitee will
not settle or compromise the Indemnification Claim without the prior written
consent of the Indemnitor, and the Indemnitor will not settle or compromise the
Indemnification Claim in any manner which would have an adverse effect on the
Indemnitee's rights under this Agreement or the scope or enforceability of the
BMS Patents Rights or BMS Know-How, without the prior written consent of the
Indemnitee, which consent, in each case, will not be unreasonably withheld. The
Indemnitee shall reasonably cooperate with the Indemnitor at the Indemnitor's
expense and will make available to the Indemnitor all pertinent information
under the control of the Indemnitee.

     12.4 INSURANCE. Vanda will, beginning with the initiation of the first
clinical trial for the Product, maintain at all times thereafter during the term
of this Agreement, and until the later of (a) six (6) years after termination or
expiration of this Agreement or (b) the date that all statutes of limitation
covering claims or suits that may be brought for personal injury based on the
sale or use of a Product have expired in all states in the U.S.A., comprehensive
general liability insurance from a recognized, creditworthy insurance company,
on a claims-made basis, with endorsements for contractual liability and product
liability, and with coverage limits of not less than Five Million Dollars
($5,000,000) per occurrence and Twenty-five Million dollars ($25,000,000) in the
aggregate. The minimum level of insurance set forth herein shall not be
construed to create a limit on Vanda's liability hereunder. Within ten days
following written request

                                      -31-

<PAGE>

from BMS, Vanda shall furnish to BMS a certificate of insurance evidencing such
coverage as of the date. Each such certificate of insurance, as well as any
certificates evidencing new or modified coverages of Vanda, shall include a
provision whereby sixty (60) days' written notice must be received by BMS prior
to coverage modification or cancellation by either Vanda or the insurer and of
any new or modified coverage. In the case of a modification or cancellation of
such coverage, Vanda shall promptly provide BMS with a new certificate of
insurance evidencing that Vanda's coverage meets the requirements in the first
sentence of this Section.

                                   ARTICLE 13

                              TERM AND TERMINATION

     13.1 TERM. This Agreement shall commence upon the Effective Date and,
unless sooner terminated in accordance with the terms hereof or by mutual
written consent, shall continue until neither Party has any obligation to the
other remaining hereunder.

     13.2 TERMINATION BY BMS. BMS shall have the right to terminate this
Agreement, at BMS' sole discretion, upon delivery of written notice to Vanda,
upon the occurrence of any of the following:

          13.2.1 INSOLVENCY. Upon the filing by Vanda in any court or agency
pursuant to any statute or regulation of the United States or any other
jurisdiction a petition in bankruptcy or insolvency or for reorganization or
similar arrangement for the benefit of creditors or for the appointment of a
receiver or trustee of Vanda or its assets, upon the proposal by Vanda of a
written agreement of composition or extension of its debts, or if Vanda is
served with an involuntary petition against it in any insolvency proceeding,
upon the ninety-first (91st) day after such service if such involuntary petition
has not previously been stayed or dismissed, or upon the making by Vanda of an
assignment for the benefit of its creditors; or

          13.2.2 BREACH. In the event of any material breach by Vanda of any
terms and conditions of this Agreement, including failure to use Commercially
Reasonable Efforts to Develop or Commercialize a Product or Compound, provided
that such breach has not been cured within ninety (90) days after written notice
thereof is given by BMS to Vanda; provided, that if such breach relates to the
failure to make a payment when due, such breach must be cured within sixty (60)
days after written notice thereof is given by BMS.

          13.2.3 TERMINATION FOR FAILURE TO EFFECT COMMERCIAL LAUNCH. If Vanda
is obligated to Commercialize a Product and fails to effect a commercial launch
in a Major Market Country within twelve (12) months of achieving an Approval for
such Product in such country; provided however, (i) that if the failure to
launch in such Major Market Country is a consequence of lack of commercial
feasibility in such country due to the pricing/reimbursement received for the
Product in such country, then this Section shall not apply to such country; and
provided, further, (ii) that subpart (i) of this Section

                                      -32-

<PAGE>

13.2.3 may not be used to excuse launch, with respect to the European Union
("EU"), to more than two Major Market Countries of the EU. Termination under
this Section 13.2.3 shall apply only to the Major Market Country affected by
such failure to launch; provided that (iii) if such failure relates to a Major
Market Country in the EU not excused under (ii), then it shall apply to the
whole EU, and (iv) if all Major Market Countries are terminated, termination
shall be as to all countries. Nothing in the foregoing shall relieve Vanda of
its obligation to use Commercially Reasonable Efforts to Commercialize a Product
once launched in a country.

          13.2.4 SCOPE OF TERMINATION. Termination under Sections 13.2.1 and
13.2.2 shall be as to all countries and all Products.

     13.3 TERMINATION BY VANDA. Subject to Section 13.3.4, Vanda shall have the
right to terminate this Agreement, at Vanda's sole discretion, upon delivery of
written notice to BMS, upon occurrence of any of the following:

          13.3.1 TERMINATION FOR ANY REASON. At Vanda's discretion, on a
country-by-country and Product-by-Product basis, it may terminate this Agreement
for any reason; provided however, such termination shall be effective not sooner
than ninety (90) days after written notice thereof; and further provided,
however, that no such termination right may be exercised as to any Major Market
Country unless all Major Market Countries are so terminated unless such
termination in a Major Market Country is a consequence of lack of commercial
feasibility in such Major Market Country due to the pricing/reimbursement
received for the Product in such Country, in which event Vanda may terminate its
license in such Major Market Country only.

          13.3.2 TERMINATION FOR BMS' FAILURE TO EFFECT COMMERCIAL LAUNCH. If
BMS is obligated to Commercialize a Product and fails to effect a commercial
launch within twelve (12) months of achieving the first Approval for such
Product in a given Major Market Country; provided however, if the failure to
launch in such Major Market Country is a consequence of lack of commercial
feasibility due to the pricing/reimbursement received for the Product in such
Country or safety issues, then this Section 13.3 shall not apply to such failure
to launch.

          13.3.3 TERMINATION FOR BMS' CESSATION OF DEVELOPMENT. If BMS elects to
cease development of a Product in its discretion with respect to a given Major
Market Country for a period exceeding six (6) months (other than for safety
reasons or regulatory reasons).

          13.3.4 SCOPE OF TERMINATION. Termination under Sections 13.3.2 and
13.3.3 shall only be as to the countries affected by the BMS action in question
and not to the entire agreement (unless such BMS action affects all Major Market
Countries).

     13.4 EFFECT OF TERMINATION.

          13.4.1 Upon termination of this Agreement under Section 13.2.1 or
13.2.2 hereof or, with respect to each applicable country as to which
termination occurs pursuant to Section 13.2.3 or 13.3.1 hereof (the rights of
Vanda in the remaining countries of the

                                      -33-

<PAGE>

Territory in which termination under Section 13.2.3 or 13.3.1 has not occurred
being unaffected by such termination):

               (a) All rights and licenses granted to Vanda in Article 2 shall
terminate with respect to each terminated country, all rights, title and
interests to the BMS Patent Rights and BMS Know-How in each terminated country
shall revert to BMS, and Vanda shall cease all use of the BMS Patent Rights and
BMS Know-How with respect to each terminated country; and

               (b) All regulatory filings (including all INDs and NDAs) and
Approvals relating to the Compounds and any Product (and all of Vanda's rights,
title and interests therein) in each terminated country shall be assigned to
BMS, and Vanda shall provide to BMS one copy of all documents and filings
contained in or referenced in any such filings, together with the raw and
summarized data for any preclinical and clinical studies of the Compounds and
Products. BMS shall have the right to obtain specific performance of Vanda's
obligations referenced in this Section 13.4.1(b) and/or in the event of failure
to obtain assignment, Vanda hereby consents and grants to BMS the right to
access and reference (without any further action required on the part of Vanda,
whose authorization to file this consent with any Regulatory Authority is hereby
granted) any and all such regulatory filings for any regulatory or other use or
purpose in each terminated country; and

               (c) All amounts due or payable to BMS that were accrued, or that
arise out of acts or events occurring, prior to the effective date of
termination shall remain due and payable; but no additional amounts will be
payable based on events occurring after the effective date of termination; and

               (d) BMS shall have the right to retain all amounts previously
paid to BMS by Vanda; and

               (e) Should Vanda have any inventory of Compound suitable for use
in clinical trials in each terminated country, Vanda shall offer to sell such
Compound to BMS at Vanda's out of pocket cost (but BMS shall be under no
obligation to purchase same unless it agrees to do so in writing at such time);
and

               (f) Should Vanda have any inventory of Product approved and
allocated prior to termination for sale in a terminated country, Vanda shall
have six (6) months thereafter in which to dispose of such inventory (subject to
the payment to BMS of any royalties due hereunder thereon);

               (g) Vanda will disclose to BMS its manufacturing patents,
processes, techniques and trade secrets for making the Product and BMS will
automatically have an exclusive, perpetual, worldwide, sublicensable right and
license under know-how and patents Controlled by Vanda and its Affiliates
relating to any composition, formulation, method of use or manufacture of the
Compounds and Products solely for (i) using, importing, selling and offering for
sale the Compounds and Products in the terminated countries and (ii) making and
having made the Compounds and

                                      -34-

<PAGE>

Products anywhere in the world for use, importation, sale and offer for sale in
the terminated countries;

               (h) Vanda shall assign to BMS any trademark or trade dress that
is specific to a Product (it being understood that the foregoing shall not
include any trademarks or tradenames that contain the name "Vanda") in each
terminted country;

               (i) Vanda shall assign to BMS its right, title and interest in
any Sole Inventions and Joint Inventions (and any patent applications filed
thereon and patents issued thereon) pertaining to the composition of matter or
method of use or utility of the Compounds or Products in each terminated
country; and

               (j) Neither Party shall be relieved of any obligation that
accrued prior to the effective date of such termination.

It is understood and agreed that BMS shall be entitled to specific performance
as a remedy to enforce the provisions of this Section 13.4.1, in addition to any
other remedy to which it may be entitled by applicable law.

          13.4.2 In the event Vanda terminates the Agreement, in whole or in
part (in accordance with Section 13.3.4), pursuant to Section 13.3.2 or 13.3.3:

               (a) BMS shall grant Vanda all necessary rights and licenses on
the same terms and conditions set forth in Article 2, to the BMS Patent Rights
and BMS Know-How solely for use in a terminated country; and

               (b) All regulatory filings (including all INDs and NDAs) and
Approvals relating to the Compounds and any Product (and all of BMS' rights,
title and interests therein) in a terminated country shall be assigned to Vanda,
and BMS shall provide to Vanda one copy of all documents and filings contained
in or referenced in any such filings, together with the raw and summarized data
for any preclinical and clinical studies of the Compounds and Products. In the
event of failure to obtain assignment, BMS hereby consents and grants to Vanda
the right to access and reference (without any further action required on the
part of BMS, whose authorization to file this consent with any Regulatory
Authority is hereby granted) any and all such regulatory filings for any
regulatory or other use or purpose with respect to each terminated country; and

               (c) All amounts due or payable to Vanda that were accrued, or
that arise out of acts or events occurring, prior to the effective date of
termination shall remain due and payable, but no additional amounts will be
payable based on events occurring after the effective date of termination; and

               (d) Vanda shall have the right to retain all amounts previously
paid to Vanda by BMS; and

               (e) BMS shall assign to Vanda any trademark or trade dress that
is specific to a Product in such terminated country (it being understood that
the

                                      -35-

<PAGE>

foregoing shall not include any trademarks or tradenames that contain the name
"BMS"); and

               (f) Vanda shall thereafter pay milestones and royalties to BMS in
accordance with Sections 8.2.1 and 8.5.1.

The remedies set forth in this Section 13.4.2 shall be Vanda's sole and
exclusive remedy for breach by BMS of its Development and/or Commercialization
obligations under this Agreement.

     13.5 SURVIVAL. Except as expressly provided herein, the following
provisions shall survive early termination of this Agreement, as well as any
other provisions which by their nature ate intended to survive termination:
Sections 4.2, 8.9.2, 9.4, 9.5, 10.1, 10.2, 10.4, 12.1, 12.2, 12.3, 12.4,
13.4.1(b), 13.4.1(f), 13.4.1(g), 13.4.2(b), 13.4.2(f), 13.5 and 13.6 and
Articles 11 and 14.

     13.6 BANKRUPTCY.

          13.6.1 All rights and licenses granted under or pursuant to this
Agreement, including amendments hereto, by each Party to the other Party are,
for all purposes of Section 365(n) of Title 11 of the U.S. Code ("TITLE 11"),
licenses of rights to intellectual property as defined in Title 11. Each Party
agrees during the term of this Agreement to create and maintain current copies
or, if not amenable to copying, detailed descriptions or other appropriate
embodiments, to the extent feasible, of all such intellectual property. If a
case is commenced by or against either Party (the "BANKRUPT PARTY") under Title
11, then, unless and until this Agreement is rejected as provided in Title 11,
the Bankrupt Party (in any capacity, including debtor-in-possession) and its
successors and assigns (including, without limitation, a Title 11 Trustee)
shall, at the election of the Bankrupt Party made within 60 days after the
commencement of the case (or, if no such election is made, immediately upon the
request of the non-Bankrupt Party) either (i) perform all of the obligations
provided in this Agreement to be performed by the Bankrupt Party including,
where applicable and without limitation, providing to the non-Bankrupt Party
portions of such intellectual property (including embodiments thereof) held by
the Bankrupt Party and such successors and assigns or otherwise available to
them or (ii) provide access or a license to the non-Bankrupt Party to all such
intellectual property (including all embodiments thereof) held by the Bankrupt
Party and such successors and assigns or otherwise available to them.

          13.6.2 If a Title 11 case is commenced by or against the Bankrupt
Party and this Agreement is rejected as provided in Title 11 and the
non-Bankrupt Party elects to retain its rights hereunder as provided in Title,
11, then the Bankrupt Party (in any capacity, including debtor-in-possession)
and its successors and assigns (including, without limitation, a Title 11
Trustee) shall provide access or a license to the non-Bankrupt Party to all such
intellectual property (including all embodiments thereof) held by the Bankrupt
Party and such successors and assigns or otherwise available to them immediately
upon the non-Bankrupt Party's written request therefor. Whenever the Bankrupt
Party or any of its successors or assigns provides access or a license to the
non-

                                      -36-

<PAGE>

Bankrupt Party to any of the intellectual property licensed hereunder (or any
embodiment thereof) pursuant to this Section 13.7, the non-Bankrupt Party shall
have the right to perform the obligations of the Bankrupt Party hereunder with
respect to such intellectual property, but neither such provision nor such
performance by the non-Bankrupt Party shall release the Bankrupt Party from any
such obligation or liability for failing to perform it.

          13.6.3 All rights, powers and remedies of the non-Bankrupt Party
provided herein are in addition to and not in substitution for any and all other
rights, powers and remedies now or hereafter existing at law or in equity
(including, without limitation, Title 11) in the event of the commencement of a
Title 11 case by or against the Bankrupt Party. The non-Bankrupt Party, in
addition to the rights, power and remedies expressly provided herein, shall be
entitled to exercise all other such rights and powers and resort to all other
such remedies as may now or hereafter exist at law or in equity (including,
without limitation, under Title 11) in such event. The Parties agree that they
intend the foregoing non-Bankrupt Party rights to extend to the maximum extent
permitted by law and any provisions of applicable contracts with Third Parties,
including without limitation for purposes of Title 11, (i) the right of access
or a license to any intellectual property (including all embodiments thereof) of
the Bankrupt Party or any Third Party with whom the Bankrupt Party contracts to
perform an obligation of the Bankrupt Party under this Agreement, and, in the
case of the Third Party, which is necessary for the development, registration
and manufacture of licensed products and (ii) the right to contract directly
with any Third Party described in (i) in this sentence to complete the
contracted work. Any intellectual property provided pursuant to the provisions
of this Section 13.6 shall be subject to the licenses set forth elsewhere in
this Agreement and the payment obligations of this Agreement, which shall be
deemed to be royalties for purposes of Title 11.

                                   ARTICLE 14

                                  MISCELLANEOUS

     14.1 PROVISIONS CONTRARY TO LAW. In performing this Agreement, the Parties
shall comply with all applicable laws. Wherever there is any conflict between
any provision of this Agreement and any law, the law shall prevail, but in such
event the affected provision of this Agreement shall be limited or eliminated
only to the extent necessary, and the remainder of this Agreement shall remain
in full force and effect. In the event the terms of this Agreement are
materially altered as a result of the foregoing, the Parties shall renegotiate
in good faith the terms of this Agreement to resolve any inequities.

     14.2 THIRD PARTY RIGHTS. Notwithstanding anything to the contrary in this
Agreement, the grant of rights by BMS under this Agreement shall be subject to
and limited in all respects by the terms of the applicable BMS in-license(s)
pursuant to which BMS acquired any licensed rights, and all rights or
sublicenses granted under this Agreement shall be limited to the extent that BMS
may grant such rights and sublicenses under such BMS in-license(s).

                                      -37-

<PAGE>

     14.3 NOTICES. Any notice required or permitted to be given by this
Agreement shall be in writing and shall be delivered by hand or overnight
courier with tracking capabilities or mailed postage prepaid by first class,
registered or certified mail addressed as set forth below unless changed by
notice so given:

     If to Vanda:

          Vanda Pharmaceuticals, Inc.
          47 Hulfish Street, Suite 310
          Princeton, New Jersey 08452
          Attention: President

     If to BMS:

          Bristol-Myers Squibb Company
          Route 206 and Province Line Road
          Princeton, New Jersey 08450
          Attention: Senior Vice President for Business Development

     With a copy to the Vice President and Senior Counsel, Corporate and
     Business Development, at the same address.

     Any such notice shall be deemed delivered on the date received. A Party may
add, delete, or change the person or address to whom notices should be sent at
any time upon written notice delivered to the Party's notices in accordance with
this Section 14.3.

     14.4 FORCE MAJEURE. Neither Party shall be liable for delay or failure in
the performance of any of its obligations hereunder if such delay or failure is
due to causes beyond its reasonable control, including, without limitation, acts
of God, fires, earthquakes, strikes and labor disputes, acts of war, civil
unrest or intervention of any governmental authority; provided, that the
affected Party promptly notifies the other Party and further provided that the
affected Party shall use its commercially reasonable efforts to avoid or remove
such causes of non-performance and shall continue performance with the utmost
dispatch whenever such causes are removed. When such circumstances arise, the
Parties shall negotiate in good faith any modifications of the terms of this
Agreement that may be necessary or appropriate in order to arrive at an
equitable solution.

     14.5 USE OF NAMES. Vanda, at its sole cost and expense, shall be
responsible for the selection, registration and maintenance of all trademarks
which it employs in connection with its activities conducted pursuant to this
Agreement, if any, and shall own and control such trademarks. Nothing in this
Agreement shall be construed as a grant to Vanda of rights, by license or
otherwise, to the use of any trademarks, service marks, logos or the name of BMS
for any purpose. Neither Party shall use the name or marks or logos of the other
Party for any purpose without the prior written consent of such other Party.

                                      -38-

<PAGE>

     14.6 ASSIGNMENT. Neither Party shall assign its rights or obligations under
this Agreement without the prior written consent of the Party, except that:

          14.6.1 BMS may, without Vanda's consent, assign all of its rights and
obligations hereunder in connection with any transfer of all of the BMS Patent
Rights and BMS Compound Know-How, to any Affiliate of BMS or another Third
Party, (including, without limitation, a successor in interest); provided, that
such Affiliate or assignee or successor in interest agrees in a writing provided
to Vanda to be bound by the terms of this Agreement; and

          14.6.2 Upon thirty (30) days advance written notice to BMS and subject
to BMS approval, not to be unreasonably withheld, conditioned, or delayed, Vanda
may assign all of its rights and obligations hereunder to an entity of equal or
superior financial condition as Vanda or to an Affiliate (and so long as such
assignment includes, without limitation, the Approvals, all manufacturing assets
relating to this Agreement, and all rights and obligations under this
Agreement), provided, that such entity or Affiliate shall have agreed prior to
such assignment to be bound by the terms of this Agreement in a writing provided
to BMS and provided that Vanda remains jointly and severally liable with such
entity or Affiliate for the performance of this Agreement where assigned to a
Third Party or an Affiliate;

          14.6.3 Vanda may assign all of its rights and obligations hereunder
without such consent to a successor in interest by reason of merger,
consolidation or sale of substantially all of the assets of Vanda (and so long
as such assignment or sale includes, without limitation, the Approvals, all
manufacturing assets relating to this Agreement, and all rights and obligations
under this Agreement), provided, that such successor in interest shall have
agreed prior to such assignment or sale to be bound by the terms of this
Agreement in a writing provided to BMS; and

          14.6.4 Subject to the foregoing, this Agreement shall inure to the
benefit of and be binding on the Parties' successors and assigns. Any assignment
in violation of the foregoing shall be null and void and wholly invalid, the
assignee in any such assignment shall acquire no rights whatsoever, and the
non-assigning Party shall not recognize, nor shall it be required to recognize,
such assignment.

     14.7 FURTHER ASSURANCES. Each Party agrees to do and perform all such
further acts and things and shall execute and deliver such other agreements,
certificates, instruments and documents necessary or that the other Party may
deem advisable in order to carry out the intent and accomplish the purposes of
this Agreement and to evidence, perfect or otherwise confirm its rights
hereunder.

     14.8 WAIVERS AND MODIFTCATIONS. The failure of any Party to insist on the
performance of any obligation hereunder shall not be deemed to be a waiver of
such obligation. Waiver of any breach of any provision hereof shall not be
deemed to be a waiver of any other breach of such provision or any other
provision on such occasion or any succeeding occasion. No waiver, modification,
release or amendment of any

                                      -39-

<PAGE>

obligation under or provision of this Agreement shall be valid or effective
unless in writing and signed by all Parties hereto.

     14.9 Choice of Law and Jurisdiction.

          14.9.1 This Agreement shall be governed by, enforced, and shall be
construed in accordance with the laws of the State of New York without regard to
its conflicts of law provisions (other than section 5.1401 of the New York
General Obligations Law).

          14.9.2 Each Party irrevocably submits to the exclusive jurisdiction of
(a) the Supreme Court of the State of New York, New York County, and (b) the
United States District Court for the Southern District of New York, for the
purposes of any suit, action or other proceeding arising out of this Agreement
or out of any transaction contemplated hereby. Each Party agrees to commence any
such action, suit or proceeding either in the United States District Court for
the Southern District of New York or if such suit, action or other proceeding
may not be brought in such court for jurisdictional reasons, in the Supreme
Court of the State of New York, New York County. Each Party further agrees that
service of any process, summons, notice or document by personal delivery, by
registered mail, or by a recognized international express delivery service to
such Party's respective address set forth above shall be effective service of
process for any action, suit or proceeding in New York with respect to any
matters to which it has submitted to jurisdiction in this Section 14.9. Each
Party irrevocably and unconditionally waives any objection to the laying of
venue of any action, suit or proceeding arising out of this Agreement or the
transactions contemplated hereby in (i) the Supreme Court of the State of New
York, New York County or (ii) the United States District Court for the Southern
District of New York, and hereby and thereby further irrevocably and
unconditionally waives and agrees not to plead or claim in any such court that
any such action, suit or proceeding brought in any such court has been brought
in an inconvenient forum.

          14.9.3 Each Party hereto hereby waives to the fullest extent permitted
by applicable law, any right it may have to a trial by jury in respect to any
litigation directly or indirectly arising out of, under or in connection with
this Agreement. Each Party hereto (a) certifies that no representative, agent or
attorney of the other Party has represented, expressly or otherwise, that such
other Party would not, in the event of litigation, seek to enforce that
foregoing waiver and (b) acknowledges that it and the other Party hereto have
been induced to enter into this Agreement, as applicable, by, among other
things, the mutual waivers and certifications in this Section 14.9.

     14.10 Publicity.

          14.10.1 Subject to Article 11, except as required by law, regulation
or order, including, without limitation, laws, regulations and orders of the
U.S. Securities and Exchange Commission, the National Association of Securities
Dealers or any national stock exchange, and except as expressly provided herein,
neither Vanda nor BMS shall make any public announcement concerning this
Agreement, including but not

                                      -40-

<PAGE>

limited to the execution of this Agreement and the economic terms of this
Agreement, without the prior written consent of the other Party. In the event of
a public disclosure required by law or regulation, including without limitation,
any required disclosure in any securities offering document, the Party making
such announcement shall at least five business days prior to such disclosure
provide the other Party with a copy of the proposed text of the disclosure, and
such other Party shall be entitled to have its reasonable comments incorporated
prior to such announcement, provided that provision of proposed text and
incorporation of comments referenced above is consistent with the disclosing
Party's legal or regulatory obligations.

          14.10.2 Notwithstanding the foregoing, in the event that Vanda decides
that it would like to issue a public announcement regarding the execution of
this Agreement following such execution, Vanda shall submit the proposed form of
such public announcement to BMS for its review and written approval. Absent such
approval of BMS, Vanda may not make such a public announcement.

     14.11 ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
between the Parties as to the subject matter of this Agreement, and supersedes
and merges all prior negotiations, representations, agreements and
understandings regarding the same.

     14.12 COUNTERPARTS. This Agreement may be executed in counter-parts with
the same effect as if both Parties had signed the same document. All such
counterparts shall be deemed an original, shall be construed together and shall
constitute one and the same instrument.

     14.13 RELATIONSHIP OF THE PARTIES. Each Party is an independent contractor
under this Agreement. Nothing contained herein is intended or is to be construed
so as to constitute BMS and Vanda as partners, agents or joint venturers.
Neither Party shall have any express or implied right or authority to assume or
create any obligations on behalf of or in the name of the other Party or to bind
the other Party to any contract, agreement or undertaking with any Third Party.

     14.14 HEADINGS. Headings and captions are for convenience only and are not
be used in the interpretation of this Agreement. Neither this Agreement nor any
provision of this Agreement shall be construed for or against any Party because
the Agreement as a whole, or any portion of it, was requested or drafted by such
Party.

     14.15 DISPUTE RESOLUTION. In the event of any dispute relating to this
Agreement, prior to instituting any lawsuit, arbitration or other dispute
resolution process on account of such dispute, the Parties shall attempt in good
faith to settle such dispute first by negotiation and consultation between
themselves, including referral of such dispute to the Chief Executive Officer of
Vanda and the (a) President of the Pharmaceutical Research Institute of BMS for
any dispute involving Development, or (b) the President of U.S. Primary Care of
BMS for any dispute involving Commercialization. In the event said executives
are unable to resolve such dispute or agree upon a mechanism to resolve such
dispute within thirty (30) days of the first written request for dispute
resolution under this

                                      -41-

<PAGE>

Section 14.35, then the Parties shall be free to pursue any remedy or rights
available to either of them at law or in equity.

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by
their respective duly authorized officers.

                                        VANDA PHARMACEUTICALS, INC.

                                        By: /s/ Mihael Polymeropoulos
                                            ------------------------------------
                                            (Signature)
                                        Name: Mihael Polymeropoulos
                                        Title: Chief Executive Officer
                                        Date: 7/22/04

                                        BRISTOL-MYERS SQUIBB COMPANY

                                        By: /s/ James Palmer
                                            ------------------------------------
                                            (Signature)
                                        Name: James Palmer
                                        Title: President, Pharmaceutical
                                               Research Institute
                                        Date: 7/25/04

                                      -42-

<PAGE>

                                  SCHEDULE 1.3

           BMS COMPOUND PATENT RIGHTS AND DESCRIPTION OF THE COMPOUNDS

BMS-214778 is a [*]

BMS-330446 is a [*]

BMS Compound Patent Rights for BMS-214778

                                       [*]

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -43-

<PAGE>

BMS Compound Patent Rights for BMS-330446

                                      [*]

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -44-

<PAGE>

                                  SCHEDULE 1.7

                         BMS MANUFACTURING PATENT RIGHTS

None

                                      -45-

<PAGE>

                                  SCHEDULE 1.19

                                DEVELOPMENT PLAN

            DEVELOPMENT TIMELINES FOR A PRODUCT CONTAINING BMS-214778

                                      [*]

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -46-

<PAGE>

                   BUDGET FOR A PRODUCT CONTAINING BMS-214778

                                      [*]

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                      -47-

<PAGE>

                                  SCHEDULE 1.25

                                    FTE RATE

The initial rate shall be $225,000.

                                      -48-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}]]